var title_f7_9_7312="Evaluation of 46 XY infant with undervirilization";
var content_f7_9_7312=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F66241&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F66241&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 595px\">",
"   <div class=\"ttl\">",
"    Algorithm for evaluation of an infant with ambiguous genitalia and a 46,XY karyotype (SRY positive)*",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 575px; height: 702px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     SRY: sex-determining region on the Y chromosome; AIS: androgen insensitivity syndrome; MIS: M&uuml;llerian inhibiting substance; T: testosterone; DHT: dihydrotestosterone; LH: luteinizing hormone; p450scc: P450 side chain cleavage.",
"     <br/>",
"     * If SRY is negative in an infant with a 46XY karyotype, this indicates SRY deletion or mutation.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_9_7312=[""].join("\n");
var outline_f7_9_7312=null;
var title_f7_9_7313="Perforation after gastric banding";
var content_f7_9_7313=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F70228&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F70228&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 602px\">",
"   <div class=\"ttl\">",
"    Perforation after gastric banding",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 582px; height: 303px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEvAkYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3n4ofEDSvhxoFvq+uW99PbTXS2irZojOHZHYEhmUYwh7+leYf8NV+B/8AoFeJP/AeD/49R+2t/wAks0r/ALDUX/oievKfgN8HvC3jr4f6p4h8TajqtmbK8lhY2ssaRrEkUbliGjY5+du/QDigD1b/AIar8D/9ArxJ/wCA8H/x6j/hqvwP/wBArxJ/4Dwf/Hq4r4XfBz4W/EnTLy80HUfGEItJhDLDdy2ySDK5VsLGw2nnHP8ACeK+X6APtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqKAPtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqKAPtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqciM7BUUsx4AAyTQB9p/8NV+B/8AoFeJP/AeD/49R/w1X4H/AOgV4k/8B4P/AI9Xyvo/gm+vAr3rC0Q9FI3Ofw7fjXpHh/wXp9jb+ZBbB5l6ySje5/oPwFAHsH/DVXgj/oFeJf8AwGg/+PUv/DVXgj/oFeJf/AaD/wCPV5vb6ZvfBVVI65UV3vgr4eSa3I5lZYoFXO7aOaALf/DVPgn/AKBPiX/wGg/+PUf8NU+Cf+gT4l/8BoP/AI9XTN8ILcBdl2ue+UrTs/hXpcYHn3Ern/ZUCgDhv+GqfBP/AECfEv8A4DQf/HqP+GqfBP8A0CfE3/gNB/8AHq9Mj+Hegp/yzmP1Yf4VYPgPQcD/AEd/ruoA8r/4ao8E/wDQJ8Tf+A0H/wAeo/4ao8E/9AnxN/4DQf8Ax6vWY/BWhJ/y5g/VjUw8I6FjH9nRfrQB5B/w1T4J/wCgT4l/8BoP/j1H/DVPgn/oE+Jf/AaD/wCPV6Td+ALG51FJfMENko5t4YgCx/3zk4/zmr58F6Kr5is41XGChGR9RnvQB5N/w1V4I/6BXiX/AMBoP/j1H/DVXgj/AKBXiX/wHg/+PV7RaeHdItowiadat33PErE/pVoaVpw6WFoP+2K/4UAeG/8ADVXgj/oFeJf/AAGg/wDj1H/DVfgf/oFeJP8AwHg/+PV7VqugadqelXunzW0ccN3A9vI0SKrhXUqcHHBwa8c/4Zd8B/8AP1r3/gVH/wDG6AIP+Gq/A/8A0CvEn/gPB/8AHqP+Gq/A/wD0CvEn/gPB/wDHqx/GP7Kuky6eW8Iaxd218oJEeoESRye25VBX64P0r5q8ceAvEngi8+z+I9LntVJxHOBuhk/3XHB+nX2oA+rf+Gq/A/8A0CvEn/gPB/8AHqP+Gq/A/wD0CvEn/gPB/wDHq+KqKAPtX/hqvwP/ANArxJ/4Dwf/AB6j/hqvwP8A9ArxJ/4Dwf8Ax6viqigD7V/4ar8D/wDQK8Sf+A8H/wAeo/4ar8D/APQK8Sf+A8H/AMer4qooA+1f+Gq/A/8A0CvEn/gPB/8AHqP+Gq/A/wD0CvEn/gPB/wDHq+KqKAPtX/hqvwP/ANArxJ/4Dwf/AB6vT9D+IGlaz8NJPHFrb3yaTHa3F2YpEQT7IS4cYDFcnyzj5vTOK/NuvtX4af8AJm15/wBgXVv/AEO4oAP+Gq/A/wD0CvEn/gPB/wDHqP8AhqvwP/0CvEn/AIDwf/Hq+ev2evh/pXxH8aXuka5cX0FtDp73atZuiOXWSNQCWVhjDnt6V3Phz4bfC7XbvRYox4/tbfWLmW0srq4lsvLklj+8pCBnX6lQKAPTP+Gq/A//AECvEn/gPB/8eo/4ar8D/wDQK8Sf+A8H/wAer5g+M3hSx8EfEnWPD2lS3M1lZ+T5b3LK0h3wo5yVAHVj2HFcTQB9q/8ADVfgf/oFeJP/AAHg/wDj1H/DVfgf/oFeJP8AwHg/+PV8VUUAfav/AA1X4H/6BXiT/wAB4P8A49R/w1X4H/6BXiT/AMB4P/j1fFVFAH2r/wANV+B/+gV4k/8AAeD/AOPUf8NV+B/+gV4k/wDAeD/49Xzt8OPgr4v8deVcWll9g0p8H7degohHqg+8/wCAx7ivc7X9k7RFt0F14l1KScD5mjgRFJ9gckfmaANb/hqvwP8A9ArxJ/4Dwf8Ax6j/AIar8D/9ArxJ/wCA8H/x6s3/AIZP8O/9DFq3/fuP/Cj/AIZP8O/9DFq3/fuP/CgDS/4ar8D/APQK8Sf+A8H/AMeo/wCGq/A//QK8Sf8AgPB/8erJuf2VfDdvA8r+IdXKqMnEcef5Ulv+yt4cngWVPEOr7WHH7uP/AAoA1/8AhqvwP/0CvEn/AIDwf/HqP+Gq/BH/AECvEv8A4Dwf/Hq5q/8A2ZPDdnOI5PEGsHvxDEeK0If2U/DksSuviLVsMMj93H/hQBq/8NV+B/8AoFeJP/AeD/49R/w1X4H/AOgV4k/8B4P/AI9WLe/ss+GrWMs/iXVFIGcGOPn9KwtU/Z38NWcRaPxDqkjAZwYox/WgDt/+Gq/A/wD0CvEn/gPB/wDHqP8AhqvwP/0CvEn/AIDwf/Hq8K1n4W6RYswi1O+bH96NBWMngHTzOEN9clSOCFXrQB9Hf8NV+B/+gV4k/wDAeD/49R/w1X4H/wCgV4k/8B4P/j1fP5+G+mHlbvUSvH8CfjUg+GmkEsBqOoMe2IlH50Ae+f8ADVfgf/oFeJP/AAHg/wDj1H/DVfgf/oFeJP8AwHg/+PV8/wAnw101IyRqF5uxwCi1QbwHp3mKBfXRU99i0AfR/wDw1X4H/wCgV4k/8B4P/j1H/DVfgj/oFeJP/AeD/wCPV863vw6tkgL2t7cOQoPzIOK4TUdJurGRlkXcqnlloA+xf+Gq/A//AECvEn/gPB/8eo/4ar8D/wDQK8Sf+A8H/wAer4qooA+1f+Gq/A//AECvEn/gPB/8eo/4ar8D/wDQK8Sf+A8H/wAer4qooA+1f+Gq/A//AECvEn/gPB/8eo/4ar8D/wDQK8Sf+A8H/wAer4qooA+1f+Gq/A//AECvEn/gPB/8eo/4ar8D/wDQK8Sf+A8H/wAer4qooA/UTw9qsGvaBpmr2aypbahaxXcSygB1SRAwDAEjOCM4JorF+E//ACSzwb/2BbL/ANEJRQB5V+2t/wAks0r/ALDUX/oieuP+Amg6z4o/Zv8AE+h+Hbi0tbu/1h4JJrlmVVhMNv5mNqkklcjHuea7D9tb/klmlf8AYai/9ET18VUAff8A4E+GWoeB/iFLqWlaot34fu9Mis7qK62JOJYQFiZVijVCoQBeeeSTmvgCiigAooooAKKkhiknlSKFGkkc4VVGSTXe+HvCEVsq3Grqss/VYM5Vf971Pt0oA5zQPDF7qxEh/wBHtf8Anq4+9/ujv/KvRtE0Oy0lcWcJMzDDSvy7f4fhVtD0AxgcADsK9M+GPgmfWLtLi4TEQ55HFAGH4e8N3Ek8Us8R2t8w+lb0FsltOyYHzgjnpXtWt6NaafokbRRqGgYfNjqDwa8z1e2ha9URIP3kgIwPzoAg0fTo7iZRINoDDn19uK9q8N2sVrpkaRAfUDHFed6EiIVO3API5r0bSrpDborEKW6UAadFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFV9RsbTUrKWz1G1gurSUbZIZ4w6OPQg8GrFFAHyV8X/wBnzT7W4ln8F3EsFw5aX7DdODEwJziN8Ar1wA2Rx1r5s1XTbzSb+Wy1O2ltbqI7XilXaR/9b3r9EfF6htW3NhlMYAHsOtfPfxg0ew1LXGtr2LeEhTy5F4ePIz8p9OnB4oA+Z6K3PEnhy70SQM/760Y4SdBwT6EdjWHQAUUUUAFFFFABX2r8NP8Akza8/wCwLq3/AKHcV8VV9q/DT/kza8/7Aurf+h3FAHlX7FP/ACVPVf8AsCy/+j4K9S8G/BjXtHk8OLKnh+wn0zVW1C41ewmka7u4ixP2cgwp8hBAOXYcdO1fFtFAHqv7Uf8AyXbxN/26/wDpLFXlVFFABRRXvXwT/Z+1Lxb5GseKxNpmgnDpDgrPdDAIKgj5UIP3up7DuADy3wJ4E8Q+OtTWy8OafJcHOJJ2BWGLjPzv0H06nsDX1/8ACz9nrw34R8m+1wJrmsoQ6vKmIIT22x9yPVs+wFeseGvD+leGNIh0vQbGGxsYvuxRLjJ6bmPVmOBknJNalAAOBgdKKKKACiiigCK6iE1vJERkOpGKhs1MEEUK8qowARyRVuigDE1nT5767URYRFGS7etWruPyLFBJOyImAfL+XP41o1DdwLc27RPjB9elAGXHp1rqEInlTzZMnl2JwaydfsLdLOVXhi3DgAgGug063ntrMRyFRjOMdq5/xL5y2eChOWJz7UAeJeKNOWRpZEAG1uR7VxN/ZrFcRlflOK9F12YLJOg5csc88AVxusyIYIZWVeGxnHUUAMhkHlKVHzelPhVssWGC3QelRWW0fMwyTyRVt5lVCQBQBFJENr7kOe3asGSLMzony85Fb11MfL3dRjFYUkwS4RyOeh+lAGxCyqoBO7jBz61zXijRhODNbLhhnp2rXSYcFepqfzPkKuAQw5FAHjd9pkUsjZBilHBwOM/SsO6tZbVsSrx2YdDXqPiXSOTPAOK5V1DK0ciAqeGU0AchRWrqGlNGDLbZaPqV6lf8ay6AEooooAKKKKAP0q+E/wDySzwb/wBgWy/9EJRR8J/+SWeDf+wLZf8AohKKAPKv21v+SWaV/wBhqL/0RPXxVX2r+2t/ySzSv+w1F/6Inr4qoAKKKKACnRqXdVGMsQOan06yn1C7jtrSMvK54HYD1PoK9AtfBumwRRee88s64LOr7VJ9hjpQBd8PaBb6LDlgst8fvy+nsvoPfvWqx9DQ7ksT3NdB4U8PTavdxkxs0eeAB96gC74B8OSavqsBkRmjLcL619V6HpcGk2EdvboFwBk+prk/CnhldM05JZIkgdBuA7iu2tplljUq4c4zkUAUfE679BvUAzmM4+teK314piG3jb0PeveLxQ9rKpAIKkEE9q+fp4HRp1CEhJDjPfBoA1dIvQI0y7EEYHNdFZTPICYpJ2jHUGYcH8a5HTRuiO0KqjgjYP51v6ajx3RCy/IwBwMCgD0fQlufsaN5xZOm2T5iR9R3rYrhrXUJrEKDM7Ix4TeetdVpdxJMpa4KiVxkKvQCgC/RRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHIeOrJ1WK8tQxcAh4x0YdePQ187/Ee5W48TTSJ9zy4gPwWvqHxKM6eG7iQc18t/EuIW/jLU4VGFSQAD0G0H+tAHODZLE8UyrJFINrowyGHoa838Y+FDpmbzTg8lifvqeWhPv6j3/OvQ0NTK5UHp70AeEUV2Pjbw0llnUNOTFqx/eRAf6onuP8AZP6Vx1ABRRRQAV9q/DT/AJM2vP8AsC6t/wCh3FfFVfavw0/5M2vP+wLq3/odxQB8VUUUUAFPjR5JFjjVndiFVVGSSewFIiNI6pGpZ2ICqoySfSvrj4Hfs8xWVrp3iLxm11DrMc8V3a2cLhPs+xgy+ZwcsSBleMdOucADPgL+z2tg0HiDx/bRTXBVZLXS3GREeu6YdC3+xyB3yeB9OUUUAFFFFABRRRQAUUUUAFZviGS7i0idrAOZxjGwZYDPJFaVIzKilmIVR1JOBQBm+HXvZNKiOpqwuckEsMEjsSKvXU628LSOCQOwqF9Qtwjsrhwvp3+nrXOanrplQpu8gejDvQBoT6y0VyqzL5CEZG4+vrXLeLNcRojtkeTY2OmAM1Jq8ovITO8v3QAef5Vw/iWbdYOV+Yrx1/WgDidU1FpLiduAGY5PWsDUt81vhctjk/UVd1FCB5i8oT1rKaWRSUTO3PXGeaAJoXlaMPHGNuOpbGasIJ5VACRgeuTWPbzSlDHvIwcfdFXYAeQJZMY6A45oAuyxzeQQTGO3esLUvkOGlU5XoBWoPL4DktnrljWJcqBNISASMgcUAaVuABtySR3NTluKo2jefEkik7SMVNLG68722ketADJ5FOVboeCK5fXNLKkzQjr29a6CRR1Gc1AqliVlOVI70AcOrbT3BqhqWnLOGmtwBL1Kjo30966vWtIMZ82DkGsENtJHIxxzQByhBBIPBFJXQ6nZLdKZIsCYD/vr/wCvXPkYOD1oASiiigD9KvhP/wAks8G/9gWy/wDRCUUfCf8A5JZ4N/7Atl/6ISigDyr9tb/klmlf9hqL/wBET18VV9q/trf8ks0r/sNRf+iJ6+KqACpIIZJ5kihRnlc7VVRkk1HXo3gbQhZ2q6jcr/pMy/ulP8CHv9SP0+tAGl4a0SPRbPaTvupQDK//ALKPYfrWkxyeakJ461C/Xp70AafhyxGpavDbMcBq+o/APhq20/T45BGFbHQjkV8v+DZRD4lsGbpv6V9iQzCPTojEwUlQcnkdKAG6q0ceNwMjEY2dqdoTKbRlQ/KjEAelYWo3RMis0hZvQDgCrPhe8RWuYmLEbtwPrxQB0Uy7omHtXj3iOBYNXuQBgMc8V6zc3aIpHBJHSvIfGdxI16GGM87hQBmWWA4WP7x6VqRTJBtCqS5PCiuRtNRK3Tdc8jOM4ratJ8n92kruf4iMc0Addp0DTv5kz/N6DkAV1Wi6gyzrC4Xy/u7+9cHps8y4jMbbm5JL9K1nuZI7UqNqntz+tAHpQORkdKKx/Dl4bm0QE7uBzjqe9bFABRRRQAUUUUAFFFFABRRRQAUUUUAY3ixXGkvNEzBoiGAB4PPevlXx/cNdeK9Tmc5Zpjk/QAf0r621squk3ZcZHlnj3r4/8WKRr9+GOSJ2BPrQBjoeakJ4qNOnHSnNwKAGsQQysAyMMFWGQQe1ea+L9B/su4+0Wo/0GU4UZyY2/un9cV6M5qC6iiureSC4XfDIu1lP8x70AeOUVoa3pkml37wP8yH5o3/vL2P1rPoAK+1fhp/yZtef9gXVv/Q7iviqvtX4af8AJm15/wBgXVv/AEO4oA+KqKK9r/Zm+Fi+OvEbatrMO7w9pjjzEYcXMuMrH9Bwze2B3yAD0X9ln4OmA2njfxNC6z/f0y0kTGARxOwPrn5R/wAC9MfUdFFABRRRQAUUUUAFFFFABRRRQAVXv4Bc2rxk8EZqxRQBw2on7HYJsZh2Yt1OPaqE0cmqWiuoWUnkY6/jXWeILBZEEoVdg+8K4i0WVb+drZikSDI54b2oAltbB/KeGRgvl9vUVh65p0ENrPkEswyDnrXQXd64G8bWJyc9xXO61eK1rMx5fb+dAHnU1tHNE4UBQeq+tYYhyjAjAHA9q3IZEIkJrIvJFSAquMk0AYjYju3CjsDVmF8kk8FuAKqyEJetxwV71Kjorhsjpjk80AW1QYBNUrtFLkYG01aaZcbtw6etUZJoyx3Mp7igA0fNtJJE7fuycp7eorUllR0O3scH61mjG0Ect29altmXLY6UAVpAd7cHGelN5xgKfxq+du47cA0zecngGgCpt3KUkXIPUVz+u6K6ZmhX/wCvXTsdpHy5p8rBYgHUlW6jrQB5oCVJB61Q1Wz81TPCBvHLAdx6/Wus8QaWikzWxz6gVzyuVbByKAOZorR1W1Eb+dEP3bHkf3TWdQB+lXwn/wCSWeDf+wLZf+iEoo+E/wDySzwb/wBgWy/9EJRQB5V+2t/ySzSv+w1F/wCiJ6+Kq+1f21v+SWaV/wBhqL/0RPXxdBC888cMSlpJGCqB3JoA3/BeijU78zXMe6yt+XB6O3Zf6n2r0svk88Zqlo9hHpemQ2keNyjMjD+Jz1P9PoKsEc5oAkY1C/J604GmsKALOjP5eq2r+kg5r6tsNUjuNOtd74IQYHc8V8l2x23EbejCvpPwxGkukWz5OSg56UAbF3deZvW2XBxjcw6VHpW+RzIhbBwMKcAYFQvDMV+XJUZwpHWtfQ7OaO2LSERxg7mY8UATPIyqdwKp3Y15r4vLzXDmEkxKc7jxXpraeb+FneVhbL2zy9cN4kESOYkyAuOD3oA4K3EttM3lnA69K3IZpHO5pD0+XbwBVFkX7SwweAcc9anhRidqnHGCM9qANq1dEdWySD1JNa8s0LQkADeTgGufgOFAbg1ehfoBigDs/Cl4Y3RVbIY4YV3FeW2F2ttscEKc8n1r0DRNQS+t+Gy6+vUigDSooooAKKKKACiiigAooooAKKKKAEYBlIIyCOlfHfjxAni7WlRQqreSgKOg+bpX2LXxv44ff4q1huxvJz/5ENAGGtK3T2poPSnP0oAruaiY+lSPUDHrQBleI9NXVNPZFA+0R5aI+/dfx/wrzVgVJDAgjgg9q9bY49a4bxlYeTdi8iXEc338dn/+v1/OgDnK+1fhp/yZtef9gXVv/Q7iviqvtX4af8mbXn/YF1b/ANDuKAPj7wzol34i1y00vT1BnuHC7m+6g7s3oAMk/Svv34bWdj4T8MW+nadBssIQFjAPzSH+Jz6szZP6dBXxv8BgzeM5o4875LRlGOvLpX2RZMriC3jI8q3QAZONzetAHoEbB0DDoRTq4+511NJDLG6ytjJzzil0vxX9oxNcoyRtwinA49TQB19FZtlrFpc5zMit2BOM0l9rNrbKQrq7jsD0+tAGnRXNDxTDvCEIXboAatw69BgCU5Y/3eooA2qKox6pbyMACcHvVwSIVyHXHrmgB1FMEiFiA65HbNPoAKKKKAM/W5glk6AbmcYxXmRvXt7l4imDzzivVJrUSuzMQCRjgdBXnPje2h0/UXAORIu8eoPpQBh3d3l+TgHr6GsPW7xfLdS24kdqg1DUHdypUoBxz3rC1G4LKcDIxQBz9xdOPlU7VPBx3Gaqu8TH5ieP0p4AcsGOKoXCEuAB8o7+tAFa+MP2hSDuBUjJOamt3ibAVc49BVW7z5kTFRzmrlvKoxgduRQBYc7hxCfxrOuWkDKFRAcda0FkHNUbnJctjjtQBLbowRC7ZJO08dKsLARn5xg80yyKzoQ2Rtb8qnihBB3hWA4yTmgCHIVjg7j7Cmkc96nlReq8Z9O1VdkpcheV7mgBkjHevA4ou5lkg2liCB1HapFgVh83OOvPWiaCEwP8m1h0OeaAM07XjCMA2fXvXNatp+12eId66ZICPmyPTFULhDvYEcZoA5BgCrRyDKngisK5hMEzIecdD6iu01GyUguBtNcpqwKzqD2X+poA/Rz4T/8AJLPBv/YFsv8A0QlFHwn/AOSWeDf+wLZf+iEooA8q/bV/5JZpX/Yai/8ARE9fLPw/08PdSahKPlh+SPP98jr+A/nX1P8AtpqW+F2kqoJY61EAPX9xPXgekWS6bptvaqBuVcufVz1/w/CgC8XOfb2oyO9N4o7UAPFBHFC0pwaAEThwc9xX0X4JnH/CP2u88gcH0r50HXNe2eDb9f8AhHoYiwDEde9AHd22o/6PK0rIEDcMvcVZ066kvnJlcpbochD/ABe/0rkbeYSoGlIS3U/KufvGtJL9Y2HlNnHXsKAOw1C9QWwiQ5JGAK8v8Y3QiuWO7kdOa2ptTdzkMcDjArhPE07Sylj70AUvtjSXKYJA3YYitZZnG0qv/wBcVzEchXDDtycVqw3BMZy2M0AdBbzSOAuIwPfNWoVbgl0HNYdpMBwx3Y9a147iLyxyN3pigC7bGR5dgIPPboK7Xw07wzKzS7cnnHpXn9hdhLlypA3c1s22psmNr474zQB67HIkihkYEGn1xOiaoJJYi8gGD90GuygmWZNykYoAkooooAKKKKACiiigAooooAZKodCDnHtXxf4jOdZvie9xLx/wNq+0JAxX5MZr4q1s51O6P/TaTr/vmgCkvpSv0pF64pX6dqAK8nrVd+uc1PJVdz9KAIn6ZrN1SBbu0lt2IG8cH0PY1oSdDVC4b3oA86lRo5GRwVdTgg9jX2l8NP8Akza8/wCwLq3/AKHcV8heJLfZdidR8svX/eHX+lfXvw0/5M2vP+wLq3/odxQB89/s7rnx3M4GSllIwH/Akr6bbVRbREQj5j1OetfMP7PpI8a3ODj/AEKQf+PJXu9xK4lEY57L/hQBpNdveXWJWIjX7+3+VaYvAeWxx90ZrCRTGpReSOWPqanDeVEC3PYD3oA0572ZVAikHPIDqDiqM0tyzZMpHqPWqTSSOSxJ+oqWMkKM5z65oA0rSNlUOHJJ6kVtWDhct/PrWLalk2lskdhWrFKXwSMdvrQBv2t2ME7RzU816Qm1XOG/hBrDjusEfJkjsKmWUeYCeO+KANhLxzGFx0HVjV211V4kRCxz+YNYXn7QC2AOvWs681OGE8YdgThe1AHX3XiUW8iosZkYnLf7NaFrrllPw0gjfGdpPJrzE6nI24MQAey9vxrFa+eO4cscbj1FAHui3sDxl45FIAz1xXl/jkeYWul52sVJHpVa18QTRAbJccYGetP1CT+0dMIVgmRh1IzigDg5W892VOePzqlLaDypA7fLj8zWv9jFq7oGJCnHviqlyAyMEAwOuTQByYA+dcfkOlQvbFVO5SAe5rTtIvNdiPzNM1KIpEw3ZJFAHIX/AD5bfwhsZqSAHGVOc+tWdUtytkcRkFeSe1YiXrRjbnBFAGyjjBJPtVdnVj8x6Gs0XZw/z4z0qIzLyWdix4wDQBflvjHlIXAwOSaal8WOA2D1bmst5GkRiAQo5ye9Vw5yCKANgan84LSnAPQipE1VvmxIpH+0KwXYgDnvSF8DA/OgDb/taSTIUAc4yOlSGa4kj3IwIzgjFYMTkN1yM5xWpb3e2Ft5GD6UAWQ5ERYtyKpbsvuc5PvUpnR7Y9iTwKrMQBwctQBFesGjYjpXEa3/AMfS/wC7/U11185WNsHrXHasSbkH/Z/rQB+jnwn/AOSWeDf+wLZf+iEoo+E//JLPBv8A2BbL/wBEJRQB5z+1uAfA3hwEAj/hILfg/wDXGevnxm+Y819B/tb/APIj+HP+xgt//RM9fPbD5qAHBs07PY0xPSnigCRaXnvTVpxGaAEHNei+FJnlsYEPEa9a8674r0/wFbtJpSORxmgDsj5ccAGAw6VWlkOVBBJPT1pbuBkYPuYKB1PFJYbGYyYO7oR6UAA81kJVSAB948VymsZ2lWIJ712t0d0b8846Vw+sEh2PfJoAygB+dW7ZtyD0qnn8qngfaCOg60AX4iVI/pVuOT3rOVyRUyOQp9qANCNvn3e1aUM67RjrWHHIR14q5A2QPQ0AdHYXZUgg4IPXNdt4a1ciYLIxYNxj3rzW3lwev5VtaddGNwQwBHSgD2VSGUEdDS1yGl69JGuGAZfrV6LxCjON6gD60AdDRVe0u4rqNWjYZPbPIqxQAUUUUAFFFFABXxHqz7r6duuZHP8A48a+23OFY+gr4g1Bt1zIfVj/ADNAEANK+cYpq0r9KAIJDVdsYNTyHmq70AQyH5TWZcntWlL901mXOcmgDnvEZzaR/wDXT+hr60+Gn/Jm15/2BdW/9DuK+S/EX/HpH/10/pX1p8NP+TNrz/sC6t/6HcUAfO3wCx/wmN2T/wA+Mn/oaV9FaRaJKGnlU/LxHnpnua+cvgKrP4yuEXq1m4/8fSvp9CIokjUYVRgCgDPkHkSOJP8AVnnd6VUnlEsmVPyDpVrUpwQY+vrWZ5fOY2If69aALXyhMcgCrtpbqRvkOB1FZ9llpMTBgq/qa1hKgjweVFAFpcBfl+6ehNSBwOe9ZnmszAE4QdAtPkuljAVASe5JoA1knjiHzHae+aqXOo/vcxnkDv0rJluC/OcmqssmBknP40Aac2oSSAkuT9TUCyh8lic+uazy2cgCkWcLwevpQBbldkycAVESDD833jUTS78Hr9ahll/vNmgCV5WVl4w/qKuLfGGKTy5CA6lX56msaWY8Be3aqxuHMhXoPTNAGkbgyRs5b5m4zULRZdk3ZjIyTVX7QsYDQnPqtSSzCe1Lxk72PI96AMdJVjlZF6A4yKrajl4/3ZIb1605UY3DAfM2Tk1YntUSH94zGQ8jBwB+FAGDcxPNauryE5yuMdK4ecFXZW6g13N6GW4wScMM8etcprNt5cplQHy2Pp0PpQBlZwckU+IGaRY1BBJxUbdasadKILjeRnjHNAF+7i8qNQvTGKx3BUnFb+oTRy20ZHGTk+1Yc5XdkUARHJAJPPpUbHOKUtyetIxGTQA45GCaeHPA5OO1QNJzk9qfbhp51QH5epPoKALqk7ADkE80owB83WpWUMcKp+opfs578++aAMnUWyCAK5TVP9ev+7XXamgUGuQ1P/Xj/d/rQB+j3wn/AOSWeDf+wLZf+iEoo+E//JLPBv8A2BbL/wBEJRQB5z+1t/yI/hz/ALGC3/8ARM9fPT/eNfQv7W3/ACI/hv8A7GC3/wDRM9fPL8MaAFTrUq1GlSCgBy8U+mCn/WgAHqa9R+H1yY9FOByDXl3OfevRPAW7+ymAI+9nFAHcs5mQPKTjHA/+tVaKaNJCUJDKSPwqsWDH96xA7ZNVZZPLB8skluuelAGnNdh+DwPSuR1tgC2059cVdnmJPJz61i6k43H0oAp7iTnPvU8JORz7VSB4wKmRjg0AaMJz1Jqwu3/61UIpMkY6HmrAb360AWlI8xauxtjispSd2ehq/BLxk/WgC+jHPercM5UjPSs4Pke9TRNnHvQB1VjcMyfKC3sKunzWAPIBHcd6wtMnwMZwR71sreMcBdpz1BoA19MuZrQ71Y4PWuotNSaRVJYcjjI4P1rjra62OySnIPXPatexuvJZtvzL/dPQ0AdhE+9QSMU+s2ymilUErhj0PTHtWhG+8ZIINADqKKKAM7Wrp7WxuZIyCVQ4BHfFfFV0f3h9a+yPEs26zmTaykI/3hgHg18Z3P3+lAAp47Urnj60xT6U56AIXqu9TPUDmgCGX7prMuO9aUn3TWbcd6AOf8R/8ekf/XT+hr60+Gn/ACZtef8AYF1b/wBDuK+TPEf/AB6R/wDXT+lfWfw0/wCTNrz/ALAurf8AodxQB89/s7kDxzcZ72MgH/fSV9HXE/lwZPU9Aa+bv2fhnxlec4xYSHP/AANK9/mn+0kMchQMYoAhkJLlmP8AiaLdDI+Oijk4pH3MwVRkk8D1q5GnkoB1x1PqaALDFFXqABxVYsWb5AEQfrTCzM2TwOtQ3FzuyoPHegCSS57IcD19agMoUYzgVUebOfaoTLvbA5NAF0zZOAMU0vjJJzUKdgaV2AHOD6UAPDNg4x9aYSFySAajMoA61A0xwSDxQBZaXA5OKjZ81VeX2zUcl0FGF5Pc0ATTttBAPJrPZssSxOfrSSzFs8/jUJYk8YoAdub5lU8GrenygOFdtoqmDn6+1Nkm2EZHFAFzzxHcsFAxnrUd5IsgGG/CqhlAbpwajkkXGT25oAguW/euwGQvBrE1aZJLWXzMYx09+1bdxdwFfmQM3pnp7muR8QXG6bykVVUDPFAGMxoU4ppPNCAswXuaAJ5pHES7uh6VUd84rRvrdvIXYM7R0FZLggn1oAGb/wDXTSSeKcilm6VbjsWYjpz0560AUDk9K3tNsWghzINs0g3EH+EdhSWenCC4DzbW28heozWkZQSfU9fegBiRDhRx9e9PKjGMU9eKYzg9DQBg62uAcVxeqf68f7tdvrX3K4jVP+PgfT+tAH6O/Cf/AJJZ4N/7Atl/6ISij4T/APJLPBv/AGBbL/0QlFAHnP7W3/Ij+G/+xgt//RM9fPT/AHjX0L+1t/yJHhv/ALGC3/8ARM9fPMn36AFX2qQVGpp4oAkWnmo1NPoAXNdv4EmItpUzjnPNcNXW+CHCM5I4I60AdfJIytlwT70rEScKDnuKiSeOZWYE8HGT2qSKTywxXOD0NAEL2/BY8e1YmrFVYhRz6mt+WQMOeKwtYQHa3egDIPftUkbcjPWoHJ/GpI+Ov50AW4m6c8Cp0f3rN80qxFPW456UAaiycjNWo37dqxVlOOprQtpMrgnNAGpG/HarEcnFUY24zT0fHrQBt2EoWTnOCK1klAZcEc1zEExWQEVprOSAc+3NAHSo+8A45AycVq2MySQ7GPGevpXK2c7B8BjjpWlbXLRSDP3T2xQB2Ngdr5DMR6E10NvdAhVlbax4Ge9cbY3YOAMGtSG+VpAr8MTwTz+NAHVUVlW+pwrIY3kBB5B9PatATq6gxlST0GaAINXQSabcggHETnB/3TXxBcY3D6V9u3s4exuUIIbynBA7fKa+IbkksPoKAGqac54qNT70rnigCJzUL/rUrVC9AEMn3TzWdP3rQk6Gs+egDA8R/wDHpH/10/oa+s/hp/yZtef9gXVv/Q7ivkzxH/x5x/8AXT+lfWfw0/5M2vP+wLq3/odxQB85fAhtvi675wDZOD/32le7pIEyCeD19q8H+BP/ACN1z/15P/6Ele7Kglly2Aq9SO9AGnbR7UEj/eI/IU2WZRlRVaaclAN+aoyzlFb+8efpQBZubrB2qenU5qlJNgZNQO+SR61Ao8xsdR60ATCQyNhTxVqNFQD19agQBB0oaU+ooAsNIF4qCSWoHl/OoXk7mgCcycYqF5sd/wABVeSbHCkfWoCxb6mgCZ5S3rj0qJmoHSmnrQAHJpaQD14pGOBxQA7ODiobnLJx1FOU5NNkPGDQBWViUOe1VLqQspUelOlmwxUdKrlC7Bc47k0AQl8bXJ7YNYusoXfzQDg9TW5dxgIVGMnAFU5GVozGyZz+VAHLtU1jt+0KWOAKfqNt5DAr91ulU0bafpQB00B+cHgjpmmXVnbHczxICBnNVFnIt1Ix0qKGT7TMAzNtxjGetADYrTz2JACIDgbR1rSgtmjTPG30q5bwKiAL0HQUSkYHYUAZ7SBcg8GqslyEyc5PaodVmbzWx0HHFYk0zMxOSTQBtyahnaoPXqKVNQDbgBx7Vzoc55qxAWJG0EigDS1Vt8Qb1FcVqf8Arx9K6/UgRCN3WuQ1P/Xj6f1oA/R74T/8ks8G/wDYFsv/AEQlFHwn/wCSWeDf+wLZf+iEooA85/a2/wCRH8Of9jBb/wDomevniQ/Oa+h/2tv+RH8Of9jBb/8AomevniX7xoARakWo1qRaAJFp5pq040ALn3rpPCb7Q2TjmuYBrovCw3s4JwPX3oA6sMA7FMYPbpUryccZqs58vtxTPPUHA60ATtIccnHtWXqsmYhyeDVlyzDJ5+lUL/cY1HvQBRyT1pYic00rjnJIpUYDpQBG7fOT70qn0qIn5jTlNAFmMmr1tIVxmqEfSrURwRigDVib3zUvGRVS3fnnPNWwQKAJoc7xk/lWvbqrttxjI65rHRxwRWlbPwCKANS2jCupDdDWkyMVPB696zbMGR++BzmugtmLIDgtQAtnJ0PccEdMVpySMsAkjHmupyAKplo48NJtTsSfSkkvraEFUkBB6gDoPagC1cyiTa20B15LVes7+WNQSz5OSNwyAK5p9St/MOSwUnIGM1Zh1i3ZdjyhT2LDFAHS3Gpl7SUSqWAjcb1bBztNfIV19/r6V9PmdJ45SJEZNjcp9OlfMN19+gCIHmhjxTc0MeKAI3qFz6VIxqJ6AI5OhrPn71ekPBqjN3oAwfEgxZR/9dP6GvrL4af8mbXn/YF1b/0O4r5O8Sf8eUX/AF0/oa+sfhp/yZtef9gXVv8A0O4oA+a/glIU8WXAX7zWjqP++lr3KR/LcIpyAOeeteGfBUhfFVwxGcWj/h8y17hchWIIbHHagCK5uFACbtx68VXMpJyxyaqXEv77g4UUiSHdyeKALm4niplwi81DHwuTwaY8nagCZ5cn2qNpOarl+evFRvIAOetAE7yYPJqvJKTwO9QPLk03JP40ASbs/wD16F5x1Apigk89KkztFAD+nem55qNn9DTA+c0ATsajkYY61GX96idx1oAmD4OSeBUM0ufpVeWX8vSkVt1AFa4B3g9qnQAJgdeuaScDZnHNRxScYoAjulYupGCB2JqpcK3AO0D2NWrqTy0DHk5wBmsu7nZnwCooAZewiWErx6g1hTxNE3I4rdC5ALMfeoJ1iZcPj6k0AUIXDRr6d6kiPlygoRVV8QyExkEU9bpCcnj2oA6i2lzEAxG6qt9crCPmNYk+pHywFODWdc3Ly/eORQA68u/NZtp6mqBNOY80gUsQAOtACbT17VtaTbko0hXKD+dQ2+nylQWHBrobSARQKoAAHagDD1f/AFZrjdS/14+n9a7XXVIz0ritS/14+lAH6PfCf/klng3/ALAtl/6ISij4T/8AJLPBv/YFsv8A0QlFAHnP7W3/ACI/hz/sYLf/ANEz187yffNfRH7W/wDyI/hz/sYLf/0TPXztIcOaABevrUq1ChqRaAJV6040xTilJoAXNdd4GEbJcLIm/PQDqPeuPzzXX+AsmWVQcE8CgDVuBLC+1smInv1FN2kjjAHtW5c2ylCGHzDnBrPlt/LXdHkj+IelAFeOPdz0FVtT4iCgZGa0VwU+Xkj26VR1T5YAT94kUAZLodvB5FRIBmnSyjotNVhu68d6AIJPldhTkPNFwMEMBTUPNAFuIE4wKvRLtQknnFV4wFjGPxqZG+UAgntigCSKQq6npV3zPU4NVoo8Dc34VKcdiRnmgCdZOOP51ftZCc96yYRl+entWnb4UDacn3oA3bW4SEJ5pwPQd6ttqR8vbCcA9a5x5jjnrmm/accdKANyS8ZlO7knrVcXJB65AFZX2g4o+0dKANKS5PGDjFMMxPXqetZzTA8UJLjrzjpQBotcMittYh8Hvg147df6w8d69Qkm+XGBXl91xK31P86AIPShjxSHrSNQBG3eom5p7VG1AET9DVKbqc1dfpVOXqaAMLxL/wAeMX/XT+hr6w+Gn/Jm15/2BdW/9DuK+T/E3/HjF/10/oa+sPhp/wAmbXn/AGBdW/8AQ7igD5q+C5A8T3eRn/Q349fmSvXZLpkUwnhugPtXjnwgl8rxJctkj/RGHH+8teqPJJIxeUAjt9KAFBy3zEVPDjO7HHaqiLvk9FHWrDSYGAfagCeSXA4NQlzznrUTPz70wvgc9KAJXkwMnr2qs7k9etRPJk0gOfegCVeTUoqJaduxQBLuAFML8mo2bmmE54NAD2Izmmk0hzzUbNtPNAD3kCjmqryEn+tNkkLGmLyaAHHJpykL0600nFNJJoAdLIApyarRyfMRwPeozbyFy33h9ajmgMQ+YgH0oArXt2rHaGJAPJrMaTJJPXNT3qquSpH0rMkYnvxQBae6YAgHPvVKWZ260gDM3AyKsLaM68g0AUGbIzmmE1oS2gjjDAcn1qGGwllIAGPrQBSNNY+tXJLGVZim3gd6ie2dXClTzQBWCFzitjS7ETKcfeHfsKsW+lhI1YggtWnbwG3T92AM8nFAD0hIVVBJx3qcJxgdaZHJjqOamJ3LwSKAOc10YQg5rhtS/wBePpXe64gCN61wWp/8fA+lAH6PfCf/AJJZ4N/7Atl/6ISij4T/APJLPBv/AGBbL/0QlFAHnP7W/wDyI3hz/sYLf/0TPXznITuNfRf7XH/IjeHP+xgt/wD0TPXzlJ980AOU08GolNPBoAmBp2c1GDTs8UALmuu8AvsuZGIyBXIZrqfANwkWpYlYKrcc+tAHozqHQluO+TWZdZD4Q9q1Jn+RtnzL71mXbBfQ55GKAKMo48yIkHuKxtXuvPAUcY7VpTuc5zx29BWPfRF8noaAKcYyfan8Z9KVePlPWkC5P0oAVl3KR2qBQd2DU+QG9qSQjIPpQA+3zux2NXIjjGeKpwckt2qdDk9aANBW7Yp2DjmoYScGn474/CgB6khvarkTEAc1QU/MPWrRcEYHUUAWmkJGAaiY0xCB160HnIFACZ/H2pCSBilJ49xTGoACxJHalEpHUZpjcfWoySCKAJpJvT8q8/veJ3/3j/Ou0lJ645rir7i4k/3j/OgCsTTWPFKTTT7UARtUTU9jTG60ARvVOXmrb9D61Vl70AYfib/jxi/66f0NfV/w0/5M2vP+wLq3/odxXyh4m/48Iv8Arp/Q19X/AA0/5M2vP+wLq3/odxQB8u/Co48RTf8AXs3/AKEtesSPlQo6mvJPheduvzH/AKdm/wDQlr1WI5Jft0FAE2QiBQelMLnNNbnvxULyYHFAEpYAetQyy57imSycdahByeTmgCUEk81Mo7moUHSpQ3GaAJN1KWqLdxTSTQBJnHelAyaiPNPM2xccGgBzMFHNU5Hy3OMUSuT3qDP5UAGcninZx7mmYI6fnTlOPrQA5h1zRxUc8yxDLECsy6vyGKoefagDZMqIuXOBWNqV8rkhPmNUZZ5psKzE+gFPhttwBc8ntQBAFeTn17mhbQHk8/Sr/ktvCAdufamyLhSMZ9aAK8aDI2gDHYVZ2ZUYwfxqoGJZtpAPWrUauyj52GfagBJEzGVOPanrGEKN1XOcDg0sttwD5jcVBLHsX7zA0AaUCwSyKwXkdjUrWsLOXKgsOntWVZO3mhdxYZ5BrZjYYOMcdqAI2A5BFR8K3vUkrAn3phAPUZxQAmFJyacVGODx6GoDkZx0HapUPFAGLryERHFef6p/x8D6V6Jrh/dMB2rzzVf+Pn8KAP0d+E//ACSzwb/2BbL/ANEJRR8J/wDklng3/sC2X/ohKKAPOP2uP+RF8O/9h+3/APRM9fOEn3q+jf2vXWPwD4fdyFQa/AST2/cz184vw5GeaAFU809Tz71EvJp4NAEop4NRA8U8GgB2a0NJlMchIxxWcDVux4Y+tAHcWfiOSODZIu9MfiKmGowzNkMwB6hh3rkYmO4gmp1bBznmgDqXCkAqeKp3QHlnFZ9vcsgIBxnt2qx5yuvXn0oAqtgrz0xUKuVKntTpH4xUfBx6UASthjTT24600HjI79qeoyMZoAkgOIj65qeHgE+tV1Ujkcex70+OQbsY6fpQBoRc8jrUi7j2qG1VmcYq1uwcEHj2oAIUzzinudg4FSfIEGfrn0qqXZ2yRx/OgCdCG6Cn4IHeq8XJHUD61OnH/wBegACknnpSnpwOKUkE0zqeaAGsOO5qIjvipGP0pvWgCvMOMiuL1Li7mH+2a7aZciuK1gYv5/8AezQBRJprdKM+tIelADGPtUbU49KjPvxQA1uhqpJ9KtNVeQc9aAMLxP8A8eMXH/LX+hr6v+Gn/Jm15/2BdW/9DuK+UfFOBYQgnkyZx+Br6u+Gn/Jm15/2BdW/9DuKAPlb4akjXpcd7dv5rXq+0rGq54xzXlfwxGfEMvtbsf1WvT5ZOgzQAO/bIqF2wM9+1HJPPSq7uGOcnAoAUt0x3p8fr2qFfmPf1qUYFAE4bjil3d+tQb+eKUEYzmgCXcKC/FQlhjrTGkwOtAEzS7Riomk55PNQM5/GkU5NAEpJJ74p2AO/NIOB70hbFAChjgjtUcsqoPmYD61BdXcdun3gX9qxbq8aZueAKAJr2ffIQDkGoI0LnJ4HrTIVLuOM5/Wte3t1j+aTG4dB2FAEdta98YB9a0o0SMcAfWo0okYAUANdgCWxVK76FgMZFTTOCetQTnMRB60AVJhskB7HrVyGQbR/KqEu9lHyEhadEd3cg0AaZmXIGRmq91IHIB6ZzVOdWCgq3K80SkkDBzQBbtVC3O4HnbV7IY7uhrItjIr72HBGK0VDEfNgfjQBIeWzmoy5UZPI/lTs9+tNPA9qAHgjOaA+OlQlhtAB4pm7GM/pQBU1psxt6V5/qv8Ax8/hXdaq++MgdMda4bVhi5H0oA/Rz4T/APJLPBv/AGBbL/0QlFHwn/5JZ4N/7Atl/wCiEooA8q/bW/5JZpX/AGGov/RE9fNmjXv27TYZWYGQDZJ/vD/EYNfSf7a3/JLNK/7DUX/oievkXwrffZr/AMhziKf5eezdj/T8aAO1U8VID+dRjr0pwJ9qAJF96epqMU4GgCQfWrVljdxVQVasz83WgDQXhwe1Tq2O9ViRge1SKc4oAmD7TxU3m8dcntVTPHNIHPIoAmBLEc1LwCMHFRRgjnrStkP/AFoAlPAznij3HFQOeR3qRDwKAJ0kyBk80138p1kGfQ0hHy5wcetRythMNnJoAvW16FJ4OfT1qx50twxx8kfcnrWVboyP17ZyKvxN+7PU7u460AWWkZnVQ+cdyOtWEBIGRg96rW5zF/eFWYzgAZOKAJY1IIIqQgYBpsbcDHSpAQeDzQBG9M3468/WpWA7VE69cGgAznvmk+lM6c5NBYkEZxQBHMRj371xuujGoSjHUg8fSuwkHWuR8RDGoP7qv8qAMrI5pG6e9Ic0hNADGPNMJpzfSmHvzQA01Cw7VKTVHV7v7FYyTA/OflT/AHj/AIdaAOZ8SXQn1AxocpCNg+vf9f5V9f8Aw0/5M2vP+wLq3/odxXxWTkkmvtT4af8AJm15/wBgXVv/AEO4oA+WPhmSNemwOfs7f+hLXpjDAyTXmnwx/wCQ/P8A9ezfzWvR5XABNAEdxLgY9etVmccAVDNLkk5psb45oAtqdox39KXfxiq2/ml3jNAFgtzQG49ag35NODDuM0ASk8c1GxNNZyeucVEz88UAScg+9TR8cnrVVXyaR3kIxHz9KALckgUZOBWRdaiGBEZwP1pl1MQu1xgnrmsyZ97fKKACSXcc5NLEGkbpSiB8qNpJPYVt2Vh5Sq8g+f09KAGWlv5Q3Py/8qs5JIp8iDtxURbaMHrQBIWIFRu2RimM/X0qNmwOPyoAC3fpTGbccntQeRURRDywye+aAHF1UckCqRcBiFanysqk7EApinJJxzmgBxl+bkN09KbHKCmDnjjpTm+/kAYxzRGcZyMMaAJre4TZgnp6ir8cgePg8DislZSGPNW4pSQQKALO/BHNNZvl61BuJznrQJPlxQA4t1+lRyybVxnk96GbJNVJpfnNAC3QHk546VxOtDF2P92uqubj5SO1ctrRzcqf9n+poA/Rn4T/APJLPBv/AGBbL/0QlFHwn/5JZ4N/7Atl/wCiEooA8q/bW/5JZpX/AGGov/RE9fFYJByDg19qftrf8ks0r/sNRf8AoieviqgD0DRb/wDtCxSUkeavyyD39fx/xrQHvXAaHqB0++VyT5LfLIB6ev1Fd6jBlDIQysAQw6EGgCQGpAf0qEU8H1oAlFWrI/PVIGrdl940AX88U5W+Xmot3HvRGd3FAE4+Y4FSxpkiiGOrSqAKAHBfkz6CkZVK5zTg+FPuKjYAqFz060AAiDDcpwewp0Qwo4waUZ6Io6c0iuMlRjPc+lAE6sD97hF/Imqx+ffIV4P3ee1R3E8eQinCL97HVvaq8s7SfLjCenqKALKOdoJ+VOmfWrUUhYhY+nX6VQjYysoC9sVct0kU45wKAL0WFA25waso2QMHmqYYn2xUiMR3oAvI3FSA5qokg6VKGoAtKR2HP0oYBunX0qAPgYzzQrehFACuvBqFlwDVjIx6mq8z4UmgCFn4Oelct4mAF2hA4MY/ma6SQll5OK53xKp82I9tp/nQBhN1pO3WkPXnrSZ4oAa36000rd6afSgBOvHWuM8SX4u7zy4yDDDlVI/iPc/0rd8Raj9itPKiP+kTDA/2V7n+n51xVABX2r8NP+TNrz/sC6t/6HcV8VV9q/DT/kza8/7Aurf+h3FAHyv8NHVdemDMAWt2CgnknIOB+AP5V3t7J8u0d68atp5La4jngcpLGwZWHYivUNP1OPVrFLmPAcja6D+Fscj6elAEkjZ4H0pQ3b261CThj7Uzfz2oAteZShx+FVg+akX9aAJ1Y5wDUm7tVfdgfjS78A80ASSv71GT8uWqNTvb+tJKd8iqDjHegCVWd/lYBQeg9qV5GhQhJDk9ABUWdnLZ9verFrGS244/GgDNmgaX7xJkPb0qzb6UWVSx2+pq5Mw3fLT7eXIxQBLDbxREFQCfU1KcdqUMAvX60wKN2aAGMM9QDVO5A7VfkqhcHrigCAMMimSt8wxTM801jk560APB5NRTPsH1pMkgc0kgzHigCk7O3O7vTos7hlsUgI3EHoaRWwx9jQBYK56sc0x0O0nec01peDgjmoY7hmZlfj0oAhkMgY4bOPWr9tI7Juxg1VyBvz161atiPIUe1AE+84B7GkJx7fWkJ4pkhwDzQAPLt+hrMnn+YkGpLibnGazZHLNxQAsshduDWRq+BOgB/h/rWlI6wRNI/QdvX2rBmkaWRnc5ZjmgD9J/hP8A8ks8G/8AYFsv/RCUUfCf/klng3/sC2X/AKISigDyr9tb/klmlf8AYai/9ET18VV9q/trf8ks0r/sNRf+iJ6+KqACun8K6pgrY3DcE/umJ6H+7XMUoJBBBwRQB6f0pwJrD8Paut7GsFw2LpR1J/1g9frW2KAH1atDgnnmqlWbbkmgC4GzUkLAE561XBweDmgSgGgDUjlUdDUhuFx1rJWX3oMnvQBoNcgkY5AphumDZGBmqJk5pC5NAF17p2HLYHoKiaZm4BwKr5yacgyRQBMhOflFPVWYjn60sGBweCasEYyPUdaAJYCEk9sdBWjG2QCKyw2DxVuB8Ac0AW2XJBHWgN68GgHig4Ye9AEgODTxKR9KrbirYY9e9Pz+VAFjcD7ino2BzVQPtNSiQP0PNAFneeMUFw3B7VDuxTQ/zUAOkUDJArnvE4Hlwn/eH8jXQscgEVieJQGs427h/wCYNAHI55NGaRutA6UAITzzVa+uorK1eeY5VegHVj2AqaaRIo2klcJGoyzHsK4XWtSfUbndjbCmRGvoPU+9AFW8uZLu5eeY5dz26D2FQUUUAFfavw0/5M2vP+wLq3/odxXxVX2r8NP+TNrz/sC6t/6HcUAfFVamgao2mXgY5MD4Eij09fqKy6KAPU1dJYg6MGVhuBHcdjUTfSuQ8N6z9kb7NcsfIY/KxP3D/hXYAh8FTke1AADkYp6selMCnvwPWlJAGPSgB4JP1pWfj+lQl/rRk49/5UAJPK0S8AZJ/KqVxdmQhQenpxVpxuG1ulVhYzNICoGPXNAFzToGYiSVmB/hzWuP3adiaq2pZIgr44/GnNJ83Ofp60AMldgfmAx2pbeT5vUdqgu33YpLfOckkUAayNwakHWqaSdgamWXBFAD5zwKyrqQhiK0ZXyuayJyTITQA0vik3DFRMccU3dzxQBLkUrMNucCoN1DPgYJoAiZdxNROpSpWYDnIqF5VYYz0NADg3yHNQg5KE985xT8jaeRULFQvXofzoAdIMkGr9tgQgEZIqiWBXrT0uAqgZ5HSgC9I4A61Qnn60TXG4ZBqjI+49SaAGyOWNNA9cD3NAGazdTu8kwxH5f4iO/tQBBf3PnyYX/Vr0Hr71UoooA/Sr4T/wDJLPBv/YFsv/RCUUfCf/klng3/ALAtl/6ISigDyr9tb/klmlf9hqL/ANET18VV9q/trf8AJLNK/wCw1F/6Inr4qoAKKKKAHxSPFIskTFXU5UjqDXc6HrEeooI5SqXY4K9N/uv+FcHTkZkdWQlWU5BHUGgD1D8KmhbaDXOaFryXYWC8Kx3PAV+gkP8AQ10AGPqKAJvMPTNANRrSj2oAlBpcn6U1BnHFTxxlm56UAMFOGO9TCMD3ppKq2WA9KAEFTRJk88U3cBzgUK+DzQBdQKMe1SHBqsrHFKGO7HrQBMP4sdKtQ8LjrVHJ/OrULHbjnigC0pIXrxT1c+tQKT3p+cdKAJiwZcGo95U+q0zcc0bvxoAk356HigOcnFQHK8r0pQ2RkdaALQl6ZpN/PGKrbj7Uoc55oAt5yvzNxWfruDpzY7Op/WrakYzVPVfm0+4GBwM/rQBxzcHtTZJEijaSVwkajLMegpmoXENpG0tw4RAcepPsB3ridY1aXUZCvKW6nKx/1PqaAH67q76jLsjylsp+VfX3NZNFFABRRRQAV9q/DT/kza8/7Aurf+h3FfFVfavw0/5M2vP+wLq3/odxQB8VUUUUAFdL4c1sRBba9fCAYSQ/w+x9q5qigD1NnDLx07VXYnpXI6HrbWoW3uSWhzhX7p/iK6uJlmQOjBlYZBHQ0AKD0pwNMPAppOKAHseKtRHCis7dzU6ycAUAXlc9uacRuGapI+CDU/nAgjNAEU7FhgU1XIAFMlkUscHjvULPk0AaUUmT1pzT7fc1QinC8Gpi4fBoAn+0EqQapSScnNOkbbUDnnPagBGbJ4phNIx9qZu55oAkzS9evNQ7hmn7sUANlRdh45quRgkccinyyEjFQnKsvpQBOgyO1P8ALBypA9KjhPIzT5JUXG88UAMdPLJB6VWkbHSprqQMBt6DpVEsSaAHM56U0ZP1pOgPbHrWZfX27McBIXoW9fpQA/UL3GYoG9mYfyFZdFFABRRRQB+lXwn/AOSWeDf+wLZf+iEoo+E//JLPBv8A2BbL/wBEJRQB5V+2t/ySzSv+w1F/6Inr4qr7V/bW/wCSWaV/2Gov/RE9fFVABRRRQAUUUUALXSaJ4keALBqBaSIcCQcsv19RXNUUAeq27x3EIlhkV4j0ZTkGrKx9M8CvLtM1O602YSWsmB3RuVb6iu50nxPZ35CT/wCiz+jt8h+jf40Ab6oF+7waeCe/Smbsde9LvoAfvFNchuuDTN1JxjFACxgA8dO1OGCfYVFyP8acHAoAtRmlJ5zUKyelKZMg8UAWVzkHOasxk5rPEowMmp45Ae9AF4N0pd9VvMzzQJPegCzupN1V9/pSh/zoAsbvc/jTG4OV6+lR78UCTmgCVXDexpQeetV2OeRVW+1S006LzL+4SEdgeWb6DqaANZWx9K5zxV4mstKhmt2bz7xlKiFD93/fPb6da5PxB45ubndDpINrB080/wCsYf8Aso+nPvXFsSzEsSSTkk96ALOoX09/OZbl9zdgOij0AqrRRQAUUUUAFFFFABX2r8NP+TNrz/sC6t/6HcV8VV9q/DT/AJM2vP8AsC6t/wCh3FAHxVRRRQAUUUUAFaWk6tPp74Hzwn70ZP8AL0NZtFAHoFnf299FvgfJA+ZD95fwp78ZrgIpZIZA8TsjjoVODW9Za8GAS8XDdPMXv9RQBuE/nSeZimI6yKGjYOp6MpyKaxI4PbvQBMZWI4NLuJ71WDZNPDe9AE26k3d81FuPWk3UATA9qdkjoSKgDetODUATA+pNI54qPJpjMRigBzGmAg01mpgNAExoHzDFRhqch60ANc4IyOlJIRgEYzmkkYFxn05qM4zgcGgCZD3FQ3HzdTTN+3pUM0owWYgAdz0oANxKn2qGaZIVJkbA7DufpVO41ALxByf7x6VnSO0jFnYsx7mgCe7vHn+UfLH2Ud/rVWiigAooooAKKKKAP0q+E/8AySzwb/2BbL/0QlFHwn/5JZ4N/wCwLZf+iEooA8q/bW/5JZpX/Yai/wDRE9fFVfpp418HaF430qLTfE9j9usophcJH50kWJArKDlGB6MwxnHNcV/wz58MP+hZ/wDJ+6/+OUAfAFFff/8Awz58MP8AoWf/ACfuv/jlH/DPnww/6Fn/AMn7r/45QB8AUV9//wDDPnww/wChZ/8AJ+6/+OUf8M+fDD/oWf8Ayfuv/jlAHwBRX3//AMM+fDD/AKFn/wAn7r/45R/wz58MP+hZ/wDJ+6/+OUAfAFFff/8Awz58MP8AoWf/ACfuv/jlH/DPnww/6Fn/AMn7r/45QB8K6Xrt9pwCwy74f+eUnzL+Hp+FdVp3iyyuNq3Qa1k7k/Mh/HqK+wP+GfPhh/0LP/k/df8Axyj/AIZ8+GH/AELP/k/df/HKAPlQanYf8/1t/wB/BR/adj/z/W3/AH9FfVf/AAz58MP+hZ/8n7r/AOOUf8M+fDD/AKFn/wAn7r/45QB8pnU7A/8AL7bf9/RTl1Ow/wCf62/7+ivqr/hnz4Yf9Cz/AOT91/8AHKP+GfPhh/0LP/k/df8AxygD5aXU9OI/4/7Uf9tRSHUtP/5/7XH/AF1FfU3/AAz58MP+hZ/8n7r/AOOUf8M+fDD/AKFn/wAn7r/45QB8sf2rYdDfWv8A39FSQ6rp4PN/a/8Af0V9R/8ADPnww/6Fn/yfuv8A45R/wz58MP8AoWf/ACfuv/jlAHzGur6d/wBBC0/7+rS/2vp3/QQtP+/y19N/8M+fDD/oWf8Ayfuv/jlH/DPnww/6Fn/yfuv/AI5QB8yf2xp3/QQtP+/y0o1jTh/zELT/AL/LX01/wz58Mf8AoWf/ACfuv/jlH/DPnww/6Fn/AMn7r/45QB8zf2zpv/QQtP8Av6Kr3fiLSrSPfJexP6LEd7H8B/WvqH/hnz4Yf9Cz/wCT91/8co/4Z8+GH/Qs/wDk/df/ABygD401bxzcSho9LhFup/5avhn/AAHQfrXIXE8tzM0txI8sjclnOSa++v8Ahnz4Yf8AQs/+T91/8co/4Z8+GH/Qs/8Ak/df/HKAPgCivv8A/wCGfPhh/wBCz/5P3X/xyj/hnz4Yf9Cz/wCT91/8coA+AKK+/wD/AIZ8+GH/AELP/k/df/HKP+GfPhh/0LP/AJP3X/xygD4Aor7/AP8Ahnz4Yf8AQs/+T91/8co/4Z8+GH/Qs/8Ak/df/HKAPgCivv8A/wCGfPhh/wBCz/5P3X/xyj/hnz4Yf9Cz/wCT91/8coA+AK+1fhp/yZtef9gXVv8A0O4rqv8Ahnz4Yf8AQs/+T91/8crtdM8HaFpng1/CljY+VoDwzW7WvnSNmOUsZBvLFud7c5yM8YoA/Muivv8A/wCGfPhh/wBCz/5P3X/xyj/hnz4Yf9Cz/wCT91/8coA+AKK+/wD/AIZ8+GH/AELP/k/df/HKP+GfPhh/0LP/AJP3X/xygD4Aor7/AP8Ahnz4Yf8AQs/+T91/8co/4Z8+GH/Qs/8Ak/df/HKAPgCivv8A/wCGfPhh/wBCz/5P3X/xyj/hnz4Yf9Cz/wCT91/8coA+Bra5mtn3QyFT6Doa0xrspUb4Y2b1yRX3N/wz58MP+hZ/8n7r/wCOUf8ADPnww/6Fn/yfuv8A45QB8M/24/8Az7p/30aP7df/AJ4J/wB9Gvub/hnz4Yf9Cz/5P3X/AMco/wCGfPhh/wBCz/5P3X/xygD4Z/t1/wDngn/fRo/tyT/ngn/fRr7m/wCGfPhh/wBCz/5P3X/xyj/hnz4Yf9Cz/wCT91/8coA+GRrsgH+oT/vo0f26+f8AUJ/30a+5v+GfPhh/0LP/AJP3X/xyj/hnz4Yf9Cz/AOT91/8AHKAPhr+3pMY8hPzNNOuOf+WCfma+5/8Ahnz4Yf8AQs/+T91/8co/4Z8+GH/Qs/8Ak/df/HKAPhf+23/54p+Zo/tp/wDnin5mvuj/AIZ8+GH/AELP/k/df/HKP+GfPhh/0LP/AJP3X/xygD4X/tp/+eKfmaUa44/5YJ+Zr7n/AOGfPhh/0LP/AJP3X/xyj/hnz4Yf9Cz/AOT91/8AHKAPhY6y5OTCufqaYdWcnPlL+Zr7s/4Z8+GH/Qs/+T91/wDHKP8Ahnz4Yf8AQs/+T91/8coA+EW1NyOI1B9cmqU0zzNmRifbsK++/wDhnz4Yf9Cz/wCT91/8co/4Z8+GH/Qs/wDk/df/ABygD4Aor7//AOGfPhh/0LP/AJP3X/xyj/hnz4Yf9Cz/AOT91/8AHKAPgCivv/8A4Z8+GH/Qs/8Ak/df/HKP+GfPhh/0LP8A5P3X/wAcoA+AKK+//wDhnz4Yf9Cz/wCT91/8co/4Z8+GH/Qs/wDk/df/ABygD4Aor7//AOGfPhh/0LP/AJP3X/xyj/hnz4Yf9Cz/AOT91/8AHKAOr+E//JLPBv8A2BbL/wBEJRXQaTp9rpGlWem6fF5NlZwpbwR7i2yNFCqMkknAA5JzRQB//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This UGI series shows a contained distal esophageal perforation that occurred during placement of an LAGB. The band was removed and the abdominal cavity drained.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Raul J Rosenthal, MD, FACS, FASMBS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_9_7313=[""].join("\n");
var outline_f7_9_7313=null;
var title_f7_9_7314="Pediculosis corporis";
var content_f7_9_7314=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F76190&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F76190&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pediculosis corporis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 256px; height: 392px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Body lice infestation of long duration can lead to hyperpigmentation and excoriations. Lesions tend to be concentrated in areas where clothing seams contact the skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John T Crissey, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_9_7314=[""].join("\n");
var outline_f7_9_7314=null;
var title_f7_9_7315="Bedwetting in children";
var content_f7_9_7315=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Bedwetting in children (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?7/9/7315/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/9/7315/contributors\" id=\"au4584\">",
"       Jan E Drutz, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/9/7315/contributors\" id=\"au1293\">",
"       Naiwen D Tu, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?7/9/7315/contributors\">",
"       Section Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/9/7315/contributors\" id=\"se4794\">",
"       Teresa K Duryea, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/9/7315/contributors\" id=\"se6027\">",
"       Laurence S Baskin, MD, FAAP",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?7/9/7315/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/9/7315/contributors\" id=\"de5754\">",
"       Mary M Torchia, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?7/9/7315?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      BEDWETTING OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Bedwetting (also called nighttime or nocturnal enuresis) is a common childhood problem. Children learn to control daytime urination as they become aware of their bladder filling. Once this occurs, the child then learns to consciously control and coordinate his or her bladder. This generally occurs by four years of age. Nighttime bladder control usually takes longer and is not expected until a child is between five and seven years old. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?42/45/43730?source=see_link\">",
"      \"Patient information: Toilet training (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The number of children with bedwetting varies by age; at five years of age, 16 percent of children have some difficulty staying dry at night. By 15 years of age, only 1 to 2 percent continue to wet the bed. Boys are twice as likely as girls to wet the bed.",
"    </p>",
"    <p>",
"     For most children, bedwetting resolves on its own without treatment. However, parents and children may worry about bedwetting since it is embarrassing and inconvenient. Some parents may also worry about underlying medical problems.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      BEDWETTING CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     Bedwetting may be related to one or more of the following:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       The child's bladder is maturing more slowly than usual",
"      </li>",
"      <li>",
"       The child's bladder holds a smaller-than-normal amount of urine",
"      </li>",
"      <li>",
"       Genetics; parents who had enuresis as children are more likely to have children with enuresis",
"      </li>",
"      <li>",
"       Diminished levels of vasopressin (a hormone that reduces urine production)",
"      </li>",
"      <li>",
"       Deep sleep that prevents a child from sensing bladder fullness (this theory is controversial)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Physical or emotional problems rarely cause bedwetting. Most children with bedwetting do not have an underlying medical problem. Medical problems that may contribute to bedwetting include diabetes, urinary tract infection, fecal soiling (encopresis), pin worms, kidney failure, seizures, and sleep problems (such as sleep apnea). Most of these conditions can be diagnosed easily.",
"    </p>",
"    <p>",
"     Constipation, a common problem in children, can also cause bedwetting. If your child's bowel movements are infrequent, you should mention this to your child's healthcare provider. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/7/15477?source=see_link\">",
"      \"Patient information: Constipation in infants and children (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      BEDWETTING DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     The age at which enuresis is considered a &ldquo;problem&rdquo; depends on when the child develops bladder control and the perspective of the parents:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       A parent who had enuresis as a child may not be concerned about his or her six-year-old with enuresis.",
"      </li>",
"      <li>",
"       Parents of a four-year-old with enuresis may worry because their older child was dry at age three.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     For most children, enuresis is a problem when it interferes with their ability to socialize with friends. However, it is understandable for parents to want reassurance that their child's bedwetting is not caused by an underlying medical problem.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      History",
"     </span>",
"     &nbsp;&mdash;&nbsp;Important points for you to mention when discussing bedwetting with a healthcare provider include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Problems with daytime accidents",
"      </li>",
"      <li>",
"       Periods of dryness",
"      </li>",
"      <li>",
"       Family history of bedwetting",
"      </li>",
"      <li>",
"       Frequency of wetting episodes",
"      </li>",
"      <li>",
"       Whether your child snores",
"      </li>",
"      <li>",
"       The impact of the problem on the child and family",
"      </li>",
"      <li>",
"       What treatments have been tried",
"      </li>",
"      <li>",
"       Unstable-family issues",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     It is also useful to record a 24-hour diary of how much the child drinks and how much urine",
"     <span class=\"nowrap\">",
"      s/he",
"     </span>",
"     passes. This includes recording the time and amount of fluids your child drinks, as well as the number of times the child urinates, including the amount urinated, if possible (",
"     <a class=\"graphic graphic_figure graphicRef63359 \" href=\"UTD.htm?36/34/37420\">",
"      figure 1",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Urinalysis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Urinalysis is a screening test for underlying medical problems. It requires testing a small sample of a child's urine. Urinalysis can usually be done in the clinician's office.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Further testing and referral",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most children who have bedwetting do not need further testing or referral. However, a child with who has daytime bladder problems or abnormal findings on urinalysis or physical examination may need further testing.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      BEDWETTING TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Initial treatment of bedwetting includes education and motivational therapy. Behavioral alarms or medication may be tried if enuresis does not improve with these interventions.",
"    </p>",
"    <p>",
"     Before beginning treatment, it is important to consider how ready and able your child is to participate in the process. Both you and your child must be motivated. If your child is not mature enough to assume some responsibility for treatment,",
"     <span class=\"nowrap\">",
"      s/he",
"     </span>",
"     should not be forced to do so.",
"    </p>",
"    <p>",
"     Treatment is often prolonged and may involve cycles of success and failure. Treatment should include consistent follow-up with a clinician (approximately every four months).",
"    </p>",
"    <p>",
"     Parents must understand that bedwetting is completely involuntary and that a child should never be punished for wetting episodes. Spanking and verbal scolding do not improve a child's ability to stay dry.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      When to seek help",
"     </span>",
"     &nbsp;&mdash;&nbsp;You should speak with your child's healthcare provider if your child has difficulty with needing to urinate frequently or urgently, extreme thirst during the day, burning with urination, swelling in the feet or ankles, or a new problem with bedwetting after weeks or months of being dry. These may be signs of a more serious condition that should be evaluated before any enuresis treatment is attempted.",
"    </p>",
"    <p>",
"     If your child does",
"     <strong>",
"      NOT",
"     </strong>",
"     have the above problems, you may seek medical advice at any time, or you may try following the general advice or motivational therapy techniques described below. Motivational therapy techniques are best suited to younger children with enuresis. Most clinicians do not suggest alarm devices or medications until a child is at least seven years old.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H366030640\">",
"     <span class=\"h2\">",
"      Bedwetting education and advice",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Bedwetting is common; it occurs at least once per week in 16 percent of five-year olds.",
"      </li>",
"      <li>",
"       Bedwetting goes away on its own in most children.",
"      </li>",
"      <li>",
"       Bedwetting is not the child&rsquo;s fault; children should not be punished for bedwetting.",
"      </li>",
"      <li>",
"       Encourage the child to urinate regularly during the day and just before going to bed (a total of four to seven times). If the child wakes at night, take",
"       <span class=\"nowrap\">",
"        him/her",
"       </span>",
"       to the toilet.",
"      </li>",
"      <li>",
"       Avoid sugary and caffeine-containing drinks, especially in the evening.",
"      </li>",
"      <li>",
"       It may be helpful to have the child drink most of his or her fluids in the morning and early afternoon to prevent overfilling of the bladder during the night. Before trying this, keep a diary of the amount of fluids your child drinks in a 24-hour period (",
"       <a class=\"graphic graphic_figure graphicRef63359 \" href=\"UTD.htm?36/34/37420\">",
"        figure 1",
"       </a>",
"       ). Based on the total, you can create a schedule to spread fluids through the morning, afternoon, and evening. One recommendation is to offer 40 percent of fluids in the morning, 40 percent in the afternoon, and only 20 percent in the evening. For example, if a child generally consumes 32 ounces in 24 hours, the parent should offer 13 ounces (about 40 percent) in the morning, 13 ounces (about 40 percent) in the afternoon, and 6 ounces (about 20 percent) in the evening.",
"      </li>",
"      <li>",
"       Remind the child every night to get out of bed and use the toilet when",
"       <span class=\"nowrap\">",
"        s/he",
"       </span>",
"       needs to urinate. Also remind the child to empty his or her bladder immediately before bedtime.",
"      </li>",
"      <li>",
"       Help the child locate the toilet easily by using night lights in the bathroom and hallway. Consider placing a portable potty seat in the child's room if the toilet is far from the child's bedroom.",
"      </li>",
"      <li>",
"       Stop using diapers, training pants, or pull-up pants at home since these may prevent a child from wanting to get out of bed, especially if the child is older than eight years. They may be used for special occasions, such as overnight visits with family or friends.",
"      </li>",
"      <li>",
"       Protect the child's mattress with a waterproof sheet to avoid urine odor.",
"      </li>",
"      <li>",
"       After wetting accidents during the night, encourage the child to go to the bathroom before changing into dry pajamas. You can place a dry towel over the wet part of the bed, or you can make the bed in several layers, alternating a fitted sheet with a waterproof pad; this allows you",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       the child to quickly and easily remove the wet items and avoids the need to re-make the bed. Leave dry pajamas and towels out so that a child can find them easily.",
"      </li>",
"      <li>",
"       Ask the child to help with morning bed clean-up, including removing and washing bed sheets. Also ensure that the child showers or bathes daily to avoid urine odor on the skin.",
"      </li>",
"      <li>",
"       Do not tease or allow siblings to tease a child who has wet the bed.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Behavior therapy for bedwetting",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h3\">",
"      Motivational therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Motivational therapy involves keeping a record of progress, with bigger rewards for longer periods of dryness. You and the child should agree about the reward in advance and might progress from a sticker on a calendar for each dry night to a favorite book for seven consecutive dry nights.",
"    </p>",
"    <p>",
"     Motivational therapy is a good method to try first for younger children",
"     <strong>",
"      .",
"     </strong>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h3\">",
"      Self-awakening",
"     </span>",
"     &nbsp;&mdash;&nbsp;Self-awakening therapies aim to teach a child how to recognize when the bladder is full during the daytime, in the hopes that",
"     <span class=\"nowrap\">",
"      s/he",
"     </span>",
"     can recognize this feeling during the night. It is most likely to be successful in children over the age of six years [",
"     <a class=\"abstract\" href=\"UTD.htm?7/9/7315/abstract/1\">",
"      1",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     The child should practice a self-awakening routine before bedtime every night. Have the child lie on the bed, pretend it is the middle of the night, and feel that the bladder is full. Ask the child to imagine that his or her bladder is saying, \"Wake up before it's too late.\" The child then goes to the bathroom.",
"    </p>",
"    <p>",
"     The child should also try to practice self-awakening techniques during the daytime. When",
"     <span class=\"nowrap\">",
"      s/he",
"     </span>",
"     feels the urge to go to the bathroom during the daytime,",
"     <span class=\"nowrap\">",
"      s/he",
"     </span>",
"     should be told to go to the bedroom and lie on the bed, and pretend he or she is sleeping. Tell the child to lie still while thinking about the bladder being full and needing to get up. After a brief period of time,",
"     <span class=\"nowrap\">",
"      s/he",
"     </span>",
"     should get up and go to the bathroom to empty.",
"    </p>",
"    <p>",
"     If self-awakening does not work, you may awaken the child at least once during the night. Use the smallest amount of prompting possible; progress from turning on a light, saying the child's name, touching the shoulder or face, gently shaking, or using an alarm. Once awake, the child should get to the bathroom without assistance.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h3\">",
"      Bedwetting alarms",
"     </span>",
"     &nbsp;&mdash;&nbsp;Enuresis alarms are the most effective method for controlling bedwetting. They are typically reserved for children older than seven years of age. Alarms are not generally used first since they are moderately priced and require the child and parent to be highly motivated. You may consider trying alarm therapy after three to six months of other behavioral training techniques, before treatment with medication.",
"    </p>",
"    <p>",
"     Alarms work by using a sensor that detects the first drops of urine in the underwear. When the sensor is activated, it sends a signal to an alarm device, which is intended to wake the child with a sound, light, or vibration. A table of available alarms is provided here (",
"     <a class=\"graphic graphic_table graphicRef60338 \" href=\"UTD.htm?37/14/38124\">",
"      table 1",
"     </a>",
"     ). The alarm helps to train the child to wake up or stop urinating before the alarm goes off.",
"    </p>",
"    <p>",
"     Children should be in charge of their alarm and should test it every night before sleeping. With the sound or vibration in mind, the child should imagine the sequence of events that will occur if the alarm goes off [",
"     <a class=\"abstract\" href=\"UTD.htm?7/9/7315/abstract/1\">",
"      1",
"     </a>",
"     ]:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       The child turns off the alarm, gets up, and finishes urinating in the toilet",
"      </li>",
"      <li>",
"       The child returns to the bedroom, changes his or her bedding and clothing (with a parent's help if needed)",
"      </li>",
"      <li>",
"       The child wipes down or replaces the sensor",
"      </li>",
"      <li>",
"       The child resets the alarm and returns to sleep",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Keep a diary of wet and dry nights. Give positive reinforcement for dry nights and for successful use of the alarm sequence.",
"    </p>",
"    <p>",
"     As alarm therapy begins, some children will not awaken when the alarm goes off. You should wake the child initially, although most children will eventually learn to awaken on their own. It is critical for success of alarm therapy that the child is awake and conscious during the process of going to the bathroom in the middle of the night and not &ldquo;sleepwalking&rdquo; through the experience. Use the alarm continuously until the child has three to four weeks of consecutively dry nights. This usually takes three to four months but can range between five weeks and six months. The alarm sequence can be restarted if bedwetting recurs.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h4\">",
"      Overlearning",
"     </span>",
"     &nbsp;&mdash;&nbsp;Overlearning can help improve the long-term success of enuresis alarms. Overlearning involves use of an enuresis alarm, as described above, until the child is dry for three to four weeks. The child is then allowed to drink 6 ounces",
"     <span class=\"nowrap\">",
"      (3/4",
"     </span>",
"     cup) of water in the hour before bedtime. The child then wears the enuresis alarm to sleep. By filling the bladder, the child's ability to awaken before wetting the bed is challenged, hence the concept of \"overlearning.\"",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h4\">",
"      Alarm clocks",
"     </span>",
"     &nbsp;&mdash;&nbsp;You may use a simple alarm clock to treat bedwetting. It can be set to awaken the child after two to three hours of sleep, whether or not the child is wet or needs to void. The waking time also can be adjusted by determining the time that the child is most likely to have a wetting episode and setting the alarm before this time.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Medication for bedwetting",
"     </span>",
"     &nbsp;&mdash;&nbsp;Desmopressin is a medication that is used to treat bedwetting in children. In most cases, motivational therapy",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     bedwetting alarms are tried for three to six months before desmopressin is considered. Medications can be expensive, have side effects, and have a higher relapse rate than behavioral therapies. Medication and behavioral therapies can be used together.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h3\">",
"      Desmopressin",
"     </span>",
"     &nbsp;&mdash;&nbsp;Desmopressin, also known as DDAVP, is a medication that decreases urine production. It is available as a pill and is taken at bedtime to reduce the amount of urine made during sleep. It is generally recommended for brief periods (eg, overnight camps or sleepovers), although it can be used on a nightly basis.",
"    </p>",
"    <p>",
"     Serious side effects with desmopressin are uncommon but can occur if the child drinks too much fluid before bedtime. For this reason, children should not drink more than 8 ounces (240 milliliters) of fluid after 5 p.m. on nights when desmopressin will be used. The child should not drink any fluid beginning one hour before and eight hours after taking desmopressin.",
"    </p>",
"    <p>",
"     Unfortunately, relapse rates are very high with desmopressin; approximately 60 to 70 percent of children have a return of nocturnal enuresis after stopping the medication.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      Complementary and alternative therapies",
"     </span>",
"     &nbsp;&mdash;&nbsp;Several complementary and alternative therapies have been tried in children with nocturnal enuresis, including acupuncture, chiropractic maneuvers, and hypnosis. However, there are not enough data from scientific studies to know if these therapies are effective. Complementary and alternative treatments are not currently recommended for children with bedwetting.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H22\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your child's healthcare provider is the best source of information for questions and concerns related to your child's medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1804395125\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23445010\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/39/37489?source=see_link\">",
"      Patient information: Bedwetting in children (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/2/21538?source=see_link\">",
"      Patient information: Daytime wetting (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/9/17554?source=see_link\">",
"      Patient information: Night terrors, confusional arousals, and nightmares in children (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23445027\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/7/15477?source=see_link\">",
"      Patient information: Constipation in infants and children (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/21/40281?source=see_link\">",
"      Etiology and evaluation of nocturnal enuresis in children",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/0/7178?source=see_link\">",
"      Management of nocturnal enuresis in children",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/45/37592?source=see_link\">",
"      Toilet training",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Diabetes and Digestive and Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://kidney.niddk.nih.gov/kudiseases/pubs/bedwetting_ez/index.htm\">",
"      file://kidney.niddk.nih.gov/kudiseases/pubs/bedwetting_ez/index.htm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Kidney Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.kidney.org/patients/bw/BWparents.cfm\">",
"      www.kidney.org/patients/bw/BWparents.cfm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Academy of Pediatrics",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.healthychildren.org/english/ages-stages/toddler/toilet-training/pages/default.aspx\">",
"      www.healthychildren.org/English/ages-stages/toddler/toilet-training/Pages/default.aspx",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Kidshealth",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://kidshealth.org/parent/general/sleep/enuresis.html\">",
"      file://kidshealth.org/parent/general/sleep/enuresis.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?7/9/7315/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 9, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?7/9/7315?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     Schmitt BD.. Bed-Wetting (Enuresis).. In: Instructions for Pediatric Patients, Saunders, 1999. p.209.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7315/abstract/2\">",
"      Glazener CM, Evans JH. Simple behavioural and physical interventions for nocturnal enuresis in children. Cochrane Database Syst Rev 2004; :CD003637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7315/abstract/3\">",
"      Glazener CM, Evans JH, Peto RE. Alarm interventions for nocturnal enuresis in children. Cochrane Database Syst Rev 2005; :CD002911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7315/abstract/4\">",
"      Glazener CM, Evans JH. Desmopressin for nocturnal enuresis in children. Cochrane Database Syst Rev 2002; :CD002112.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f7_9_7315=[""].join("\n");
var outline_f7_9_7315=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           BEDWETTING OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           BEDWETTING CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           BEDWETTING DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           BEDWETTING TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H22\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/34/37420\" title=\"figure 1\">",
"           24 hour fluid diary PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?37/14/38124\" title=\"table 1\">",
"           Enuresis alarms PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f7_9_7316="Taliglucerase alfa (glucocerebrosidase): Drug information";
var content_f7_9_7316=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Taliglucerase alfa (glucocerebrosidase): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?22/6/22627?source=see_link\">",
"    see \"Taliglucerase alfa (glucocerebrosidase): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F14279985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Elelyso&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F14264724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Enzyme",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F14286854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Pretreatment with antihistamines and/or corticosteroids can be considered for prevention of subsequent infusion reactions in patients with an infusion reaction requiring symptomatic treatment; during clinical studies, patients were not routinely premedicated prior to infusion. Round up to the next whole vial when determining the number of vials needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Gaucher&rsquo;s disease (type 1):",
"     </b>",
"     I.V.: Initial: 60 units/kg every 2 weeks; dosing is individualized based on disease severity. Dosing range: 11-73 units/kg every 2 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Conversion from imiglucerase:",
"     </i>",
"     Initiate taliglucerase alfa using the patient&rsquo;s same previous imiglucerase dose and administer every 2 weeks.",
"     <b>",
"      Note:",
"     </b>",
"     Conversion to taliglucerase alfa is based on a single study of patients stabilized on a biweekly imiglucerase dose for &ge;6 months.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F14286855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F14286856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F14286857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F14279986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Elelyso&trade;: 200 units [contains polysorbate 80]",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F14286828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product access is restricted to the Gaucher Personal Support (GPS) program. Healthcare providers and patients may obtain additional information by contacting the GPS program at 855-353-5976.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F14286858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Initiate infusion at a rate of 1.3 mL/minute; rate may be increased to 2.3 mL/minute based on patient tolerance and/or a minimal infusion time of 60 minutes (usual infusion time: 60-120 minutes). Administer using a low protein-binding infusion set with a 0.2 micron in-line filter.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F14286891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F14264726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Long-term enzyme replacement therapy for patients with type 1 Gaucher's disease",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F14287277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     &ge;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (11% to 19%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Urinary tract infection/pyelonephritis (9% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (11% to 13%), back pain (3% to 11%), limb pain (&le;11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Upper respiratory tract infection/nasopharyngitis (18% to 22%), pharyngitis (4% to 19%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: IgG antibody formation (14% to 53%), infusion reactions (44% to 46%, including headache [16%], chest discomfort/pain [6%], asthenia [7%], back pain/arthralgia [7%], urticaria [7%], flushing [6%], erythema [5%], fatigue [5%], blood pressure increased [5%]), flu-like syndrome (4% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;2% to &lt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Chest discomfort, flushing, peripheral edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dizziness, fatigue, insomnia, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Erythema, pruritus, rash, skin irritation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, nausea, throat irritation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: ALT increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Infusion site pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Bone pain, muscle spasm, musculoskeletal discomfort/pain, paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Dyspnea, pharyngolaryngeal pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &le;2% (Limited to important or life-threatening): Anaphylaxis, infusion/allergic reactions (including angioedema, wheezing, cough, cyanosis, hypotension)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F14286832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F14286833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Anaphylactic reactions: Use with caution in patients who have exhibited hypersensitivity reactions to taliglucerase alfa or other enzyme replacement therapies. Anaphylaxis has occurred; appropriate medical support should be readily available in the event of a serious reaction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Antibody formation: The development of IgG anti-drug antibodies (ADA) has been reported; the clinical significance is unknown. Patients who develop immune or infusion reactions to taliglucerase alfa or who have had an immune response to other enzyme replacement therapies and who are switching to taliglucerase alfa should be monitored for antibody development; it is unknown if presence of antibodies is related to a higher risk of infusion reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Infusion-related reaction: Infusion-related reactions (eg, headache, chest pain, fatigue, urticaria, arthralgia), including allergic reactions, occurring within 24 hours were the most commonly reported adverse drug reactions in clinical trials. Management strategies for reactions include symptomatic treatment, pretreatment with antihistamines, antipyretics, and/or corticosteroids, and slowing of the infusion rate.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F14395111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F14395109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F14286829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14286830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F14286831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Elelyso Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 unit (1): $714.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F14286867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hemoglobin, platelet count, angiotensin converting enzyme, tartrate-resistant acid phosphatase, chitotriosidase, IgG anti-drug antibody formation (in patients who experience, or previously experienced, immune or infusion reactions to enzyme replacement therapy); liver volume, spleen volume; bone density; ECG, echocardiogram, chest x-ray",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F14286839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Taliglucerase alfa is an analogue of glucocerebrosidase; it is produced by recombinant DNA technology using plant (carrot) cell culture. Glucocerebrosidase is an enzyme deficient in Gaucher's disease. It is needed to catalyze the hydrolysis of glucocerebroside to glucose and ceramide, thereby reducing liver and spleen size and improving anemia and thrombocytopenia.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F14286841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      ss",
"     </sub>",
"     : 7.3-11.7 L (dose-dependent; increased with higher doses)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: 19-29 minutes (dose-dependent; increased with higher doses)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Baldellou A, Andria G, Campbell PE, et al, \"Paediatric Non-Neuronopathic Gaucher Disease: Recommendations for Treatment and Monitoring,\"",
"      <i>",
"       Eur J Pediatr",
"      </i>",
"      , 2004, 163(2):67-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/9/7316/abstract-text/14677062/pubmed\" id=\"14677062\" target=\"_blank\">",
"        14677062",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Charrow J, Andersson HC, Kaplan P, et al, \"Enzyme Replacement Therapy and Monitoring for Children With Type 1 Gaucher Disease: Consensus Recommendations,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2004, 144(1):112-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/9/7316/abstract-text/14722528/pubmed\" id=\"14722528\" target=\"_blank\">",
"        14722528",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jmoudiak M and Futerman AH, \"Gaucher Disease: Pathological Mechanisms and Modern Management,\"",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 2005, 129(2):178-88.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/9/7316/abstract-text/15813845/pubmed\" id=\"15813845\" target=\"_blank\">",
"        15813845",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pastores GM, Weinreb NJ, Aerts H, et al, \"Therapeutic Goals in the Treatment of Gaucher Disease,\"",
"      <i>",
"       Semin Hematol",
"      </i>",
"      , 2004, 41(4 Suppl 5):4-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/9/7316/abstract-text/15468045/pubmed\" id=\"15468045\" target=\"_blank\">",
"        15468045",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weinreb NJ, Aggio MC, Andersson HC, et al, \"Gaucher Disease Type 1: Revised Recommendations on Evaluations and Monitoring for Adult Patients,\"",
"      <i>",
"       Semin Hematol",
"      </i>",
"      , 2004, 41(4 Suppl 5):15-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/9/7316/abstract-text/15468046/pubmed\" id=\"15468046\" target=\"_blank\">",
"        15468046",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zimran A, Brill-Almon E, Chertkoff R, et al, \"Pivotal Trial With Plant Cell-Expressed Recombinant Glucocerebrosidase, Taliglucerase Alfa, a Novel Enzyme Replacement Therapy for Gaucher Disease,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2011, 118(22):5767-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/9/7316/abstract-text/21900191/pubmed\" id=\"21900191\" target=\"_blank\">",
"        21900191",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83880 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.247-9F1D191359-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_9_7316=[""].join("\n");
var outline_f7_9_7316=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14279985\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14264724\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14286854\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14286855\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14286856\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14286857\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14279986\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14286828\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14286858\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14286891\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14264726\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287277\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14286832\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14286833\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14395111\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14395109\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14286829\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14286830\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14286831\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322936\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14286867\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14286839\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14286841\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/83880\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/83880|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?22/6/22627?source=related_link\">",
"      Taliglucerase alfa (glucocerebrosidase): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_9_7317="Clorazepate: Patient drug information";
var content_f7_9_7317=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"13\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Clorazepate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14023?source=see_link\">",
"     see \"Clorazepate: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/39/22134?source=see_link\">",
"     see \"Clorazepate: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F153709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tranxene&reg; T-Tab&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F153710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Clorazepate&reg;;",
"     </li>",
"     <li>",
"      Novo-Clopate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10381164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10017077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691707",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat alcohol withdrawal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691728",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat anxiety.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692054",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat seizures.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10017076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701844",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to clorazepate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703742",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10017081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697180",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for more than 10 days, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10017082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697935",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in balance.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10017084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698512",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If seizures are worse or not the same after starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10017079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695723",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tablet can be crushed and mixed with food or liquid.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695322",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting products: Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10017080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10017085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10017086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12325 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.16.9.173-D52E307D49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_9_7317=[""].join("\n");
var outline_f7_9_7317=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153709\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153710\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10381164\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017077\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017076\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017081\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017082\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017084\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017079\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017080\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017085\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017086\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14023?source=related_link\">",
"      Clorazepate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/39/22134?source=related_link\">",
"      Clorazepate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_9_7318="Structure of immunoglobulins";
var content_f7_9_7318=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Structure of immunoglobulins",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/9/7318/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/9/7318/contributors\">",
"     Francisco A Bonilla, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/9/7318/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/9/7318/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/9/7318/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/9/7318/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/9/7318/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunoglobulin (Ig) molecules are multifunctional tools used by cells to mediate interactions of antigen molecules with a variety of cellular and humoral effector mechanisms. The effector mechanisms include activation of the following systems: signal transduction machinery in the B cell cytoplasm (in the case of surface Ig receptors), receptors for the constant region of IgG, and the complement system. They also play a role in the afferent limb of the immune system both through antigen presentation and by interacting with regulatory receptors on immune cells.",
"   </p>",
"   <p>",
"    The basic aspects of immunoglobulin structure will be reviewed here. A discussion of their function, the derivation of monoclonal antibodies, and the various laboratory and clinical applications of Ig reagents is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/53/40792?source=see_link\">",
"     \"Function and clinical applications of immunoglobulins\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     STRUCTURE OF IMMUNOGLOBULIN PROTEINS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Four-chain unit",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Ig molecule contains four separate polypeptides (",
"    <a class=\"graphic graphic_figure graphicRef56393 \" href=\"UTD.htm?1/2/1071\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Two identical light (L) chains of molecular weight (MW) 23 kilodaltons (kd)",
"     </li>",
"     <li>",
"      Two identical heavy (H) chains of MW around 55 kd",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Each subunit folds into Ig domains [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7318/abstract/1\">",
"     1",
"    </a>",
"    ]. L chains have two domains; H chains have four or five. The domain structures and the complete four-chain unit, (H2L2) are maintained by covalent and non-covalent interactions within and between H and L chains.",
"   </p>",
"   <p>",
"    The variable region of the L chain (VL) is the N (amino)-terminal half of the protein (",
"    <a class=\"graphic graphic_figure graphicRef56393 \" href=\"UTD.htm?1/2/1071\">",
"     figure 1",
"    </a>",
"    ), and is encoded by a V kappa or V lambda gene. The L chain joining region (JL) is a small region at the C (carboxy)-terminal end encoded by a separate J kappa or J lambda gene (",
"    <a class=\"graphic graphic_figure graphicRef68398 \" href=\"UTD.htm?12/32/12813\">",
"     figure 2",
"    </a>",
"    ). The L chain constant region (CL) is the C-terminal half of the chain, and is encoded by a C kappa or C lambda gene.",
"   </p>",
"   <p>",
"    Similarly, the H chain variable region (VH) is at the amino-terminal end of the molecule (",
"    <a class=\"graphic graphic_figure graphicRef56393 \" href=\"UTD.htm?1/2/1071\">",
"     figure 1",
"    </a>",
"    ). At the C-terminus of VH is the D (diversity) region, followed by the H chain joining region (JH) region (",
"    <a class=\"graphic graphic_figure graphicRef68398 \" href=\"UTD.htm?12/32/12813\">",
"     figure 2",
"    </a>",
"    ). The H chain constant region (CH) is much larger. The VH, VL, and CL regions all consist of only one domain, while CH contains three or four domains. The domains of the CH region are numbered with CH1 nearest VH, and CH3 or CH4 at the C-terminus (",
"    <a class=\"graphic graphic_figure graphicRef56393 \" href=\"UTD.htm?1/2/1071\">",
"     figure 1",
"    </a>",
"    ). When any Ig is produced as an integral membrane protein by B cells, there is a hydrophobic transmembrane sequence that comes after the last CH region and anchors the Ig into the cell membrane. This sequence is not present on secreted Igs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Combining site",
"    </span>",
"    &nbsp;&mdash;&nbsp;The variable regions of each pair of H and L chains form an antibody combining site, the portion of the antibody that interacts with antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7318/abstract/2\">",
"     2",
"    </a>",
"    ]. Thus a single four-chain Ig molecule contains two combining sites and is said to be bivalent. Within each H or L chain V region amino acid sequence, greater variety of amino acids occurs in certain positions. These highly variable sections are called the hypervariable regions. Between them are the less variable framework regions. The hypervariable regions are juxtaposed in the tertiary protein structure to form the combining site that makes contact with antigen. They are therefore referred to as complementarity-determining regions (CDRs) (",
"    <a class=\"graphic graphic_figure graphicRef68398 \" href=\"UTD.htm?12/32/12813\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Hinge region",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hinge region is between CH1 and CH2 of certain antibody classes (IgG, IgA, and IgD) (",
"    <a class=\"graphic graphic_figure graphicRef56393 \" href=\"UTD.htm?1/2/1071\">",
"     figure 1",
"    </a>",
"    ). This area is more flexible than a standard CH domain. The hinge region permits a single Ig molecule to be able to bind to two sites on one antigen particle or molecule. IgM and IgE possess hinge-like regions at the C terminal end of CH2.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Carbohydrate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibody molecules contain several glycosylation sites distributed in their sequences; these occur mainly on the H chain. Saccharides increase Ig solubility and protect it from enzymatic degradation. Sugars also contribute to several of the biological properties of Ig by influencing interactions with Ig receptors, binding factors, and other serum proteins (such as the complement system) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7318/abstract/3\">",
"     3",
"    </a>",
"    ]. The sialic acid content of H chain oligosaccharides has been implicated in important antiinflammatory mechanisms of IgG. Ig molecules with high sialic acid content have lower affinity for Fc receptors generally, but are thought to interact with a still hypothetical class of &ldquo;regulatory macrophages&rdquo; to suppress inflammation and inflammatory immune responses [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7318/abstract/4\">",
"     4",
"    </a>",
"    ]. Structural features of these saccharides have also been implicated in certain disease processes, such as rheumatoid arthritis, where antibody reactions with other antibodies may be an important pathogenetic mechanism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41210?source=see_link\">",
"     \"Pathogenesis of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     IMMUNOGLOBULIN CLASSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibody H and L chain classes and subclasses are distinguished by major structural differences (eg, four versus five H chain domains, the covalent association of four-chain units to form dimers or pentamers) and by their primary amino acid sequence. As previously mentioned, mammals possess two classes of light chains, kappa and lambda. The proportion of antibodies containing kappa versus lambda light chains varies among species, the ratio is approximately 3:2 in humans.",
"   </p>",
"   <p>",
"    Five major classes of H chains are found in mammals, designed mu, delta, gamma, alpha, and epsilon. These five types of H chain correspond to the five major classes of immunoglobulins, respectively: IgM, IgD, IgG, IgA, and IgE.",
"   </p>",
"   <p>",
"    In humans, IgG is further divided into four subclasses: IgG1, IgG2, IgG3, and IgG4. IgA is subdivided into IgA1 and IgA2. Any heavy chain class or subclass can combine with either light chain class to build the four-chain unit.",
"   </p>",
"   <p>",
"    IgG, IgA, and IgD have three constant region domains; IgM and IgE have four (",
"    <a class=\"graphic graphic_figure graphicRef56393 \" href=\"UTD.htm?1/2/1071\">",
"     figure 1",
"    </a>",
"    ). Various properties of the different antibody classes and subclasses are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef74659 \" href=\"UTD.htm?42/29/43484\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Note that the variable region, which interacts with antigen, is encoded by gene segments that are distinct from those that encode the constant regions. The constant regions determine the various classes of Ig (eg, IgM, IgA or IgG) through the process of class-switch recombination. Because the variable region genes are distinct, antibodies of different classes could have the same variable region. Class-switch recombination occurs during antigen-dependent B cell activation and development and is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37702?source=see_link&amp;anchor=H13#H13\">",
"     \"Immunoglobulin genetics\", section on 'Immunoglobulin class-switching'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     IgG",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgG is the most abundant immunoglobulin and constitutes 75 percent of serum immunoglobulin in an adult human; the concentration is between 500 and 1500",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5 to 15",
"    <span class=\"nowrap\">",
"     g/L).",
"    </span>",
"    IgG is monomeric (H2L2), and has a molecular weight (MW) of 150 kd. IgG is also found throughout internal tissues because of its abundance and relatively small size. The mean half-life of IgG in the blood is 23 days, although this property varies with subclass.",
"   </p>",
"   <p>",
"    IgG subclasses are present in the serum at varying concentrations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IgG1 at 300 to 1000",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3 to 10",
"      <span class=\"nowrap\">",
"       g/L)",
"      </span>",
"     </li>",
"     <li>",
"      IgG2 at 100 to 350",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1 to 3.5",
"      <span class=\"nowrap\">",
"       g/L)",
"      </span>",
"     </li>",
"     <li>",
"      IgG3 at 30 to 100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.3 to 1",
"      <span class=\"nowrap\">",
"       g/L)",
"      </span>",
"     </li>",
"     <li>",
"      IgG4 at 20 to 50",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.2 to 0.5",
"      <span class=\"nowrap\">",
"       g/L)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35078?source=see_link\">",
"     \"IgG subclasses: Physical properties, genetics, and biologic functions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     IgM",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgM occurs as a monomer when located in the B cell membrane, and as a pentamer (H2L2)5 with a MW of 950 kd when secreted. Hexameric forms of IgM have also been observed, but their biological significance is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7318/abstract/5\">",
"     5",
"    </a>",
"    ]. Pentameric IgM is covalently linked by disulfide bonds with a separate molecule called the J chain (which should not be confused with the J regions of Ig H and L chains). The serum concentration of IgM is about 50 to 400",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.5 to 4",
"    <span class=\"nowrap\">",
"     g/L);",
"    </span>",
"    its half-life in the circulation is five days. Because of its size, the majority of IgM is found in the circulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     IgA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The IgA concentration in serum is about 50 to 350",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.5 to 3.5",
"    <span class=\"nowrap\">",
"     g/L),",
"    </span>",
"    but it is the predominant antibody class in secretions. IgA occurs mainly as monomers (MW 160 kd) and as dimers (H2L2)2 held together by the same J chain found in pentameric IgM. IgA has a serum half-life of about six days.",
"   </p>",
"   <p>",
"    IgA has a shorter half-life than IgG, and tremendous quantities are secreted into various body spaces and onto mucosal surfaces (the gut lumen, the pharynx and sinuses, the larger airways, although not the alveoli). As a result, IgA is the isotype with the highest rate of production, although its serum concentration is less than IgG. In a 70 kg adult, approximately 4.5 g of IgA is produced each day, compared with 2.4 g of IgG, and 0.6 g of IgM. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24570?source=see_link&amp;anchor=H2#H2\">",
"     \"Selective IgA deficiency: Clinical manifestations, pathophysiology, and diagnosis\", section on 'Normal biology of IgA'",
"    </a>",
"    .) IgA in the circulation is primarily monomeric.",
"   </p>",
"   <p>",
"    The IgA in secretions, called secretory IgA (SIgA, MW 400 kd) is mostly dimeric; it contains an additional protein, the secretory component (SC, also called the secretory piece), which is synthesized by epithelial cells. SC is a fragment of the epithelial cell poly-Ig receptor (poly-IgR or PIgR) which binds the J chain in polymeric IgA and IgM.",
"   </p>",
"   <p>",
"    IgA, produced by B cells within the mucosa, is taken up as a complex with poly-IgR at the basolateral surfaces of epithelial cells. Poly-IgR undergoes proteolysis at the apical surface where SIgA is secreted. Some pentameric IgM is also secreted in this fashion [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7318/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     IgD",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgD is present at low levels in serum, &lt;10",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (&lt;0.1",
"    <span class=\"nowrap\">",
"     g/L).",
"    </span>",
"    However, along with IgM, IgD is predominant among the surface receptors of mature B cells, where it plays a key role in B cells activation. IgD has MW 170 kd and a serum half-life of three days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     IgE",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgE has the lowest concentration in normal human serum. The concentration is usually expressed as international units (IU); one unit is equivalent to 2.4 ng. Approximately 100",
"    <span class=\"nowrap\">",
"     IU/mL,",
"    </span>",
"    or 250",
"    <span class=\"nowrap\">",
"     &micro;g/L,",
"    </span>",
"    is the upper limit of normal. In disease states such as atopic dermatitis, the IgE concentration can rise proportionally very high (eg, 100-fold or more). IgE has a MW of 190 kd, as it is heavily glycosylated and has 5 CH domains. While it has a short serum half-life of about three days, it plays a prominent role in immune responses to helminth parasites, and in allergic reactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8608107\">",
"    <span class=\"h1\">",
"     ANTIBODY FRAGMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a number of clinical and experimental applications, antibodies are chemically modified to generate reagents with particular properties. The example given here involves chemical modification of IgG, although antibodies of other classes can be similarly altered. These fragments generally have greatly shortened half-lives compared to the native molecule which negatively impacts their therapeutic potential.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8012461\">",
"    <span class=\"h2\">",
"     Papain digestion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The protease papain cleaves the IgG hinge region, yielding three antibody fragments, two of which are identical (",
"    <a class=\"graphic graphic_figure graphicRef56393 \" href=\"UTD.htm?1/2/1071\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7318/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8012447\">",
"    <span class=\"h3\">",
"     Fab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two identical fragments are generated, each bearing one combining site. These fragments are called Fab (antigen-binding), since they react with antigen. A Fab fragment contains a complete L chain, and the VH and CH1 domains of the H chain. Clinical applications of Fab fragments are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/53/40792?source=see_link&amp;anchor=H10#H10\">",
"     \"Function and clinical applications of immunoglobulins\", section on 'Neutralization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8012454\">",
"    <span class=\"h3\">",
"     Fc",
"    </span>",
"    &nbsp;&mdash;&nbsp;The other papain cleavage product is called Fc, an abbreviation for the fragment that is &ldquo;crystallizable.&rdquo; The Fc portion contains the binding site for C1q of the classical complement pathway, although Fc alone cannot bind or activate complement because it is monovalent. The Fc portion of IgG is comprised of the CH2 and CH3 domains. Several distinct receptor systems on leukocytes interact with the Fc of various Ig isotypes (collectively referred to as Fc receptors) and influence a variety of cellular processes influencing both innate and adaptive immune functions. The function and clinical application of the Fc portion of antibody molecules are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/53/40792?source=see_link\">",
"     \"Function and clinical applications of immunoglobulins\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8012482\">",
"    <span class=\"h2\">",
"     Pepsin digestion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pepsin cleaves IgG near the site at which papain acts, but leaves the hinge regions joined, yielding a fragment containing both combining sites. This fragment is called F(ab')2 (\"f-a-b-prime-two\"). Since F(ab')2 is bivalent (has two combining sites), it may bind two particles simultaneously, and agglutinate and precipitate antigens. In contrast, Fab has only one combining site and cannot participate in these reactions. The clinical applications of agglutination and precipitation are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/53/40792?source=see_link\">",
"     \"Function and clinical applications of immunoglobulins\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ANTIGENIC DIFFERENCES AMONG ANTIBODIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;If an antibody is introduced into a foreign host under appropriate conditions, it can elicit a specific immune response, as can any other glycoprotein antigen. This process of generating antibodies to antibodies reveals various types of differences among them. Immunoglobulin molecules have different antigenic determinants, which are defined by their variation among species (isotype), among individuals within a species (allotype) or within an individual (idiotype) (",
"    <a class=\"graphic graphic_figure graphicRef70298 \" href=\"UTD.htm?19/52/20295\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7318/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Isotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term isotype is often used interchangeably with the terms class and subclass. Isotypic determinants are immunoglobulin structures characteristic of a particular class or subclass of antibody H or L chains (",
"    <a class=\"graphic graphic_figure graphicRef70298 \" href=\"UTD.htm?19/52/20295\">",
"     figure 3",
"    </a>",
"    ). Isotypes are defined in relation to H and L chain C (constant) regions only. All isotypes are found among the immunoglobulins of all healthy individuals of a species. Thus, antibodies specific for isotypes are generally observed with immunization of a different species (heterogeneic or xenogeneic immunization) such as human antibodies to horse Ig or to mouse monoclonal antibodies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Allotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some of the genes encoding antibody C regions are polymorphic and thus may differ between individuals. The antigenic determinants distinguishing an antibody of a particular isotype encoded by allele \"a\" from an antibody of the same isotype encoded by allele \"b\" are called allotypic determinants (allotypes) (",
"    <a class=\"graphic graphic_figure graphicRef70298 \" href=\"UTD.htm?19/52/20295\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Allotypes have been defined serologically by examining reactivity patterns of anti-allotypic antisera; they occur in all subclasses of IgG, IgA2, and kappa light chains. Human allotypes are named with a letter and number designating the antibody class and subclass, followed by the letter \"m\" and a number in parentheses, such as G1m(1), A2m(1), and Km(1).",
"   </p>",
"   <p>",
"    Protein sequence data correlate allotypes with particular amino acid residues in certain locations in the H or L chain. Allotype-specific antibodies may be obtained by immunizing an individual of the same species who does not express the allotype (allogeneic immunization). Fortunately, anti-allotypic antibodies are generally not an issue in the therapeutic administration of human Ig.",
"   </p>",
"   <p>",
"    Allotypes may correlate with variations in function or immune responsiveness, such as response to polysaccharide vaccines and atopy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7318/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Mechanisms have not yet been described, but are likely to involve both structural correlates as well as linked elements in the immunoglobulin heavy chain gene complex on chromosome 14.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Idiotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;An idiotype is an antigenic determinant that is located in the variable region of an Ig molecule. The variety of idiotypic determinants, or idiotypes, occurring in one individual is vastly greater than the number of isotypes or allotypes. This is because there are many more V region genes (including D and J) than there are C region genes, which determine the Ig isotypes and allotypes. In addition, immunoglobulin V genes undergo tremendous diversification during B cell development (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37702?source=see_link\">",
"     \"Immunoglobulin genetics\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Idiotypes may be unique to one antibody, may be shared by antibodies with the same or different antigen specificities, may be found in the same or different individuals of a species, and may even be observed on antibodies from different species (",
"    <a class=\"graphic graphic_figure graphicRef70298 \" href=\"UTD.htm?19/52/20295\">",
"     figure 3",
"    </a>",
"    ). It is also possible to obtain antibodies specific for an idiotype (anti-Id antibodies) in the same individual that produced the Id-bearing antibody. Anti-Id antibodies are observed in many natural antibody responses to infection or antigen administration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8608264\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An immunoglobulin (Ig) molecule contains four chains: two light (L) chains and two heavy (H) chains (",
"      <a class=\"graphic graphic_figure graphicRef56393 \" href=\"UTD.htm?1/2/1071\">",
"       figure 1",
"      </a>",
"      ). Each chain is composed of domains. L chains have two domains; H chains have four or five. Each chain also has a variable region on one end, and a constant region on the other. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Four-chain unit'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The variable regions of the H and L chains together form the antibody combining site, which is the portion of the antibody which interacts with antigens and provides the specificity for the antibody&rsquo;s target. A simple four-chain Ig molecule contains two combining sites and is therefore bivalent. Within this combining site, certain areas contain a greater variety of amino acids and are called the hypervariable regions or complementarity-determining regions (CDRs). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Combining site'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antibody H and L chain classes and subclasses are distinguished by major structural differences determined by their primary amino acid sequence. Five major classes of H chains are found in mammals (mu, delta, gamma, alpha, and epsilon). These five types of H chain correspond to the five major classes of immunoglobulins, respectively: IgM, IgD, IgG, IgA, and IgE. In humans, IgG is further divided into four subclasses: IgG1, IgG2, IgG3, and IgG4. IgA is subdivided into IgA1 and IgA2 (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Immunoglobulin classes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The various antibody classes and subclasses have distinct properties based on the effector function associated with their specific Fc sequence (",
"      <a class=\"graphic graphic_table graphicRef74659 \" href=\"UTD.htm?42/29/43484\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Antibody molecules can be chemically modified to yield fragments that can be used in clinical applications, such as Fab (antibody binding), Fc and F(ab')2. F(ab')2 has two combining sites and can be used to agglutinate and precipitate antigens. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/53/40792?source=see_link\">",
"       \"Function and clinical applications of immunoglobulins\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Immunoglobulin molecules have different antigenic determinants, which are defined by their location on the antibody molecule, and their occurrence on antibodies of different classes (",
"      <a class=\"graphic graphic_figure graphicRef70298 \" href=\"UTD.htm?19/52/20295\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7318/abstract/1\">",
"      Edmundson AB, Ely KR, Abola EE, et al. Conformational isomerism, rotational allomerism, and divergent evolution in immunoglobulin light chains. Fed Proc 1976; 35:2119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7318/abstract/2\">",
"      Capra JD, Edmundson AB. The antibody combining site. Sci Am 1977; 236:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7318/abstract/3\">",
"      Raju TS. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol 2008; 20:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7318/abstract/4\">",
"      Nimmerjahn F, Ravetch JV. The antiinflammatory activity of IgG: the intravenous IgG paradox. J Exp Med 2007; 204:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7318/abstract/5\">",
"      Brewer JW, Randall TD, Parkhouse RM, Corley RB. IgM hexamers? Immunol Today 1994; 15:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7318/abstract/6\">",
"      Mostov KE. Transepithelial transport of immunoglobulins. Annu Rev Immunol 1994; 12:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7318/abstract/7\">",
"      PORTER RR. The hydrolysis of rabbit y-globulin and antibodies with crystalline papain. Biochem J 1959; 73:119.",
"     </a>",
"    </li>",
"    <li>",
"     Kabat EA, Wu TT, Perry HM, et al. Sequences of proteins of immunological interest, 5th ed. US Department of Health and Human Services, Public Health Service, National Institutes of Health, NIH Publication No. 91-3242, 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7318/abstract/9\">",
"      Pandey JP. Immunoglobulin GM and KM allotypes and vaccine immunity. Vaccine 2000; 19:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7318/abstract/10\">",
"      Oxelius VA. Immunoglobulin constant heavy G subclass chain genes in asthma and allergy. Immunol Res 2008; 40:179.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3971 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.80.101-F119FB24C4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_9_7318=[""].join("\n");
var outline_f7_9_7318=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8608264\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      STRUCTURE OF IMMUNOGLOBULIN PROTEINS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Four-chain unit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Combining site",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Hinge region",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Carbohydrate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      IMMUNOGLOBULIN CLASSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      IgG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      IgM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      IgA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      IgD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      IgE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8608107\">",
"      ANTIBODY FRAGMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8012461\">",
"      Papain digestion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8012447\">",
"      - Fab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8012454\">",
"      - Fc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8012482\">",
"      Pepsin digestion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ANTIGENIC DIFFERENCES AMONG ANTIBODIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Isotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Allotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Idiotype",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8608264\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/3971\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3971|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/2/1071\" title=\"figure 1\">",
"      Antibody structure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/32/12813\" title=\"figure 2\">",
"      Immunoglobulin variable region",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/52/20295\" title=\"figure 3\">",
"      Differences among antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3971|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/29/43484\" title=\"table 1\">",
"      Features antibody classes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/53/40792?source=related_link\">",
"      Function and clinical applications of immunoglobulins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35078?source=related_link\">",
"      IgG subclasses: Physical properties, genetics, and biologic functions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37702?source=related_link\">",
"      Immunoglobulin genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41210?source=related_link\">",
"      Pathogenesis of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24570?source=related_link\">",
"      Selective IgA deficiency: Clinical manifestations, pathophysiology, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_9_7319="Intracranial dissection with intimal flap";
var content_f7_9_7319=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F55635&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F55635&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 600px\">",
"   <div class=\"ttl\">",
"    Intracranial dissection with intimal flap",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 580px; height: 586px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A, B) Diffusion-weighted sequence of MRI of the brain shows acute infarction in the right middle cerebral artery (MCA) territory.",
"    <br>",
"     (C, D) Catheter angiography showed irregularities of the right supraclinoid internal carotid artery, extending into the M1 segment of the right MCA. An intimal flap (arrow) indicates dissection.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced with permission from: Suter B, El-Hakam LM. Child neurology: stroke due to nontraumatic intracranial dissection in a child. Neurology 2009; 72:e100. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_9_7319=[""].join("\n");
var outline_f7_9_7319=null;
var title_f7_9_7320="Clinical manifestations and diagnosis of chronic thromboembolic pulmonary hypertension";
var content_f7_9_7320=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of chronic thromboembolic pulmonary hypertension",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/9/7320/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/9/7320/contributors\">",
"     Peter F Fedullo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/9/7320/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/9/7320/contributors\">",
"     Jess Mandel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/9/7320/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/9/7320/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/9/7320/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Improvement following acute pulmonary embolism is usually sufficient to restore normal pulmonary hemodynamics, gas exchange, and exercise tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7320/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. However, a minority of patients develop chronic thromboembolic pulmonary hypertension (CTEPH) following an acute pulmonary embolism [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7320/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence, possible etiologies, presentation, clinical features, diagnosis, and differential diagnosis of CTEPH are reviewed here. Treatment of CTEPH is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34293?source=see_link\">",
"     \"Overview of the treatment of chronic thromboembolic pulmonary hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10503?source=see_link\">",
"     \"Chronic thromboembolic pulmonary hypertension: Surgical treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/31/14837?source=see_link\">",
"     \"Chronic thromboembolic pulmonary hypertension: Medical treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of CTEPH is uncertain. A well-done prospective cohort study of 232 patients with pulmonary embolism found that 3.8 percent of patients had evidence of CTEPH within two years. However, this may be an overestimate since other studies have found an incidence among survivors of acute pulmonary embolism of approximately 1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7320/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is unknown why some patients with acute pulmonary embolism develop CTEPH and others do not [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7320/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several studies suggest that an underlying hypercoagulable state may be responsible in some patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Factor VIII: An observational study that included 122 patients with CTEPH and 82 healthy controls found that elevated levels of factor VIII (defined as &gt;230",
"      <span class=\"nowrap\">",
"       IU/dL)",
"      </span>",
"      were more common among patients with CTEPH than controls (41 versus 5 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/9/7320/abstract/7\">",
"       7",
"      </a>",
"      ]. The levels remained elevated after thromboendarterectomy. These findings were supported by a larger observational study that followed 360 patients with venous thromboembolism for a mean of 30 months [",
"      <a class=\"abstract\" href=\"UTD.htm?7/9/7320/abstract/8\">",
"       8",
"      </a>",
"      ]. Patients whose factor VIII levels were above the 90th percentile (&gt;234",
"      <span class=\"nowrap\">",
"       IU/dL)",
"      </span>",
"      had an increased risk of recurrent venous thromboembolism compared to patients with lower levels (37 versus 5 percent).",
"     </li>",
"     <li>",
"      Antiphospholipid antibodies: Another prothrombotic marker, antiphospholipid antibodies, has been identified in 10 to 20 percent of patients with CTEPH [",
"      <a class=\"abstract\" href=\"UTD.htm?7/9/7320/abstract/7,9,10\">",
"       7,9,10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link\">",
"       \"Clinical manifestations of the antiphospholipid syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, not all abnormalities associated with a hypercoagulable state have been associated with CTEPH [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7320/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Activated protein C resistance seems to occur with similar frequency among patients with CTEPH and the general population",
"     </li>",
"     <li>",
"      Less than 1 percent of patients with CTEPH have deficiencies of antithrombin, protein C, or protein S",
"     </li>",
"     <li>",
"      No defect in fibrinolytic activity has been consistently identified",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Alternative hypotheses also exist. One hypothesis postulates that patients who develop CTEPH represent those few patients with pulmonary emboli whose endogenous fibrinolytic mechanisms are overcome by the age, extent, or location of the obstructing embolus. Another hypothesis proposes that patients with CTEPH have fibrin variants that are resistant to plasmin-mediated lysis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7320/abstract/12\">",
"     12",
"    </a>",
"    ]. A final hypothesis suggests that pulmonary arteriopathy or in situ thrombosis may underlie many cases of this syndrome, instead of thromboembolic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7320/abstract/13\">",
"     13",
"    </a>",
"    ]. This is based upon the recognition that animal models of CTEPH are difficult to produce by repeatedly embolizing thrombotic material and that most hypercoagulable states do not appear to confer risk for CTEPH. Most clinicians experienced in the management of CTEPH disagree with this hypothesis, instead favoring a thromboembolic basis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7320/abstract/10,14\">",
"     10,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9358410\">",
"    <span class=\"h2\">",
"     Presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with CTEPH usually present with progressive dyspnea and exercise intolerance. Occasionally, a patient will have waited to seek medical attention despite these symptoms and will report additional symptoms and signs related to right ventricular dysfunction, such as peripheral edema, exertional chest pain, syncope, or near-syncope.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with CTEPH have dyspnea. The dyspnea initially occurs during exertion only, but then progresses to occur at rest and becomes more severe [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7320/abstract/15\">",
"     15",
"    </a>",
"    ]. Dyspnea and exercise intolerance are usually more troubling to patients who are active and, therefore, such patients tend to be evaluated earlier than patients who live a sedentary lifestyle. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16553?source=see_link\">",
"     \"Approach to the patient with dyspnea\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many patients provide a history consistent with an acute pulmonary embolic event (eg, pleuritic chest pain, lower extremity discomfort, or a prolonged atypical pneumonia) months to years prior to the onset of the dyspnea, although documentation of venous thromboembolism may be absent. Alternatively, they may describe a hospitalization or surgical procedure from which they never fully recovered. The absence of a diagnosis of venous thromboembolism is not surprising since venous thrombosis and pulmonary embolism are frequently overlooked in the population at large [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7320/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As the CTEPH progresses, patients may begin to report symptoms or signs related to progressive pulmonary hypertension complicated by right ventricular dysfunction. This may include lower extremity edema, exertional chest pain, near-syncope, or syncope [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7320/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Findings on physical examination may be subtle early in the course of CTEPH. As an example, the only abnormalities may be narrowing of the aortic-pulmonic splitting of the second heart sound or subtle accentuation of the pulmonic component.",
"   </p>",
"   <p>",
"    More obvious physical findings become apparent once significant right ventricular hypertrophy or overt right ventricular failure develops. Findings include a right ventricular lift, jugular venous distension, prominent A and V wave venous pulsations, fixed splitting of the second heart sound, a right ventricular S3, murmurs of tricuspid regurgitation or pulmonic insufficiency, hepatomegaly, ascites, and peripheral edema. The peripheral edema may be a result of chronic lower extremity venous outflow obstruction related to the venous thromboembolic disease or right ventricular failure related to the progressive pulmonary hypertension.",
"   </p>",
"   <p>",
"    A unique physical finding in some patients with CTEPH is the presence of flow murmurs over the lung fields. These subtle bruits appear to originate from turbulent flow through partially obstructed or recanalized pulmonary arteries. They are high pitched and blowing in quality, heard over the lung fields rather than the precordium, accentuated during inspiration, and frequently heard only during periods of breath-holding. They have not been described in patients with other types of pulmonary hypertension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10889851\">",
"    <span class=\"h2\">",
"     Initial evaluation of symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;CTEPH is rarely suspected when a patient presents with progressive dyspnea and exercise intolerance and, therefore, diagnosis is typically delayed [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7320/abstract/17\">",
"     17",
"    </a>",
"    ]. More often, common conditions are suspected (eg, coronary artery disease, cardiomyopathy, chronic obstructive airways disease, asthma, interstitial lung disease, or deconditioning) and the patient is evaluated with echocardiography, pulmonary function testing,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chest radiography. In patients with CTEPH, these studies often suggest pulmonary hypertension:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Echocardiography &ndash; The tricuspid regurgitant velocity and estimated systolic pulmonary artery pressure are usually increased. Right atrial enlargement and right ventricular hypertrophy with reduced systolic function may be apparent (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef82034 \" href=\"UTD.htm?15/5/15455\">",
"       image 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/9/7320/abstract/18\">",
"       18",
"      </a>",
"      ]. There may also be leftward displacement of the septum, which can impair left ventricular filling and performance. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2041?source=see_link&amp;anchor=H6#H6\">",
"       \"Clinical features and diagnosis of pulmonary hypertension in adults\", section on 'Echocardiography'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pulmonary function tests &ndash; Most patients have a reduction in the single breath diffusing capacity for carbon monoxide (DLCO), which is out of proportion to any abnormalities in spirometry. A mild restrictive or obstructive defect may be present, although spirometry is often normal. The restrictive defect may be related to parenchymal scarring [",
"      <a class=\"abstract\" href=\"UTD.htm?7/9/7320/abstract/19\">",
"       19",
"      </a>",
"      ], while the obstructive defect may be due to mucosal hyperemia caused by bronchial arterial collateral circulation. For those patients who have an arterial blood gas performed as part of their pulmonary function tests, an increased alveolar-arterial (A-a) oxygen gradient and a decline in the arterial oxygen tension (PaO",
"      <sub>",
"       2",
"      </sub>",
"      ) with exercise are typical. The resting PaO",
"      <sub>",
"       2",
"      </sub>",
"      may be normal. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2041?source=see_link&amp;anchor=H7#H7\">",
"       \"Clinical features and diagnosis of pulmonary hypertension in adults\", section on 'Pulmonary function tests'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chest radiography &ndash; Chest radiography may demonstrate abnormalities related to either pulmonary embolic disease or pulmonary hypertension (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef69313 \" href=\"UTD.htm?28/29/29140\">",
"       image 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/9/7320/abstract/15,20\">",
"       15,20",
"      </a>",
"      ]. Pulmonary embolic disease may cause areas of hypoperfusion or hyperperfusion, as well as evidence of old unilateral or bilateral pleural disease. Pulmonary hypertension can cause enlargement of both main pulmonary arteries, asymmetry in the size of the central pulmonary arteries, right atrial enlargement, or right ventricular enlargement. Right ventricular enlargement is suggested by encroachment into the normally empty retrosternal space on a lateral radiograph. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2041?source=see_link&amp;anchor=H4#H4\">",
"       \"Clinical features and diagnosis of pulmonary hypertension in adults\", section on 'Chest radiograph'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10889858\">",
"    <span class=\"h2\">",
"     Evaluation of suspected pulmonary hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once pulmonary hypertension becomes suspected, CTEPH should always be considered, particularly among patients with a history of venous thromboembolic disease, symptoms consistent with venous thromboembolic disease, or risk factors for venous thromboembolic disease.",
"   </p>",
"   <p>",
"    Although falling out of favor as a diagnostic technique for acute pulmonary embolism, ventilation-perfusion",
"    <span class=\"nowrap\">",
"     (V/Q)",
"    </span>",
"    lung scanning represents the initial imaging procedure of choice in patients presenting with newly diagnosed pulmonary hypertension. It can differentiate proximal large vessel types of pulmonary hypertension (eg, CTEPH, pulmonary artery sarcoma) from distal small vessel types (eg, group 1 pulmonary arterial hypertension), which are the most common competing diagnostic possibilities [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7320/abstract/21\">",
"     21",
"    </a>",
"    ]. Patients with CTEPH generally have at least one (usually several) segmental or larger mismatched ventilation-perfusion defects, while patients with group 1 pulmonary arterial hypertension usually have a normal or mottled perfusion scan characterized by subsegmental defects.",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     V/Q",
"    </span>",
"    lung scanning is preferred over computed tomographic pulmonary angiography (CT-PA) as the initial test because it detects CTEPH with greater sensitivity. In other words, patients with CTEPH are more likely to have an abnormal",
"    <span class=\"nowrap\">",
"     V/Q",
"    </span>",
"    lung scan than an abnormal CT-PA. This was illustrated by an observational study that included 227 patients with pulmonary hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7320/abstract/22\">",
"     22",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     V/Q",
"    </span>",
"    lung scanning and CT-PA identified CTEPH with a sensitivity of 96 and 51 percent, respectively.",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     V/Q",
"    </span>",
"    lung scanning is imperfect, as it often understates the extent of central pulmonary vascular obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7320/abstract/23\">",
"     23",
"    </a>",
"    ]. Channels through central obstructing lesions or partial flow around them (a result of complex patterns of recanalization and organization that follow an embolic event) allow the radioisotopic agent to reach the periphery of the lung. These areas may appear normal or as hypoperfused gray zones, depending upon the distribution of flow. In addition, there are pulmonary hypertensive disorders other than CTEPH that can also be associated with segmental or larger perfusion defects on",
"    <span class=\"nowrap\">",
"     V/Q",
"    </span>",
"    lung scanning, including pulmonary artery sarcoma, pulmonary veno-occlusive disease, fibrosing mediastinitis, large vessel pulmonary vasculitides, and extrinsic pulmonary vascular compression (arterial or venous).",
"   </p>",
"   <p>",
"    For those patients whose",
"    <span class=\"nowrap\">",
"     V/Q",
"    </span>",
"    lung scanning suggests CTEPH, an additional imaging study is required. Computed tomographic pulmonary angiography (CT-PA) is capable of detecting competing diagnostic possibilities, such as fibrosing mediastinitis. Both right heart catheterization and pulmonary angiography are indicated to confirm pulmonary hypertension, quantify the degree of pulmonary hypertension, exclude competing diagnoses, define the surgical accessibility of the obstructing thrombotic lesions, and confirm that an acceptable component of the elevated pulmonary vascular resistance is due to surgically accessible disease and not from distal obstruction, a secondary arteriopathy, or pulmonary venous hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7320/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Right heart catheterization &ndash; In patients with CTEPH, hemodynamic measurements at rest may demonstrate only a modest degree of pulmonary hypertension. In this situation, the measurements should be repeated after a short period of exercise. Exercise-related increases in cardiac output are accompanied by a disproportionate elevation of the pulmonary artery pressure when the normal compensatory mechanisms of pulmonary artery distension and recruitment are overcome by the chronic thromboembolic obstruction. Thus, pulmonary artery hypertension that is elicited by exercise but not present at rest may be an early indication of CTEPH [",
"      <a class=\"abstract\" href=\"UTD.htm?7/9/7320/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pulmonary angiography &ndash; The angiographic findings in chronic thromboembolic disease bear little resemblance to the sharply defined intraluminal defects seen with acute pulmonary embolism. Five angiographic patterns are associated with the presence of organized thromboembolic material during thromboendarterectomy (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef59507 \" href=\"UTD.htm?32/36/33359\">",
"       image 3",
"      </a>",
"      ): pouch defects, pulmonary artery webs or bands, intimal irregularities, abrupt narrowing of the major pulmonary arteries, and obstruction of lobar or segmental vessels at their origin, with complete absence of blood flow to the pulmonary segments that are normally perfused by those vessels. Biplanar angiography provides a second dimensional viewpoint; the addition of a lateral view to the anterior view improves visualization of the lobar and segmental branches of the pulmonary artery, thereby enhancing interpretation (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef53088 \" href=\"UTD.htm?24/20/24898\">",
"       image 4",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      The safety of performing pulmonary angiography in patients with pulmonary hypertension is a common concern. Many clinicians believe that the vasodilation induced by the contrast agent might induce hypotension. This was addressed in a study that measured pulmonary and systemic hemodynamics during pulmonary angiography [",
"      <a class=\"abstract\" href=\"UTD.htm?7/9/7320/abstract/26\">",
"       26",
"      </a>",
"      ]. Multiple bolus injections of nonionic contrast media did not cause any major adverse hemodynamic effects, even in the presence of severe pulmonary hypertension. All of the patients received supplemental oxygen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pulmonary angioscopy was useful in a few patients in confirming the presence of chronic thromboembolic obstruction and in determining whether the obstruction is accessible to surgical intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7320/abstract/27\">",
"     27",
"    </a>",
"    ]. However, advances in noninvasive imaging techniques have essentially eliminated the need for angioscopy.",
"   </p>",
"   <p>",
"    The pulmonary angioscope is a fiberoptic device that allows intraluminal visualization of the pulmonary arteries to the segmental level (",
"    <a class=\"graphic graphic_picture graphicRef73668 \" href=\"UTD.htm?23/10/23712\">",
"     picture 1",
"    </a>",
"    ). Normal pulmonary arteries have a round or oval contour with a smooth, pale, glistening intima (",
"    <a class=\"graphic graphic_picture graphicRef52629 \" href=\"UTD.htm?37/62/38894\">",
"     picture 2",
"    </a>",
"    ). Bright red blood normally fills the lumen. Organized chronic thromboemboli are characterized by roughening or pitting of the intimal surface, bands and webs across the lumen, pitted masses of chronic embolic material within the lumen, and partial recanalization (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64437 \" href=\"UTD.htm?3/7/3199\">",
"     image 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10889872\">",
"    <span class=\"h2\">",
"     Alternatives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rarely, patients can be diagnosed with presumed CTEPH and referred for surgical correction without right heart catheterization or pulmonary angiography. In such patients, the diagnosis of CTEPH is made on the basis of echocardiographic findings plus either CT-PA or magnetic resonance imaging (MRI) abnormalities.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      CT-PA &ndash; A variety of abnormalities may be seen on CT-PA in patients with CTEPH. These include right ventricular enlargement, chronic thromboembolic material within dilated central pulmonary arteries, bronchial artery collateral flow, and mosaic attenuation of the pulmonary parenchyma [",
"      <a class=\"abstract\" href=\"UTD.htm?7/9/7320/abstract/28,29\">",
"       28,29",
"      </a>",
"      ]. CT-PA was compared to conventional pulmonary angiography in an observational study that evaluated 55 patients who were suspected of having CTEPH [",
"      <a class=\"abstract\" href=\"UTD.htm?7/9/7320/abstract/30\">",
"       30",
"      </a>",
"      ]. Central pulmonary emboli were detected with similar accuracy by CT-PA and conventional pulmonary angiography, although segmental disease was detected more reliably with conventional pulmonary angiography. The limitations of CT-PA include its poor sensitivity in detecting chronic thromboemboli at the segmental level and its inability to differentiate an intraluminal thrombus from a well endothelialized chronic thrombus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      MRI &ndash; MRI and magnetic resonance angiography (MRA) have been used to visualize the pulmonary vascular system in patients with CTEPH [",
"      <a class=\"abstract\" href=\"UTD.htm?7/9/7320/abstract/31\">",
"       31",
"      </a>",
"      ]. MRI can also provide information about right ventricular size and function. However, studies that directly compare MRI and MRA to conventional angiography are limited.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC CRITERIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of CTEPH requires that both of the following criteria be met:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary hypertension must be present, defined as a mean pulmonary arterial pressure (PAP) &ge;25 mmHg at rest in the absence of an elevated pulmonary capillary wedge pressure (ie, PCWP is &le;15 mmHg) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/9/7320/abstract/32\">",
"       32",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2041?source=see_link&amp;anchor=H5397869#H5397869\">",
"       \"Clinical features and diagnosis of pulmonary hypertension in adults\", section on 'Pulmonary hypertension'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Thromboembolic occlusion of the proximal or distal pulmonary vasculature must exist and be the presumed cause of the pulmonary hypertension.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9358616\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;CTEPH presents with progressive dyspnea and exercise intolerance. These symptoms can be caused by many conditions including coronary artery disease, heart failure, chronic obstructive airways disease, asthma, interstitial lung disease, pulmonary hypertension, and deconditioning. The precise cause of the symptoms can usually be determined by history, physical exam, and diagnostic testing, such as pulmonary function tests, echocardiography, electrocardiography,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cardiac stress testing. More than one cause of dyspnea may present, in which case the clinician should try to determine the relative contribution of each. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26521?source=see_link\">",
"     \"Stress testing for the diagnosis of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=see_link\">",
"     \"Evaluation of the patient with suspected heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30954?source=see_link\">",
"     \"Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19482?source=see_link\">",
"     \"Diagnosis of asthma in adolescents and adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16681?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Diagnostic testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2041?source=see_link\">",
"     \"Clinical features and diagnosis of pulmonary hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When the initial diagnostic evaluation indicates that the likely cause of the dyspnea and exercise intolerance is pulmonary hypertension, the various types of pulmonary hypertension become the alternative possible diagnoses. The exact cause of the pulmonary hypertension may be obvious based upon the previous evaluation. As an example, the patient may have known systemic sclerosis or congenital heart disease, suggesting that the pulmonary hypertension is a consequence of these conditions. If the cause of the pulmonary hypertension is not apparent, additional testing is indicated. This may include chest computed tomography, ventilation-perfusion",
"    <span class=\"nowrap\">",
"     (V/Q",
"    </span>",
"    scanning), overnight oximetry, polysomnography, and laboratory testing (eg, HIV serology, liver function tests, and antinuclear antibodies). The diagnostic evaluation of pulmonary hypertension is described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2041?source=see_link\">",
"     \"Clinical features and diagnosis of pulmonary hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/61/39889?source=see_link\">",
"       \"Patient information: Pulmonary hypertension in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Improvement following acute pulmonary embolism is usually sufficient to restore normal pulmonary hemodynamics, gas exchange, and exercise tolerance. However, a minority of patients develop chronic thromboembolic pulmonary hypertension (CTEPH) following a single or recurrent episode of acute pulmonary embolism. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"      <br/>",
"     </li>",
"     <li>",
"      Patients with CTEPH usually present with progressive dyspnea and exercise intolerance. Occasionally, a patient will have waited to seek medical attention despite these symptoms and will report additional symptoms and signs related to pulmonary hypertension with right ventricular dysfunction, such as peripheral edema, exertional chest pain, syncope, or near-syncope. Many patients provide a history consistent with an acute pulmonary embolic event (eg, pleuritic chest pain, lower extremity discomfort, or a prolonged atypical pneumonia) months to years prior to the onset of the dyspnea, although documentation of venous thromboembolism is frequently absent. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"      <br/>",
"     </li>",
"     <li>",
"      CTEPH is rarely suspected when a patient initially presents with progressive dyspnea and exercise intolerance. More often, common conditions are suspected (eg, coronary artery disease, cardiomyopathy, chronic obstructive airways disease, asthma, interstitial lung disease, or deconditioning) and the patient is evaluated with echocardiography, pulmonary function testing,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      chest radiography. In patients with CTEPH, these studies often suggest pulmonary hypertension. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9358616\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"      <br/>",
"     </li>",
"     <li>",
"      Once pulmonary hypertension becomes suspected, CTEPH should always be considered. Ventilation-perfusion",
"      <span class=\"nowrap\">",
"       (V/Q)",
"      </span>",
"      lung scanning represents the initial imaging procedure of choice when CTEPH is being considered; patients with CTEPH generally have at least one (usually several) segmental or larger mismatched ventilation-perfusion defects. For those patients with evidence of CTEPH on",
"      <span class=\"nowrap\">",
"       V/Q",
"      </span>",
"      lung scanning, right heart catheterization and pulmonary angiography are indicated to confirm pulmonary hypertension, quantify the degree of pulmonary hypertension, exclude competing diagnoses, define the surgical accessibility of the obstructing thrombotic lesions, and confirm that an acceptable component of the elevated pulmonary vascular resistance is due to surgically accessible disease and not from distal obstruction or a secondary arteriopathy. On occasion, patients can be referred for surgery based upon echocardiographic findings in conjunction with either computed tomographic pulmonary angiography (CT-PA) or magnetic resonance imaging (MRI) findings. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"      <br/>",
"     </li>",
"     <li>",
"      The diagnosis of CTEPH requires that both of the following criteria be confirmed (see",
"      <a class=\"local\" href=\"#H21\">",
"       'Diagnostic criteria'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Pulmonary hypertension, defined as a mean pulmonary arterial pressure (PAP) &ge;25 mmHg at rest in the absence of an elevated pulmonary capillary wedge pressure (ie, PCWP is &le;15 mmHg).",
"     </li>",
"     <li>",
"      Thromboembolic occlusion of the proximal or distal pulmonary vasculature must exist and be the presumed cause of the pulmonary hypertension.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7320/abstract/1\">",
"      Dartevelle P, Fadel E, Mussot S, et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J 2004; 23:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7320/abstract/2\">",
"      Nijkeuter M, Hovens MM, Davidson BL, Huisman MV. Resolution of thromboemboli in patients with acute pulmonary embolism: a systematic review. Chest 2006; 129:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7320/abstract/3\">",
"      Kearon C. Natural history of venous thromboembolism. Circulation 2003; 107:I22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7320/abstract/4\">",
"      Benotti JR, Ockene IS, Alpert JS, Dalen JE. The clinical profile of unresolved pulmonary embolism. Chest 1983; 84:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7320/abstract/5\">",
"      Klok FA, van Kralingen KW, van Dijk AP, et al. Prospective cardiopulmonary screening program to detect chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embolism. Haematologica 2010; 95:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7320/abstract/6\">",
"      Lang IM, Pesavento R, Bonderman D, Yuan JX. Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a current understanding. Eur Respir J 2013; 41:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7320/abstract/7\">",
"      Bonderman D, Turecek PL, Jakowitsch J, et al. High prevalence of elevated clotting factor VIII in chronic thromboembolic pulmonary hypertension. Thromb Haemost 2003; 90:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7320/abstract/8\">",
"      Kyrle PA, Minar E, Hirschl M, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 2000; 343:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7320/abstract/9\">",
"      Auger WR, Permpikul P, Moser KM. Lupus anticoagulant, heparin use, and thrombocytopenia in patients with chronic thromboembolic pulmonary hypertension: a preliminary report. Am J Med 1995; 99:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7320/abstract/10\">",
"      Wolf M, Boyer-Neumann C, Parent F, et al. Thrombotic risk factors in pulmonary hypertension. Eur Respir J 2000; 15:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7320/abstract/11\">",
"      Sompradeekul, S, Fedullo, PF, Le, DT. Congenital and acquired thrombophilias in patients with chronic thromboembolic pulmonary hypertension. Am J Resp Crit Care Med 1999; 159:A358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7320/abstract/12\">",
"      Morris TA, Marsh JJ, Chiles PG, et al. Fibrin derived from patients with chronic thromboembolic pulmonary hypertension is resistant to lysis. Am J Respir Crit Care Med 2006; 173:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7320/abstract/13\">",
"      Egermayer P, Peacock AJ. Is pulmonary embolism a common cause of chronic pulmonary hypertension? Limitations of the embolic hypothesis. Eur Respir J 2000; 15:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7320/abstract/14\">",
"      Fedullo PF, Rubin LJ, Kerr KM, et al. The natural history of acute and chronic thromboembolic disease: the search for the missing link. Eur Respir J 2000; 15:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7320/abstract/15\">",
"      Moser KM, Auger WR, Fedullo PF. Chronic major-vessel thromboembolic pulmonary hypertension. Circulation 1990; 81:1735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7320/abstract/16\">",
"      Monreal M, Ru&iacute;z J, Olazabal A, et al. Deep venous thrombosis and the risk of pulmonary embolism. A systematic study. Chest 1992; 102:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7320/abstract/17\">",
"      Pepke-Zaba J, Delcroix M, Lang I, et al. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation 2011; 124:1973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7320/abstract/18\">",
"      Raisinghani A, Ben-Yehuda O. Echocardiography in chronic thromboembolic pulmonary hypertension. Semin Thorac Cardiovasc Surg 2006; 18:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7320/abstract/19\">",
"      Morris TA, Auger WR, Ysrael MZ, et al. Parenchymal scarring is associated with restrictive spirometric defects in patients with chronic thromboembolic pulmonary hypertension. Chest 1996; 110:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7320/abstract/20\">",
"      Wakamatsu K, Inoue H, Aizawa H, et al. Recurrent chest opacities in a patient with thromboembolic pulmonary hypertension. Respiration 1998; 65:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7320/abstract/21\">",
"      Fishman AJ, Moser KM, Fedullo PF. Perfusion lung scans vs pulmonary angiography in evaluation of suspected primary pulmonary hypertension. Chest 1983; 84:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7320/abstract/22\">",
"      Tunariu N, Gibbs SJ, Win Z, et al. Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med 2007; 48:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7320/abstract/23\">",
"      Ryan KL, Fedullo PF, Davis GB, et al. Perfusion scan findings understate the severity of angiographic and hemodynamic compromise in chronic thromboembolic pulmonary hypertension. Chest 1988; 93:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7320/abstract/24\">",
"      Nicod P, Peterson K, Levine M, et al. Pulmonary angiography in severe chronic pulmonary hypertension. Ann Intern Med 1987; 107:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7320/abstract/25\">",
"      Kovacs G, Berghold A, Scheidl S, Olschewski H. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J 2009; 34:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7320/abstract/26\">",
"      Pitton MB, D&uuml;ber C, Mayer E, Thelen M. Hemodynamic effects of nonionic contrast bolus injection and oxygen inhalation during pulmonary angiography in patients with chronic major-vessel thromboembolic pulmonary hypertension. Circulation 1996; 94:2485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7320/abstract/27\">",
"      Shure D, Gregoratos G, Moser KM. Fiberoptic angioscopy: role in the diagnosis of chronic pulmonary arterial obstruction. Ann Intern Med 1985; 103:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7320/abstract/28\">",
"      Hasegawa I, Boiselle PM, Hatabu H. Bronchial artery dilatation on MDCT scans of patients with acute pulmonary embolism: comparison with chronic or recurrent pulmonary embolism. AJR Am J Roentgenol 2004; 182:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7320/abstract/29\">",
"      King MA, Ysrael M, Bergin CJ. Chronic thromboembolic pulmonary hypertension: CT findings. AJR Am J Roentgenol 1998; 170:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7320/abstract/30\">",
"      Bergin CJ, Sirlin CB, Hauschildt JP, et al. Chronic thromboembolism: diagnosis with helical CT and MR imaging with angiographic and surgical correlation. Radiology 1997; 204:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7320/abstract/31\">",
"      Kreitner KF, Kunz RP, Ley S, et al. Chronic thromboembolic pulmonary hypertension - assessment by magnetic resonance imaging. Eur Radiol 2007; 17:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7320/abstract/32\">",
"      Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC), European Respiratory Society (ERS), International Society of Heart and Lung Transplantation (ISHLT), et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34:1219.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8254 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-D1AB04EF24-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_9_7320=[""].join("\n");
var outline_f7_9_7320=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9358410\">",
"      Presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10889851\">",
"      Initial evaluation of symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10889858\">",
"      Evaluation of suspected pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10889872\">",
"      Alternatives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      DIAGNOSTIC CRITERIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9358616\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/8254\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/8254|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/5/15455\" title=\"diagnostic image 1\">",
"      Chronic thromboemoli US",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?28/29/29140\" title=\"diagnostic image 2\">",
"      Chronic thromboemboli PA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?32/36/33359\" title=\"diagnostic image 3\">",
"      Chronic thromboemboli Angio",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/20/24898\" title=\"diagnostic image 4\">",
"      Chrn thromboemboli angio II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?3/7/3199\" title=\"diagnostic image 5\">",
"      Pulmonary angioscopy II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/8254|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/10/23712\" title=\"picture 1\">",
"      Pulmonary angioscope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/62/38894\" title=\"picture 2\">",
"      Pulmonary angioscopy I",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16681?source=related_link\">",
"      Approach to the adult with interstitial lung disease: Diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16553?source=related_link\">",
"      Approach to the patient with dyspnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30954?source=related_link\">",
"      Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/31/14837?source=related_link\">",
"      Chronic thromboembolic pulmonary hypertension: Medical treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10503?source=related_link\">",
"      Chronic thromboembolic pulmonary hypertension: Surgical treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2041?source=related_link\">",
"      Clinical features and diagnosis of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=related_link\">",
"      Clinical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19482?source=related_link\">",
"      Diagnosis of asthma in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=related_link\">",
"      Evaluation of the patient with suspected heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34293?source=related_link\">",
"      Overview of the treatment of chronic thromboembolic pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/61/39889?source=related_link\">",
"      Patient information: Pulmonary hypertension in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26521?source=related_link\">",
"      Stress testing for the diagnosis of coronary heart disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_9_7321="AIDS-related lymphomas: Primary central nervous system lymphoma";
var content_f7_9_7321=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   AIDS-related lymphomas: Primary central nervous system lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/9/7321/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/9/7321/contributors\">",
"     Lawrence D Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/9/7321/contributors\">",
"     James L Rubenstein, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/9/7321/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/9/7321/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/9/7321/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/9/7321/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/9/7321/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection with HIV predisposes to the development of neoplasms. There are currently four AIDS-defining malignancies: Kaposi's sarcoma, non-Hodgkin lymphoma (NHL) of high-grade pathologic type and of B cell or unknown immunologic phenotype, primary CNS lymphoma (PCL), and invasive cervical carcinoma. AIDS-related NHL is generally divided into three types: systemic NHL, PCL, and the primary effusion (\"body cavity\") lymphomas [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. More unusual types, such as plasmablastic lymphoma, also occur. These disorders are primarily encountered in patients with more advanced HIV infection, with a CD4 count that is usually below",
"    <span class=\"nowrap\">",
"     100/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/36/20042?source=see_link\">",
"     \"AIDS-related lymphomas: Epidemiology, risk factors, and pathobiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27206?source=see_link&amp;anchor=H1560489307#H1560489307\">",
"     \"HIV infection and malignancy: Epidemiology and pathogenesis\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The major issues relating to AIDS-related PCL will be reviewed here. Reviews of the diagnosis and treatment of PCL not associated with HIV infection are presented separately. Although CNS involvement also occurs in AIDS-related systemic lymphoma in the form of secondary spread of the tumor to the meninges, the disease is limited to the CNS in PCL. Evaluation of the CNS in patients with AIDS-related systemic lymphoma is discussed separately. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30217?source=see_link\">",
"     \"Clinical presentation, pathologic features, and diagnosis of primary central nervous system lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37914?source=see_link\">",
"     \"Treatment and prognosis of primary central nervous system lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/4/7242?source=see_link\">",
"     \"AIDS-related lymphomas: Clinical manifestations, diagnosis, and staging of systemic lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of PCS is strongly related to Epstein-Barr virus infection. This is described in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/36/20042?source=see_link&amp;anchor=H12#H12\">",
"     \"AIDS-related lymphomas: Epidemiology, risk factors, and pathobiology\", section on 'Pathobiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19462779\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;PCL accounts for up to 15 percent of non-Hodgkin lymphomas (NHLs) in HIV-infected patients compared with only 1 percent of NHLs in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/2\">",
"     2",
"    </a>",
"    ]. The reported incidence of PCL in HIV-infected patients is 2 to 6 percent (at least 1000 times higher than in the general population) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/4\">",
"     4",
"    </a>",
"    ] and has been as high as 10 percent in autopsy series [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/5\">",
"     5",
"    </a>",
"    ]. The most common histology was diffuse large B-cell lymphoma (immunoblastic variant) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=see_link\">",
"     \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of PCL increases with prolonged survival from HIV-1 infection and requires a more severe degree of immunosuppression than most other AIDS-related complications; the CD4 counts in affected patients are generally less than",
"    <span class=\"nowrap\">",
"     50/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. Thus, PCL is rarely an initial AIDS-defining illness.",
"   </p>",
"   <p>",
"    PCL can present with a variety of focal or nonfocal signs and symptoms. The clinical presentation may be characterized by confusion, lethargy, memory loss, hemiparesis, aphasia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    seizures that have usually been present for less than three months. Compared with non-AIDS patients with PCL, patients with AIDS are more likely to present with mental status changes and seizures (50 versus 35 percent in a literature review) and less likely to have increased intracranial pressure (14 versus 32 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Constitutional symptoms (systemic \"B\" symptoms) occur in over 80 percent of patients with PCL [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients presenting with signs or symptoms suggestive of CNS disease should be evaluated with imaging. Although magnetic resonance imaging (MRI) has a higher diagnostic yield, computed tomography (CT) scan may also be used. Approximately 20 to 30 percent of CNS lesions in patients with AIDS are ultimately found to be PCL with toxoplasmosis and progressive multifocal leukoencephalopathy accounting for many of the remaining cases [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/12-15\">",
"     12-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If there is a mass lesion or lesions (approximately one-half of patients with PCL have multiple lesions) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/6,16\">",
"     6,16",
"    </a>",
"    ], the usual next step is to distinguish between PCL and toxoplasmosis, the other common cause of intracranial mass lesions in HIV-infected patients. This distinction can be made using a combination of cerebrospinal fluid (CSF) cytology, toxoplasmosis serologic testing, an empiric trial of antibiotics, measurement of EBV DNA in a CSF sample, and, if necessary, brain biopsy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41128?source=see_link\">",
"     \"Approach to HIV-infected patients with central nervous system lesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     CT scan and MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;On CT scan, a primary central nervous system lymphoma is typically a well-defined focal lesion, isodense or hyperdense to the gray matter (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68209 \" href=\"UTD.htm?2/59/2992\">",
"     image 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Calcification, hemorrhage, and cysts are unusual [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30217?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical presentation, pathologic features, and diagnosis of primary central nervous system lymphoma\", section on 'Radiographic features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The appearance of the lesions on MRI scan, which have a higher diagnostic yield, is variable. In one series, all lesions were isointense or hypointense on T1-weighted images, while hypointense, isointense, or hyperintense lesions could be seen on T2-weighted images [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the absence of corticosteroid therapy, AIDS-related PCLs show a high degree of enhancement on both CT and MRI following intravenous contrast injection. The enhancement is typically irregular and inhomogeneous [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/16,18\">",
"     16,18",
"    </a>",
"    ], a finding that is unusual in the HIV-seronegative population [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. This difference is due to the more rapid growth rate of AIDS-related intracranial lymphomas, resulting in a high degree of central necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/16,19\">",
"     16,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Location, size, and the presence or absence of mass effect may also be helpful diagnostically.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lesions that involve the corpus callosum, periventricular, or periependymal areas are more likely to be due to a lymphoma [",
"      <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/7,18\">",
"       7,18",
"      </a>",
"      ]. Less than 10 percent of lymphomas involve the posterior fossa; thus, posterior fossa lesions are more likely to be due to an infection [",
"      <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Lesions that are over 4 cm in size are more likely to be due to lymphoma than an infectious process [",
"      <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      PCL and toxoplasmosis usually produce a mass effect on CT or MRI. In one series of HIV-infected patients with focal brain lesions, the probability of progressive multifocal leukoencephalopathy was 81 percent among those without a mass effect [",
"      <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Corticosteroids are often given when a symptomatic mass lesion is identified. This has important implications for further evaluation since significant shrinkage of the tumor can occur within only a few days [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/7,16\">",
"     7,16",
"    </a>",
"    ]. Steroid therapy can convert enhancing into nonenhancing lesions, and biopsy in this situation may yield only necrotic or nondiagnostic tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/16\">",
"     16",
"    </a>",
"    ]. Thus, in the absence of severe manifestations, such as cerebral herniation, the evaluation of an intracranial mass should be done",
"    <strong>",
"     prior",
"    </strong>",
"    to the administration of steroids. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41128?source=see_link&amp;anchor=H18#H18\">",
"     \"Approach to HIV-infected patients with central nervous system lesions\", section on 'Corticosteroids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     SPECT scanning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several agents being investigated in HIV-infected patients with intracranial mass lesions include thallium-201 and 99Tc(m)-sestamibi SPECT (single-photon emission computed tomography) scanning [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. In a comparative study of 17 patients, both had sensitivity of 100 percent, but thallium had a lower specificity (54 versus 69 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/21\">",
"     21",
"    </a>",
"    ]. Medical treatment of toxoplasmosis, with a healing pattern on biopsy, was an important cause of the false positive results.",
"   </p>",
"   <p>",
"    Several subsequent studies suggest that specificity can be improved with better quantitation and evaluation of delayed images [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. One report, for example, evaluated thallium uptake on early and late images and calculated the retention index of thallium in 49 patients with AIDS who presented with focal lesions on CT",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/22\">",
"     22",
"    </a>",
"    ]. The absence of thallium uptake on early images excluded the diagnosis of lymphoma with a high degree of confidence. In the presence of early uptake, delayed imaging and calculation of the retention index were necessary to distinguish lymphoma from nonmalignant lesions. The overall sensitivity was 96 percent. Specificity was 76 percent by counting all studies with abnormal thallium uptake but increased to 100 percent when the retention index was also considered.",
"   </p>",
"   <p>",
"    Another possible method to increase the specificity is to combine imaging with measurement of EBV DNA in a cerebrospinal fluid sample. One study considered the value of combined thallium SPECT and measurement of EBV-DNA in 13 patients with PCL and 18 patients with non-tumor disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/24\">",
"     24",
"    </a>",
"    ]. The presence of increased uptake",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    positive EBV-DNA had 100 percent sensitivity and almost 100 percent negative predictive value, suggesting that brain biopsy could be avoided in these patients. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Detection of EBV DNA'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Establishing the diagnosis of cerebral mass lesion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lumbar puncture is relatively noninvasive and may provide a diagnosis of PCL. In the HIV-seronegative population, the yield of CSF cytology for diagnosis of PCL is only 26 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/25\">",
"     25",
"    </a>",
"    ]. The incidence of positive CSF cytology in AIDS-related PCL is as yet unknown, but since meningeal involvement in AIDS-related PCL is 25 to 35 percent it is likely that the diagnostic yield of CSF cytology may be similar to that in the HIV-seronegative population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30217?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical presentation, pathologic features, and diagnosis of primary central nervous system lymphoma\", section on 'Cerebrospinal fluid analysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If CSF cytology does not establish the diagnosis, toxoplasma serologies should be obtained. Most patients are treated empirically with antitoxoplasma therapy, while serology is pending. Patients with a positive serology can be treated for two weeks before stereotactic biopsy; a response to therapy obviates the need for biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/15,26\">",
"     15,26",
"    </a>",
"    ]. However, this approach may delay appropriate therapy for other disorders. In one series, the probability of toxoplasmic encephalitis in seropositive patients with a mass effect was 87 percent in those not receiving antitoxoplasma prophylaxis and only 59 percent in those receiving prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal management of patients who are seronegative for toxoplasmosis is uncertain. Such patients can be treated empirically or, because of the potential for rapid, clinical deterioration, undergo early brain biopsy. Evaluation of this issue by formal decision analysis supported early biopsy in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/26\">",
"     26",
"    </a>",
"    ]. In one series, the likelihood of PCL was 74 percent in seronegative patients with a mass effect on imaging studies; this value increased to 96 percent if EBV DNA was detected in the CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22471?source=see_link\">",
"     \"Decision analysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Stereotactic brain biopsy is an effective diagnostic procedure in HIV-infected patients with focal brain lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/15,17,27\">",
"     15,17,27",
"    </a>",
"    ]. The safety and yield of this technique was evaluated in a retrospective review of 435 HIV-seropositive patients presenting with focal intracranial lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/15\">",
"     15",
"    </a>",
"    ]. The postbiopsy morbidity within 30 days was 8.4 percent and mortality was 2.9 percent. Similar values (12 percent morbidity and 2 percent mortality) were noted in another report [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/17\">",
"     17",
"    </a>",
"    ], but the risk is likely to vary with local expertise.",
"   </p>",
"   <p>",
"    A definitive diagnosis was obtained by brain biopsy in 88 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      PCL &mdash; 30 percent overall but 65 percent in those biopsied after failure of antitoxoplasma therapy",
"     </li>",
"     <li>",
"      Progressive multifocal leukoencephalopathy (PML) &mdash; 25 percent",
"     </li>",
"     <li>",
"      Toxoplasmosis &mdash; 16 percent",
"     </li>",
"     <li>",
"      Other &mdash; 17 percent; as an example, primary intracranial tumors (such as gliomas) can occur in HIV-infected patients [",
"      <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/28\">",
"       28",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is likely that these percentages are changing since the advent of antitoxoplasma chemoprophylaxis has led to a decline in toxoplasmic encephalitis as a cause of focal brain lesions and a relative increase in PCL and PML [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Detection of EBV DNA",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of evidence demonstrates that Epstein-Barr virus (EBV) infection is central to the pathobiology of AIDS-related PCL with the absence of EBV-specific CD4+ T-cell effector function likely contributing to the development of PCL in HIV-infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/30\">",
"     30",
"    </a>",
"    ]. The link to EBV infection has provided a basis for non-invasive detection of PCL in that a possible alternative to brain biopsy in patients who are seronegative for toxoplasmosis is the detection of EBV DNA in the CSF, usually by polymerase chain reaction (PCR). It can also be performed in seropositive patients who are receiving a trial of antibiotics. While the detection of EBV DNA in CSF by PCR may be a useful tool to exclude the diagnosis of AIDS-related PCL, there remains an unmet need for biomarkers with greater specificity and predictive value for active PCL arising in the setting of HIV infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/36/20042?source=see_link&amp;anchor=H17#H17\">",
"     \"AIDS-related lymphomas: Epidemiology, risk factors, and pathobiology\", section on 'EBV coinfection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    EBV analysis of CSF has a sensitivity of 80 to 90 percent, and a specificity that approaches 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/31-34\">",
"     31-34",
"    </a>",
"    ]. For example, in one series of HIV-infected patients with focal brain lesions, EBV DNA sequences were detected in 24 of 30 patients (80 percent) with PCL, compared with none of 61 patients without PCL [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/31\">",
"     31",
"    </a>",
"    ]. In another report, the probability of PCL in toxoplasma-seronegative patients with a mass effect increased from 74 percent overall to more than 96 percent if EBV DNA were present [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, as with other tests, the positive predictive value depends upon the prevalence of disease within the population. Several investigators have demonstrated the poor predictive value of quantitative EBV DNA in the CSF of HIV-infected patients and correlate its association with miscellaneous neurological diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. As an example, EBV DNA was detected by PCR in the CSF of seven out of 26 HIV-infected patients in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/35\">",
"     35",
"    </a>",
"    ]. Notably, only two of the patients with EBV DNA detected in the CSF received a diagnosis of PCL; five had alternative diagnoses including HIV encephalopathy, toxoplasmosis encephalitis, and cryptococcoma. Moreover, none of these five patients went on to develop HIV-associated PCL over a median follow-up of 37 months. Thus, EBV DNA detection by PCR had a positive predictive value of 29 percent for the diagnosis of AIDS-associated PCL.",
"   </p>",
"   <p>",
"    Measurement of EBV DNA may have value in patients in whom a brain biopsy may not be acceptable to the patient or the neurosurgeon [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/38\">",
"     38",
"    </a>",
"    ]. In the first study referred to above, measurement of EBV DNA would have allowed the diagnosis of 63 percent of the case patients and exclusion of PCL in 76 percent of the control patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/31\">",
"     31",
"    </a>",
"    ]. These numbers are lower than the sensitivity and specificity because the test could not be performed in some patients due to perceived danger of lumbar puncture. The Eastern Cooperative Oncology Group has agreed to use EBV DNA measurement as a surrogate for brain biopsy in a new treatment trial [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Measurement of Epstein-Barr virus DNA in CSF also provides a surrogate marker to monitor the response to therapy for PCL [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/40\">",
"     40",
"    </a>",
"    ]. This was illustrated in a report of nine patients who underwent multimodality therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/40\">",
"     40",
"    </a>",
"    ]. The two patients who had a response showed a reduction in the mean EBV DNA concentration after chemotherapy, the four patients with progressive disease had increasing mean values, and the three patients with stable disease had stable values.",
"   </p>",
"   <p>",
"    PCR of the CSF has also been used to detect and identify other infectious agents in patients with AIDS and neurologic syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/17,41\">",
"     17,41",
"    </a>",
"    ]. Positive tests were found in one study for JC virus in six of seven biopsy proven cases of PML, for CMV in one case of CMV encephalitis, and for Mycobacterium tuberculosis in one case of tuberculous encephalitis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/7/44151?source=see_link\">",
"     \"Clinical manifestations and diagnosis of JC, BK, and other polyomavirus infections\"",
"    </a>",
"    .) None of the five patients with toxoplasmic encephalitis was positive for T gondii DNA.",
"   </p>",
"   <p>",
"    A similar increase in diagnostic accuracy was noted in another report. In seronegative patients without a mass effect, the probability of PML increased from 81 percent overall to 99 percent if JC virus DNA were present in the CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of the soluble B-cell marker CD23 (sCD23) in CSF may be useful in the diagnosis of AIDS-related NHL. In one series, the sensitivity and specificity of sCD23 in CSF as a marker for detection of brain NHL were 77 and 94 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/42\">",
"     42",
"    </a>",
"    ]. High levels of sCD23 were found in CSF from patients with NHL involving the brain independent of the presence or absence of positivity for Epstein-Barr virus DNA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Staging is of value in only a minority of patients with systemic lymphoma and is generally not indicated in patients with PCL. This disorder almost always remains confined to the central nervous system, but within this space may spread to all compartments including the leptomeninges, spinal cord, and eye [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/7\">",
"     7",
"    </a>",
"    ]. Ocular involvement documented by slit lamp examination has been described in 5 to 20 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/10\">",
"     10",
"    </a>",
"    ]. The multifocal nature of AIDS-related, primary CNS lymphomas is due to dissemination of a single clone, rather than transformation of multiple B cell clones [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4729669\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal therapy for PCL is not yet defined. However, therapy for AIDS-related PCL should take into consideration that, within the central nervous system, it is a multifocal disease even if apparently unifocal on radiologic studies performed at the time of diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/6,7,16\">",
"     6,7,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Our experience and that of others has been that high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    therapy (eg, 3",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    for four to eight cycles) administered concurrently with steroids and potent antiretroviral therapy offers palliation for up to 12 to 18 months [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. The addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    to combination chemotherapy is feasible in the treatment of HIV-associated lymphomas [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/47\">",
"     47",
"    </a>",
"    ]. In carefully selected patients, it is likely that induction therapy for HIV-related PCL with high-dose methotrexate plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    and rituximab, such as that used for non-HIV-related PCL, may be an optimal approach to elicit complete response and obviate the need for whole brain irradiation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/48\">",
"     48",
"    </a>",
"    ]. After the initial response and resolution of tumor-associated mass effect, steroids should be tapered and discontinued in order to avoid side effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37914?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment and prognosis of primary central nervous system lymphoma\", section on 'Initial Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These patients usually have advanced AIDS, often with strains of HIV-1 that are resistant to many of the currently available antiretroviral medications. Nevertheless, every effort should be made to find an antiretroviral regimen that is effective, since enhancement of the immune system is one of the major therapeutic interventions that can be made with PCL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     High-dose methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;For most patients with HIV-related PCL, we suggest the use of high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    -based chemotherapy regimens given in conjunction with anti-retroviral therapy. Small retrospective and prospective studies of this approach, given with or without radiation therapy, suggest a benefit to the subgroup of patients with relatively high CD4 cell counts [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/7,8,49\">",
"     7,8,49",
"    </a>",
"    ]. Further data supporting the use of high-dose methotrexate can be extrapolated from its use in PCL arising in patients without HIV infection, where it has demonstrated a survival benefit. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37914?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment and prognosis of primary central nervous system lymphoma\", section on 'Methotrexate-based induction chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following are small series that have investigated the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    -based chemotherapy in patients with AIDS-related PCL:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report of nine patients treated at diagnosis, chemotherapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35414?source=see_link\">",
"       thiotepa",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/45/24279?source=see_link\">",
"       procarbazine",
"      </a>",
"      was followed by whole brain radiation therapy; another patient with recurrent disease was given chemotherapy alone [",
"      <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/49\">",
"       49",
"      </a>",
"      ]. No patient responded to corticosteroids. Four of seven assessable patients had a complete response to chemotherapy prior to radiation and six of seven had a complete response after radiation was completed. The median survival was only seven months for the eight patients who completed therapy (3.5 months for the groups as a whole); only two patients survived for one year or more. Eight of the deaths were due to opportunistic infection.",
"     </li>",
"     <li>",
"      A separate study of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/45/24279?source=see_link\">",
"       procarbazine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      in HIV negative patients with PCL that allowed reduced-dose whole brain radiation produced an overall response rate of 93 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/50\">",
"       50",
"      </a>",
"      ]. While there was no treatment-related neurotoxicity reported, the protocol was associated with significant myelotoxicity. Moreover, there are concerns over the use of rituximab in HIV-positive patients since they have an underlying significant immunosuppression.",
"     </li>",
"     <li>",
"      A small pilot study evaluated the efficacy of high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (3",
"      <span class=\"nowrap\">",
"       g/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      given intravenously without radiation therapy in 15 patients with PCL and a mean CD4 cell count of",
"      <span class=\"nowrap\">",
"       30/microL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/44\">",
"       44",
"      </a>",
"      ]. Methotrexate is a relatively small molecule that readily crosses the blood-brain barrier. Forty-seven percent of patients had a complete response, defined as clinical improvement and disappearance of the lesion(s) on CT scan or MRI, and the median survival was 19 months. This occurred without the neurologic impairment that can occur with radiation therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Anti-retroviral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Receipt of highly active anti-retroviral therapy (potent ART) after a diagnosis of AIDS-related PCL is associated with a prolongation of survival compared with those who receive only radiation therapy and steroids without antiretroviral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/45,51,52\">",
"     45,51,52",
"    </a>",
"    ]. The survival benefit is particularly evident in those who attain at least a 0.5 log(10) decrease in the viral load and an increase in the CD4 lymphocyte count by at least 50",
"    <span class=\"nowrap\">",
"     cells/microL.",
"    </span>",
"    In multivariate analysis, the institution of potent ART is independently associated with an increase in survival by a factor of 6.1 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/46\">",
"     46",
"    </a>",
"    ]. Potent ART may act, in part, by increasing the radiosensitivity of the B cells that comprise the lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/53\">",
"     53",
"    </a>",
"    ]. In addition, long-term remission has been described in HIV-associated PCL patients who decline whole brain irradiation and who demonstrate rapid immune recovery and prolonged lymphoma regression and neurocognitive improvement with potent ART alone [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/54\">",
"     54",
"    </a>",
"    ]. Therefore a reasonable approach would be combination high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    plus initiation of potent ART with deferral of whole brain irradiation with its associated neurotoxicity.",
"   </p>",
"   <p>",
"    In a murine model of head and neck carcinoma, the protease inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    was shown to enhance the apoptosis induced by ionizing radiation and to have anti-angiogenic effects [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/55\">",
"     55",
"    </a>",
"    ]. Whether this extends to radiation therapy for AIDS-related primary CNS lymphoma is unclear. However, an antiretroviral regimen that incorporates ritonavir, at least to boost another protease inhibitor, seems reasonable.",
"   </p>",
"   <p>",
"    Unfortunately, those HIV-infected individuals who have a drop in their CD4 lymphocyte counts to the low levels typically seen at the onset of a primary CNS lymphoma (&lt;50",
"    <span class=\"nowrap\">",
"     cells/microL),",
"    </span>",
"    and thus are at the greatest risk of developing the lymphoma, often have a multi-resistant viral strain(s). Therefore, the therapeutic possibilities for control of the HIV infection are very limited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4729446\">",
"    <span class=\"h2\">",
"     Is there a role for radiation therapy?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, the standard approach to the treatment of AIDS-related PCL has been radiation therapy and corticosteroids, which achieves complete responses in 20 to 50 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/6,7,11,15,56\">",
"     6,7,11,15,56",
"    </a>",
"    ]. However, survival is one to three months from the time of presentation in untreated patients; the outcome is not substantially improved by therapy, with reported median survivals of up to 3.5 months [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/6,7,49\">",
"     6,7,49",
"    </a>",
"    ]. Moreover, whole brain irradiation is associated with devastating neurologic consequences in CNS lymphoma patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37914?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment and prognosis of primary central nervous system lymphoma\", section on 'Is there a role for radiation therapy?'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Short survival in this setting is largely due to opportunistic infections. This is largely due to profound immunodeficiency in which most AIDS-related PCLs develop, since the majority of deaths are due to opportunistic infections [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/44,49\">",
"     44,49",
"    </a>",
"    ]. As noted above, the CD4 cell counts are usually less than",
"    <span class=\"nowrap\">",
"     50/microL",
"    </span>",
"    at presentation of the lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37914?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment and prognosis of primary central nervous system lymphoma\", section on 'Is there a role for radiation therapy?'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Palliation of these tumors can often be achieved with aggressive radiation therapy, if tolerated, and especially with control of the HIV infection. In an analysis of 163 patients, the overall palliative response was 53 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/56\">",
"     56",
"    </a>",
"    ]. The two predictors of a complete response were high performance status and the delivery of higher, biologically effective radiation doses. However, many patients cannot tolerate the full course of radiation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/6,56\">",
"     6,56",
"    </a>",
"    ]. In one series of 75 patients in which the median survival was only 1.3 months, cranial radiation was given to 72 percent of patients but only one-half completed the course of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/6\">",
"     6",
"    </a>",
"    ]. Longer survival was associated with better performance status. In another review, the median survival of patients who received cranial irradiation was only 29 days longer than untreated patients (50 versus 21 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7321/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary central nervous system lymphoma (PCL) is an AIDS-defining malignancy that is strongly related to EBV infection and immunosuppression. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PCL can present with a variety of focal or nonfocal signs and symptoms including confusion, lethargy, memory loss, hemiparesis, aphasia,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      seizures. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis is made using a combination of cerebrospinal fluid cytology, toxoplasmosis serologic testing, an empiric trial of antibiotics, measurement of EBV DNA in a CSF sample, and, if necessary, brain biopsy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Since the optimal therapy for these lymphomas has yet to be found, affected patients should be referred to clinical trials if possible. If this cannot be done, our experience and that of others has been that high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      administered concurrently with steroids and potent antiretroviral therapy offers palliation for up to 12 to 18 months. After the initial response and resolution of tumor-associated mass effect, steroids should be tapered and discontinued in order to avoid side effects. As noted, a regimen that contains",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      seems reasonable based on results in animal studies for other types of carcinomas. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After the initial course of radiation and steroids, the latter should be tapered and discontinued in order to avoid side effects. These patients usually have advanced AIDS, often with strains of HIV-1 that are resistant to many of the currently available antiretroviral medications. Nevertheless, every effort should be made to find an antiretroviral regimen that is effective, since enhancement of the immune system is one of the major therapeutic interventions that can be made with PCL.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/1\">",
"      Sandler AS, Kaplan LD. Diagnosis and management of systemic non-Hodgkin's lymphoma in HIV disease. Hematol Oncol Clin North Am 1996; 10:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/2\">",
"      Cot&eacute; TR, Biggar RJ, Rosenberg PS, et al. Non-Hodgkin's lymphoma among people with AIDS: incidence, presentation and public health burden. AIDS/Cancer Study Group. Int J Cancer 1997; 73:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/3\">",
"      Pluda JM, Yarchoan R, Jaffe ES, et al. Development of non-Hodgkin lymphoma in a cohort of patients with severe human immunodeficiency virus (HIV) infection on long-term antiretroviral therapy. Ann Intern Med 1990; 113:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/4\">",
"      Flinn IW, Ambinder RF. AIDS primary central nervous system lymphoma. Curr Opin Oncol 1996; 8:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/5\">",
"      MacMahon EM, Glass JD, Hayward SD, et al. Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet 1991; 338:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/6\">",
"      Raez LE, Patel P, Feun L, et al. Natural history and prognostic factors for survival in patients with acquired immune deficiency syndrome (AIDS)-related primary central nervous system lymphoma (PCNSL). Crit Rev Oncog 1998; 9:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/7\">",
"      Forsyth PA, DeAngelis LM. Biology and management of AIDS-associated primary CNS lymphomas. Hematol Oncol Clin North Am 1996; 10:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/8\">",
"      DeMario MD, Liebowitz DN. Lymphomas in the immunocompromised patient. Semin Oncol 1998; 25:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/9\">",
"      Fine HA, Mayer RJ. Primary central nervous system lymphoma. Ann Intern Med 1993; 119:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/10\">",
"      Maher EA, Fine HA. Primary CNS lymphoma. Semin Oncol 1999; 26:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/11\">",
"      Baumgartner JE, Rachlin JR, Beckstead JH, et al. Primary central nervous system lymphomas: natural history and response to radiation therapy in 55 patients with acquired immunodeficiency syndrome. J Neurosurg 1990; 73:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/12\">",
"      Beral V, Peterman T, Berkelman R, Jaffe H. AIDS-associated non-Hodgkin lymphoma. Lancet 1991; 337:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/13\">",
"      Biggar RJ, Burnett W, Mikl J, Nasca P. Cancer among New York men at risk of acquired immunodeficiency syndrome. Int J Cancer 1989; 43:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/14\">",
"      Cot&eacute; TR, Manns A, Hardy CR, et al. Epidemiology of brain lymphoma among people with or without acquired immunodeficiency syndrome. AIDS/Cancer Study Group. J Natl Cancer Inst 1996; 88:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/15\">",
"      Skolasky RL, Dal Pan GJ, Olivi A, et al. HIV-associated primary CNS lymorbidity and utility of brain biopsy. J Neurol Sci 1999; 163:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/16\">",
"      Johnson BA, Fram EK, Johnson PC, Jacobowitz R. The variable MR appearance of primary lymphoma of the central nervous system: comparison with histopathologic features. AJNR Am J Neuroradiol 1997; 18:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/17\">",
"      Antinori A, Ammassari A, De Luca A, et al. Diagnosis of AIDS-related focal brain lesions: a decision-making analysis based on clinical and neuroradiologic characteristics combined with polymerase chain reaction assays in CSF. Neurology 1997; 48:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/18\">",
"      Thurnher MM, Thurnher SA, Schindler E. CNS involvement in AIDS: spectrum of CT and MR findings. Eur Radiol 1997; 7:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/19\">",
"      Jenkins CN, Colquhoun IR. Characterization of primary intracranial lymphoma by computed tomography: an analysis of 36 cases and a review of the literature with particular reference to calcification haemorrhage and cyst formation. Clin Radiol 1998; 53:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/20\">",
"      D'Amico A, Messa C, Castagna A, et al. Diagnostic accuracy and predictive value of 201T1 SPET for the differential diagnosis of cerebral lesions in AIDS patients. Nucl Med Commun 1997; 18:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/21\">",
"      Naddaf SY, Akisik MF, Aziz M, et al. Comparison between 201Tl-chloride and 99Tc(m)-sestamibi SPET brain imaging for differentiating intracranial lymphoma from non-malignant lesions in AIDS patients. Nucl Med Commun 1998; 19:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/22\">",
"      Lorberboym M, Wallach F, Estok L, et al. Thallium-201 retention in focal intracranial lesions for differential diagnosis of primary lymphoma and nonmalignant lesions in AIDS patients. J Nucl Med 1998; 39:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/23\">",
"      Kessler LS, Ruiz A, Donovan Post MJ, et al. Thallium-201 brain SPECT of lymphoma in AIDS patients: pitfalls and technique optimization. AJNR Am J Neuroradiol 1998; 19:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/24\">",
"      Antinori A, De Rossi G, Ammassari A, et al. Value of combined approach with thallium-201 single-photon emission computed tomography and Epstein-Barr virus DNA polymerase chain reaction in CSF for the diagnosis of AIDS-related primary CNS lymphoma. J Clin Oncol 1999; 17:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/25\">",
"      Balmaceda C, Gaynor JJ, Sun M, et al. Leptomeningeal tumor in primary central nervous system lymphoma: recognition, significance, and implications. Ann Neurol 1995; 38:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/26\">",
"      Mathews C, Barba D, Fullerton SC. Early biopsy versus empiric treatment with delayed biopsy of non-responders in suspected HIV-associated cerebral toxoplasmosis: a decision analysis. AIDS 1995; 9:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/27\">",
"      Chappell ET, Guthrie BL, Orenstein J. The role of stereotactic biopsy in the management of HIV-related focal brain lesions. Neurosurgery 1992; 30:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/28\">",
"      Blumenthal DT, Raizer JJ, Rosenblum MK, et al. Primary intracranial neoplasms in patients with HIV. Neurology 1999; 52:1648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/29\">",
"      Ammassari A, Scoppettuolo G, Murri R, et al. Changing disease patterns in focal brain lesion-causing disorders in AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/30\">",
"      Gasser O, Bihl FK, Wolbers M, et al. HIV patients developing primary CNS lymphoma lack EBV-specific CD4+ T cell function irrespective of absolute CD4+ T cell counts. PLoS Med 2007; 4:e96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/31\">",
"      Cingolani A, De Luca A, Larocca LM, et al. Minimally invasive diagnosis of acquired immunodeficiency syndrome-related primary central nervous system lymphoma. J Natl Cancer Inst 1998; 90:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/32\">",
"      Cinque P, Brytting M, Vago L, et al. Epstein-Barr virus DNA in cerebrospinal fluid from patients with AIDS-related primary lymphoma of the central nervous system. Lancet 1993; 342:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/33\">",
"      Plebani A, Pinzani R, Vago L, et al. Epstein-Barr virus DNA in the cerebrospinal fluid of an HIV patient with primary cerebral lymphoma. Eur J Pediatr 1998; 157:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/34\">",
"      Yarchoan R, Jaffe ES, Little R. Diagnosing central nervous system lymphoma in the setting of AIDS: a step forward. J Natl Cancer Inst 1998; 90:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/35\">",
"      Ivers LC, Kim AY, Sax PE. Predictive value of polymerase chain reaction of cerebrospinal fluid for detection of Epstein-Barr virus to establish the diagnosis of HIV-related primary central nervous system lymphoma. Clin Infect Dis 2004; 38:1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/36\">",
"      Chaudhari VV, Yim CM, Hathout H, et al. Atypical imaging appearance of toxoplasmosis in an HIV patient as a butterfly lesion. J Magn Reson Imaging 2009; 30:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/37\">",
"      Corcoran C, Rebe K, van der Plas H, et al. The predictive value of cerebrospinal fluid Epstein-Barr viral load as a marker of primary central nervous system lymphoma in HIV-infected persons. J Clin Virol 2008; 42:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/38\">",
"      Corn BW, Trock BJ, Curran WJ Jr. Management of primary central nervous system lymphoma for the patient with acquired immunodeficiency syndrome. Confronting a clinical catch-22. Cancer 1995; 76:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/39\">",
"      McNeil C. Evidence mounts that Epstein-Barr test may help diagnose AIDS brain lymphoma. J Natl Cancer Inst 1998; 90:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/40\">",
"      Antinori A, Cingolani A, De Luca A, et al. Epstein-Barr virus in monitoring the response to therapy of acquired immunodeficiency syndrome-related primary central nervous system lymphoma. Ann Neurol 1999; 45:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/41\">",
"      d'Arminio Monforte A, Cinque P, Vago L, et al. A comparison of brain biopsy and CSF-PCR in the diagnosis of CNS lesions in AIDS patients. J Neurol 1997; 244:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/42\">",
"      Bossolasco S, Nilsson A, de Milito A, et al. Soluble CD23 in cerebrospinal fluid: a marker of AIDS-related non-Hodgkin's lymphoma in the brain. AIDS 2001; 15:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/43\">",
"      Pilozzi E, Talerico C, Uccini S, et al. B cell clonality in multiple localizations of primary central nervous system lymphomas in AIDS patients. Leuk Lymphoma 2003; 44:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/44\">",
"      Jacomet C, Girard PM, Lebrette MG, et al. Intravenous methotrexate for primary central nervous system non-Hodgkin's lymphoma in AIDS. AIDS 1997; 11:1725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/45\">",
"      Newell ME, Hoy JF, Cooper SG, et al. Human immunodeficiency virus-related primary central nervous system lymphoma: factors influencing survival in 111 patients. Cancer 2004; 100:2627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/46\">",
"      Hoffmann C, Tabrizian S, Wolf E, et al. Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery. AIDS 2001; 15:2119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/47\">",
"      Sparano JA, Lee JY, Kaplan LD, et al. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood 2010; 115:3008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/48\">",
"      Wieduwilt MJ, Valles F, Issa S, et al. Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI. Clin Cancer Res 2012; 18:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/49\">",
"      Forsyth PA, Yahalom J, DeAngelis LM. Combined-modality therapy in the treatment of primary central nervous system lymphoma in AIDS. Neurology 1994; 44:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/50\">",
"      Shah GD, Yahalom J, Correa DD, et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol 2007; 25:4730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/51\">",
"      Skiest DJ, Crosby C. Survival is prolonged by highly active antiretroviral therapy in AIDS patients with primary central nervous system lymphoma. AIDS 2003; 17:1787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/52\">",
"      Bayraktar S, Bayraktar UD, Ramos JC, et al. Primary CNS lymphoma in HIV positive and negative patients: comparison of clinical characteristics, outcome and prognostic factors. J Neurooncol 2011; 101:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/53\">",
"      Pajonk F, McBride WH. Survival of AIDS patients with primary central nervous system lymphoma may be improved by the radiosensitizing effects of highly active antiretroviral therapy. AIDS 2002; 16:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/54\">",
"      Travi G, Ferreri AJ, Cinque P, et al. Long-term remission of HIV-associated primary CNS lymphoma achieved with highly active antiretroviral therapy alone. J Clin Oncol 2012; 30:e119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/55\">",
"      Maggiorella L, Wen B, Frascogna V, et al. Combined radiation sensitizing and anti-angiogenic effects of ionizing radiation and the protease inhibitor ritonavir in a head and neck carcinoma model. Anticancer Res 2005; 25:4357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7321/abstract/56\">",
"      Corn BW, Donahue BR, Rosenstock JG, et al. Palliation of AIDS-related primary lymphoma of the brain: observations from a multi-institutional database. Int J Radiat Oncol Biol Phys 1997; 38:601.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4751 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-FE77A46CF4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_9_7321=[""].join("\n");
var outline_f7_9_7321=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19462779\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CT scan and MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SPECT scanning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Establishing the diagnosis of cerebral mass lesion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Detection of EBV DNA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      STAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4729669\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      High-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Anti-retroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4729446\">",
"      Is there a role for radiation therapy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4751\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4751|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/59/2992\" title=\"diagnostic image 1\">",
"      Primary CNS lymphoma MRI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/4/7242?source=related_link\">",
"      AIDS-related lymphomas: Clinical manifestations, diagnosis, and staging of systemic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/36/20042?source=related_link\">",
"      AIDS-related lymphomas: Epidemiology, risk factors, and pathobiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41128?source=related_link\">",
"      Approach to HIV-infected patients with central nervous system lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/7/44151?source=related_link\">",
"      Clinical manifestations and diagnosis of JC, BK, and other polyomavirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30217?source=related_link\">",
"      Clinical presentation, pathologic features, and diagnosis of primary central nervous system lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22471?source=related_link\">",
"      Decision analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=related_link\">",
"      Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27206?source=related_link\">",
"      HIV infection and malignancy: Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37914?source=related_link\">",
"      Treatment and prognosis of primary central nervous system lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_9_7322="Treatment of acromegaly";
var content_f7_9_7322=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of acromegaly",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/9/7322/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/9/7322/contributors\">",
"     Shlomo Melmed, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/9/7322/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/9/7322/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/9/7322/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/9/7322/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/9/7322/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acromegaly is almost always caused by a somatotroph (growth hormone [GH]-secreting) adenoma of the pituitary gland and is associated with increased morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/1\">",
"     1",
"    </a>",
"    ]. As a result, almost all patients should be treated, even those who are asymptomatic and those in whom the disorder does not seem to be progressing. One exception is a patient with a short life expectancy who is not expected to live long enough to benefit from therapy. The suggested approach to therapy is summarized in the algorithm (",
"    <a class=\"graphic graphic_algorithm graphicRef61609 \" href=\"UTD.htm?31/8/31886\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The treatment of acromegaly will be reviewed here. The clinical manifestations and diagnosis of acromegaly are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30776?source=see_link\">",
"     \"Causes and clinical manifestations of acromegaly\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43076?source=see_link\">",
"     \"Diagnosis of acromegaly\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GOALS OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of therapy in acromegaly are to lower the serum insulin-like growth factor-1 (IGF-1) concentration to within the reference range for the patient's age and gender and to lower the serum GH concentration to &lt;1.0",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (1.0",
"    <span class=\"nowrap\">",
"     mcg/L)",
"    </span>",
"    as measured by immunoradiometric or chemiluminescent assay after a glucose load.",
"   </p>",
"   <p>",
"    The IGF-1 criterion is probably better, since some patients who appear to have active disease clinically and by elevated IGF-1 concentration have serum GH values that suppress to &lt;1.0",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Serum IGF-1 concentrations also correlate better than serum GH with insulin sensitivity in patients with acromegaly [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With normalization of serum IGF-1 concentrations, the life expectancy of patients with acromegaly is similar to that of the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Therapy should also ameliorate symptoms, if any, due to the size of the somatotroph adenoma, but it should not cause hypopituitarism.",
"   </p>",
"   <p>",
"    To achieve these goals, the adenoma secreting GH (or rarely growth hormone-releasing hormone) must be identified and then treated (",
"    <a class=\"graphic graphic_table graphicRef55079 \" href=\"UTD.htm?30/56/31628\">",
"     table 1",
"    </a>",
"    ). When effective control of GH hypersecretion is achieved, serum GH and IGF-1 concentrations decline to normal [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/7\">",
"     7",
"    </a>",
"    ], the characteristic tissue overgrowth and related symptoms gradually recede, and the metabolic abnormalities, such as diabetes mellitus, improve. Unfortunately, restoration of completely normal GH secretion is not often achieved.",
"   </p>",
"   <p>",
"    Even if the serum IGF-1 returns to normal, bony abnormalities generally do not regress and joint symptoms persist. This was illustrated in a study of 118 patients with acromegaly who were in long-term remission, as judged by serum normal IGF-1 concentration; 77 percent reported joint symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30776?source=see_link&amp;anchor=H10#H10\">",
"     \"Causes and clinical manifestations of acromegaly\", section on 'Bone and joints'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H689545547\">",
"    <span class=\"h1\">",
"     SUGGESTED APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;A strategy for managing patients with acromegaly and a summary of treatment effects are summarized in the algorithm and table (",
"    <a class=\"graphic graphic_algorithm graphicRef61609 \" href=\"UTD.htm?31/8/31886\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef55079 \" href=\"UTD.htm?30/56/31628\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For a patient who has a microadenoma, a macroadenoma that appears to be fully resectable, or a macroadenoma causing impairment of vision, we recommend transsphenoidal surgery (performed by a neurosurgeon with considerable experience). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Transsphenoidal surgery'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      For patients whose adenoma does not appear to be fully resectable and that do not abut the chiasm, or for those patients whose risk of surgery is great or who choose not to have surgery, we suggest primary therapy with a long-acting somatostatin analog. Macroadenomas abutting or adjacent to the chiasm should be decompressed surgically. Subsequent medical treatment may also be more effective after surgical debulking. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Somatostatin analogs'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      If transsphenoidal surgery results in normalization of serum IGF-1 concentration, we suggest no further therapy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Transsphenoidal surgery'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      If transsphenoidal surgery does not result in normalization of serum IGF-1 concentration, we suggest therapy with a long-acting somatostatin analog. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Somatostatin analogs'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      If somatostatin analog treatment (with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7206?source=see_link\">",
"       cabergoline",
"      </a>",
"      ) is not entirely effective, we suggest adding",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/23/24948?source=see_link\">",
"       pegvisomant",
"      </a>",
"      . Although this approach has not been approved, some reports indicate that the combination of a somatostatin analog and pegvisomant is safe and effective in normalizing IGF1 levels in patients who are partially resistant to somatostatin analogs alone. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'GH receptor antagonist'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      If adenoma size increases despite medical therapy (ie, somatostatin analog plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/23/24948?source=see_link\">",
"       pegvisomant",
"      </a>",
"      ), we suggest radiotherapy or repeat surgery. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Radiation therapy'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The approach to management during pregnancy is reviewed below. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Management during pregnancy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TRANSSPHENOIDAL SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selective transsphenoidal surgical resection is the treatment of choice for patients with somatotroph adenomas that are small, large but still resectable, or large and cause visual impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Surgery may also be considered for large adenomas that are not entirely accessible surgically (eg, those with cavernous sinus extension), with the goal of removing a sufficient mass of tissue to increase the likelihood that somatostatin analog treatment will be effective postoperatively. Some authorities recommend somatostatin analog treatment perioperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Medical therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Transsphenoidal surgery has been widely employed to treat pituitary adenomas, including somatotroph adenomas, since the 1970s. The approach during much of this time has been sublabial and transseptal using an operating microscope. During the past decade an endoscopic approach has gained acceptance, because it provides superior visualization of the suprasellar compartment and cavernous sinus walls. Studies describing patients treated for acromegaly by endoscopic surgery suggest that although this approach is promising, outcomes for acromegaly are not definitively superior to previously published microscopic series [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When transsphenoidal surgery is performed by the",
"    <strong>",
"     most experienced",
"    </strong>",
"    pituitary neurosurgeons, GH secretion falls to normal in about 80 to 90 percent of patients with microadenomas (less than 10 mm in diameter) and pituitary secretion of other hormones is preserved [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/5,10,14\">",
"     5,10,14",
"    </a>",
"    ]. The success rate is lower in patients with macroadenomas",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    higher preoperative serum GH concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/9,10,14,15\">",
"     9,10,14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If surgery is successful, serum GH concentrations typically fall to normal within one to two hours, depending upon the degree of elevation. Serum IGF-1 concentrations fall more slowly, from 7 to 10 days to several months [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/16\">",
"     16",
"    </a>",
"    ]. There is a rapid diuresis, and soft tissue swelling and hyperglycemia can diminish remarkably in a few days. Vision, if impaired, and headaches can also improve in days. Sleep apnea [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/17\">",
"     17",
"    </a>",
"    ] and cartilaginous overgrowth also improve [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Surgical cure rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accurate interpretation and comparison of studies reporting surgical cure rates in patients with acromegaly is difficult, since both the duration of follow-up and the biochemical criteria for cure have varied. The current goal is a serum IGF-1 concentration normal for age and gender and a serum GH concentration less than 1.0",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    or lower by immunoradiometric or chemiluminescent assay.",
"   </p>",
"   <p>",
"    The cure rate using these criteria is illustrated in a report of 57 patients followed for at least 12 months post-operatively [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/19\">",
"     19",
"    </a>",
"    ]. Surgical remission rates were 70, 67, and 61 percent, as assessed by normal serum IGF-1, random serum GH concentration &lt;2.5",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    and glucose-suppressed GH concentration &lt;1.0",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although summarizing surgical cure rates across studies is difficult for the reasons noted above, the early cure rate in patients with acromegaly is 80 to 90 percent for microadenomas and less than 50 percent for macroadenomas [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/2,5,6,9,10,14,15,19,20\">",
"     2,5,6,9,10,14,15,19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies with several years of follow-up provide information on recurrence rates. Approximately 3 to 10 percent of patients in whom the operation is initially successful, as determined by normal basal and normal post-glucose serum GH concentrations, have a recurrence several years or more after surgery, probably due to incomplete adenoma resection [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/5,6,9,14,19\">",
"     5,6,9,14,19",
"    </a>",
"    ]. Higher rates of recurrence (eg, 19 percent) have been reported in series in which initial surgical cure rates were lower than those cited above [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even if the nadir of the serum GH concentrations after a glucose load is only slightly above the target values, the risk of recurrence is greater, as illustrated by a study of 77 patients with apparent biochemical remission after surgery (normal serum IGF-1 concentrations) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/21\">",
"     21",
"    </a>",
"    ]. The patients were stratified according to the nadir serum GH concentration after an oral glucose load. Fifty patients (group I) were considered to have a normal nadir GH (&lt;0.14",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    based upon mean levels in normal healthy controls) and 26 had an abnormal nadir (&gt;0.14",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    group II). At a mean follow-up of 3.2 years, the following results were seen in group II patients when compared with group I patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Higher mean hourly GH concentrations (based upon hourly GH sampling for eight hours)",
"     </li>",
"     <li>",
"      Higher rate of recurrence, defined as an elevated serum IGF-1 concentration, in patients for whom longitudinal OGTT data were available (5 of 19 versus 0 of 49)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, patients with even subtle abnormalities in post-suppression GH levels may have a greater risk of recurrence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The perioperative mortality rate is less than 1 percent in patients with large invasive adenomas and negligible in patients with smaller ones.",
"   </p>",
"   <p>",
"    Long-term deficiency of one or more pituitary hormones has been reported in up to 70 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/6,14\">",
"     6,14",
"    </a>",
"    ]. Patients treated with both surgery and radiation are particularly prone to develop pituitary hormonal deficiencies, including GH deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H22740699\">",
"     'Treatment of GH deficiency'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Other major complications of surgery occur in about 8 percent of patients. These include central diabetes insipidus (2 percent), cerebrospinal fluid rhinorrhea (2 percent), and meningitis (2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/6,9\">",
"     6,9",
"    </a>",
"    ]. All are more common in patients with macroadenomas.",
"   </p>",
"   <p>",
"    These complication rates reflect results from neurosurgeons with the most experience with transsphenoidal surgery. Rates with less experienced surgeons are much higher [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MEDICAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several medications are now available for treating acromegaly, including some that inhibit GH secretion and one that inhibits its action. Pharmacologic treatment is used when surgery alone has not reduced serum GH and IGF-1 to normal. Its role as primary therapy has not been clearly established.",
"   </p>",
"   <p>",
"    Patients for whom a medication can be considered as primary therapy include those who have unacceptable surgical risk, refuse surgery, or have adenomas that are unlikely to be cured surgically [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/1,25\">",
"     1,25",
"    </a>",
"    ]. One disadvantage of most of these medications is their high cost.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Somatostatin analogs",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     Octreotide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/34/7717?source=see_link\">",
"     lanreotide",
"    </a>",
"    are analogs of somatostatin (growth hormone-inhibitory hormone) that inhibit GH secretion more effectively than native somatostatin because of their greater potency and longer plasma half-life (two hours versus two minutes).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1740166\">",
"    <span class=\"h3\">",
"     Mechanisms of action",
"    </span>",
"   </p>",
"   <p>",
"    Somatostatin analogs inhibit GH secretion by binding to specific receptors for somatostatin and its analogs [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/26\">",
"     26",
"    </a>",
"    ]. Their effect is greater when the number of receptors is high [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/27\">",
"     27",
"    </a>",
"    ]; repetitive administration does not result in desensitization or loss of therapeutic efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/28\">",
"     28",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Somatostatin analogs also cause pituitary adenoma shrinkage in some patients (see",
"    <a class=\"local\" href=\"#H2963829\">",
"     'Adenoma size'",
"    </a>",
"    below). The mechanism of the shrinkage remains unclear. In a study of tissue samples from 32 surgically resected somatotroph macroadenomas, the mean growth fraction of adenomas exposed to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    was 83 percent less than those not exposed [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/29\">",
"     29",
"    </a>",
"    ]. However, in another report, octreotide exhibited an antiproliferative effect, but no effect on the apoptotic index [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/30\">",
"     30",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Efficacy should be judged by normalization of the serum GH and IGF-1 concentrations, which should eventually be followed by regression of the soft tissue manifestations of acromegaly and by shrinkage of adenoma size. The two once-monthly preparations,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    long-acting release (Sandostatin LAR) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/34/7717?source=see_link\">",
"     lanreotide",
"    </a>",
"    (Somatuline Depot), appear to be equivalent for control of biochemical markers and symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/31\">",
"     31",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H337158\">",
"    <span class=\"h4\">",
"     Serum IGF-1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normalization of serum IGF-1 concentration with somatostatin analogs occurs in 40 to 75 percent of patients. The success rate varies markedly with study design, ranging in two reports from 38 percent in patients who were not preselected for responsiveness (",
"    <a class=\"graphic graphic_figure graphicRef62473 \" href=\"UTD.htm?38/10/39086\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/32\">",
"     32",
"    </a>",
"    ] to a mean of 66 percent in a review of several studies, most of which included patients who had been preselected for responsiveness to the short-acting form [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/33\">",
"     33",
"    </a>",
"    ]. Combined therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7206?source=see_link\">",
"     cabergoline",
"    </a>",
"    and a somatostatin analog may be effective when either alone is not [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H337175\">",
"    <span class=\"h4\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;A somewhat greater percentage of patients appear to experience improvement in symptoms with somatostatin analogs than exhibit IGF-1 normalization, presumably because even a partial decrease in GH results in some degree of symptomatic improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/35\">",
"     35",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Successful therapy is associated with an improvement in the following clinical manifestations during the year following a decrease in biochemical parameters:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Soft tissue swelling, carpal tunnel syndrome, and snoring [",
"      <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/33\">",
"       33",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Sleep apnea [",
"      <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/36,37\">",
"       36,37",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Left ventricular mass and left ventricular function [",
"      <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/38-40\">",
"       38-40",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2963829\">",
"    <span class=\"h4\">",
"     Adenoma size",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somatostatin analog therapy leads to a reduction in adenoma size of about 20 to 50 percent in approximately 30 percent of patients (",
"    <a class=\"graphic graphic_figure graphicRef65053 \" href=\"UTD.htm?7/5/7250\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64387 \" href=\"UTD.htm?5/1/5136\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/33\">",
"     33",
"    </a>",
"    ]. In a 2005 systematic review of patients with acromegaly receiving a somatostatin analog as primary medical therapy (before or as an alternative to surgery and radiotherapy), approximately 37 percent experienced a significant reduction in adenoma size (mean, 19 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/41\">",
"     41",
"    </a>",
"    ]. In a subsequent study of 99 patients who received somatostatin analogs as primary therapy, 45 percent had normalization of serum IGF-1 concentration, and 44 percent had a &gt;50 percent reduction of adenoma size [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h4\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somatostatin analogs have few side effects. About one-third of patients have nausea, abdominal discomfort, bloating, loose stools, and fat malabsorption during the first several weeks of therapy, after which the symptoms usually subside spontaneously with continued use [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     Octreotide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/34/7717?source=see_link\">",
"     lanreotide",
"    </a>",
"    transiently inhibit insulin secretion, but their clinical impact on glucose homeostasis is minimal. This was illustrated by a meta-analysis of 18 trials in patients receiving these analogs for acromegaly. Fasting insulin concentrations were significantly reduced and glucose levels were slightly higher on an oral glucose tolerance test, but there were no significant changes in fasting glucose or A1C values [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More important,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    reduces postprandial gallbladder contractility and delays gallbladder emptying. As a result, approximately 25 percent of patients develop asymptomatic cholesterol gallstones or sludge during the first 18 months of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/33\">",
"     33",
"    </a>",
"    ]. The incidence of gallstones is geographically variable, with the highest rates occurring in China [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H337139\">",
"    <span class=\"h4\">",
"     Dose and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two somatostatin analogs,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/34/7717?source=see_link\">",
"     lanreotide",
"    </a>",
"    , are widely available.",
"   </p>",
"   <p>",
"    The long-acting form of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    is given as an intramuscular injection once a month. The initial dose is 20 mg once a month. If the serum IGF-1 concentration does not decrease to normal within two months, the dose can be increased to 30 mg and then to 40 mg a month.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/34/7717?source=see_link\">",
"     Lanreotide",
"    </a>",
"    is available in different forms in different countries. An intramuscular form (lanreotide sustained release [SR]) is given as 30 mg every 7 to 14 days. A deep subcutaneous form (lanreotide autogel or depot) is given as 60 to 120 mg every four to six weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Dopamine agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dopamine agonists, especially",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7206?source=see_link\">",
"     cabergoline",
"    </a>",
"    , may inhibit GH secretion in some patients with acromegaly but do not work as well as somatostatin analogs. Their oral route of administration is an advantage over the other treatments, which are administered parenterally. Cabergoline is the most effective dopamine agonist for the adjuvant management of acromegaly and is therefore the drug of choice in this category [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H337399\">",
"    <span class=\"h3\">",
"     Cabergoline",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a meta-analysis of 15 studies of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7206?source=see_link\">",
"     cabergoline",
"    </a>",
"    therapy in 227 patients with acromegaly, cabergoline achieved normal serum IGF-1 levels in 51 of 149 patients (34 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/46\">",
"     46",
"    </a>",
"    ]. In studies where cabergoline was added to a somatostatin analog, 40 of 77 (52 percent) achieved normal IGF-1 levels. However, these results should be interpreted with caution as some of the studies included in the meta-analysis included poorly defined patient groups and nonrigorous IGF-1 assays.",
"   </p>",
"   <p>",
"    Although dopamine agonists are occasionally effective at reducing adenoma size in pure GH-secreting pituitary adenomas [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/47\">",
"     47",
"    </a>",
"    ], for most patients they are not [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based on the data above, which show that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7206?source=see_link\">",
"     cabergoline",
"    </a>",
"    has a modest effect in some patients, we recommend using cabergoline principally in combination with a somatostatin analog in patients in whom somatostatin analog treatment alone has reduced serum IGF-1 concentrations almost to normal. This combination offers the possibility of reducing the IGF-1 further to mid-normal with the addition of a relatively inexpensive medication administered orally. Cabergoline could also be tried as primary therapy in the occasional patient who has a mild elevation of IGF-1 and a small adenoma, is not a good candidate for surgery, and refuses monthly injections of a somatostatin analog.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H408702\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7206?source=see_link\">",
"     cabergoline",
"    </a>",
"    are nausea, light headedness, and mental fogginess. Less common are nasal stuffiness, depression, and constipation. Because the high doses of cabergoline used in Parkinson&rsquo;s disease have been reported to be associated with valvular heart disease, the effect of the much smaller doses used for lactotroph adenomas has been evaluated. No association with valvular heart disease has yet been found, but the studies so far have been of small numbers of subjects taking doses less than 2 mg a week and evaluated retrospectively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32762?source=see_link&amp;anchor=H19#H19\">",
"     \"Pharmacologic treatment of Parkinson disease\", section on 'Valvular heart disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31561?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment of hyperprolactinemia due to lactotroph adenoma and other causes\", section on 'Valvular heart disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H337380\">",
"    <span class=\"h3\">",
"     Dose and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7206?source=see_link\">",
"     cabergoline",
"    </a>",
"    should be 0.5 mg once a week or 0.25 mg twice a week. The dose should be increased, if necessary, to 1.0 mg twice a week. Higher doses are not likely to decrease GH further [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     GH receptor antagonist",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/23/24948?source=see_link\">",
"     Pegvisomant",
"    </a>",
"    is a GH receptor antagonist that is a mutated growth hormone molecule to which polymers have been attached at several sites to prolong its half-life [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/50\">",
"     50",
"    </a>",
"    ]. The mutation results in increased affinity to site one on the GH receptor but decreased binding to site two. As a result, pegvisomant blocks native GH from binding but does not activate the intracellular signaling that mediates its action.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Dose and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/23/24948?source=see_link\">",
"     Pegvisomant",
"    </a>",
"    is administered as a daily subcutaneous injection. The initial daily dose is 10 mg. The serum IGF-1 concentration should be measured every four to six weeks and the dose adjusted, in 5 mg increments, to a maximum of 30",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    to keep the serum IGF-1 within the normal range. Preliminary data suggest that alternate-day dosing may be effective in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of factors affect the dose required to normalize serum IGF-1 concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/52\">",
"     52",
"    </a>",
"    ]. Higher doses are needed the higher the baseline IGF-1 concentration and the greater the patient's weight, and women need higher doses than men for the same weight. Lower doses are needed for patients who have had radiotherapy for comparable IGF-1 values.",
"   </p>",
"   <p>",
"    Serum GH cannot be used to monitor the effectiveness of treatment, since",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/23/24948?source=see_link\">",
"     pegvisomant",
"    </a>",
"    inhibits the action of GH rather than its secretion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/23/24948?source=see_link\">",
"     Pegvisomant",
"    </a>",
"    is an effective therapy for lowering serum IGF-1 concentrations. In a 12-week study of 112 patients, most of whom had received other treatment, pegvisomant doses of 10 mg, 15 mg, or 20 mg daily resulted in dose-dependent reductions in serum IGF-1 concentrations, as well as in fatigue, soft-tissue swelling, perspiration, and ring size, compared with no changes in the placebo group [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When the same patients and 48 others were treated with up to 40",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for an average of 425 days, 97 percent of those treated for 12 months or more achieved normal IGF-1 concentrations (",
"    <a class=\"graphic graphic_figure graphicRef66653 \" href=\"UTD.htm?25/56/26500\">",
"     figure 3",
"    </a>",
"    ). This is a much higher response rate for IGF-1 levels than achieved by any other therapy. At the same time, the serum GH concentration increased by a mean 12.5",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The results in clinical practice may not be as good as in clinical trials. In an international surveillance registry of 1288 patients with acromegaly receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/23/24948?source=see_link\">",
"     pegvisomant",
"    </a>",
"    for an average of 3.7 years [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/55\">",
"     55",
"    </a>",
"    ], only 56.6 percent of subjects had normal IGF-1 concentrations one year after beginning pegvisomant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Adenoma size",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/23/24948?source=see_link\">",
"     pegvisomant",
"    </a>",
"    does not inhibit GH secretion and its use is associated with an increase in the serum GH concentration, somatotroph adenoma size presumably could continue to grow during its use. However, this appears to be uncommon, as illustrated by the surveillance registry study cited above [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/55\">",
"     55",
"    </a>",
"    ]. In 30 of 936 patients (3.2 percent) for whom MRI data was available, an increase in adenoma size was noted in an average 2.1 years of follow-up. Based upon such observations, patients receiving pegvisomant should have adenoma size assessed by MRI at least once a year [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the registry study noted above [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/55\">",
"     55",
"    </a>",
"    ], 30 subjects (2.5 percent) developed elevated liver enzymes greater than three times the upper limit of normal. In the 23 subjects for whom follow-up data was available, liver enzymes returned to normal after decrease or discontinuation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/23/24948?source=see_link\">",
"     pegvisomant",
"    </a>",
"    . There were no reports of liver failure [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/23/24948?source=see_link\">",
"     Pegvisomant",
"    </a>",
"    should therefore not be prescribed to patients who have clearly abnormal liver function, and patients who are treated should be monitored by liver function tests once a month during the first six months of treatment and every four to six months thereafter. Pegvisomant has also been shown to be associated with lipohypertrophy both at the injection site and at distant sites [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/57,58\">",
"     57,58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H420273\">",
"    <span class=\"h3\">",
"     Combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of a long-acting somatostatin analog and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/23/24948?source=see_link\">",
"     pegvisomant",
"    </a>",
"    , in a few reports [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/59-61\">",
"     59-61",
"    </a>",
"    ], decreased serum IGF-1 concentrations to normal in a majority of patients, but the combination was not clearly better than pegvisomant alone. For example, in 27 patients who were suboptimally controlled while taking long-acting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    alone, randomization to either the combination of the analog combined with pegvisomant or pegvisomant alone led to normalization of IGF-1 in 62 and 56 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/60\">",
"     60",
"    </a>",
"    ]. The combination, however, seems to be associated with a greater incidence of transaminase elevations than either alone, as high as 38 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/59-61\">",
"     59-61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     RADIATION THERAPY",
"    </span>",
"   </p>",
"   <p>",
"    Radiation therapy is effective in reducing the size of somatotroph adenomas and decreasing GH and IGF-1 concentrations, often to normal, but because the decreases in GH and IGF-1 usually take years to occur, it is used mainly for patients whose disease is not controlled by surgery or medical therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H408852\">",
"    <span class=\"h2\">",
"     Types of radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following types of radiation are available for all pituitary adenomas, including somatotroph adenomas [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/62\">",
"     62",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      X-radiation from a linear accelerator. For several decades, the only type of radiation therapy widely available was fractionated x-radiation from a linear accelerator. This radiation is now referred to as &ldquo;conventional radiation.&rdquo; This type of radiation is still the most widely used but has been modified, by the use of computer programs, to conform the radiation to the shape of adenoma, which is called intensity modulated radiation therapy (IMRT). Radiation can also be administered from a linear accelerator attached to a robotic arm in a single large dose or up to five doses by an instrument called a &ldquo;Cyberknife&rdquo; (although there is no &ldquo;knife&rdquo;).",
"     </li>",
"     <li>",
"      Gamma radiation can be administered from a cobalt source, but only as a single large dose. This is called &ldquo;Gamma knife&rdquo; (although there is no knife).",
"     </li>",
"     <li>",
"      Protons can be administered from a cyclotron in either a single large dose or multiple fractions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Radiation administered as a single dose (often called &ldquo;stereotactic radiosurgery,&rdquo; although there is no surgery), whether by linear accelerator, gamma radiation or protons, has the advantage of patient convenience and possibly faster control of hormonal hypersecretion [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/62\">",
"     62",
"    </a>",
"    ]. However, a single dose of radiation cannot be used unless the adenoma is separated by several millimeters from the optic chiasm and optic nerves, which would be severely damaged by such a high dose, resulting in blindness. In this situation, fractionated radiation must be used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H408862\">",
"    <span class=\"h3\">",
"     Fractionated radiation",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H408870\">",
"    <span class=\"h4\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum GH and IGF-1 concentrations decline on average about 20 percent per year, so that serum GH concentrations may not reach 5 to 10",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    until 5 to 10 years or more after treatment if the initial value is very high [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By 20 years, up to 90 percent of patients have serum GH concentrations less than 5",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    and 10 to 77 percent in different studies eventually achieved serum GH concentrations &lt;2.5",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef55079 \" href=\"UTD.htm?30/56/31628\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/63-68\">",
"     63-68",
"    </a>",
"    ]. However, few patients achieve the current goal of therapy, ie, a basal serum GH concentration less than 1",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"    In one series, as an example, only 5 of 30 patients (17 percent) followed for 10 or more years reached this goal [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Normalization of the serum IGF-1 concentration occurs in approximately 55 to 70 percent of patients after 10 years, but the results vary among studies [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/65-68\">",
"     65-68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The largest study of conventional radiation, a retrospective series of 884 patients with acromegaly who had received conventional pituitary irradiation, had somewhat more favorable results than other reports [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/63\">",
"     63",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Twenty-two percent of patients achieved a serum GH concentration &lt;2.5",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      by two years, 60 percent by 10 years, and 77 percent by 20 years.",
"     </li>",
"     <li>",
"      Sixty-three percent of patients had a normal serum IGF-1 concentration by 10 years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h4\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Within 10 years, an appreciable proportion of patients treated with pituitary radiation develop deficiency of one or more pituitary hormones [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/63,66\">",
"     63,66",
"    </a>",
"    ], and the incidence continues to increase thereafter. Gonadotropin deficiency is most common, followed by corticotropin and then TSH deficiency.",
"   </p>",
"   <p>",
"    The range of frequency of hormone deficiency can be illustrated by the following findings in two reports cited above:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the series of 884 patients, the percentage of patients with new hormone deficiencies 10 years after irradiation were 18, 15, and 27 percent for",
"      <span class=\"nowrap\">",
"       LH/FSH,",
"      </span>",
"      ACTH, and TSH, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the series of 128 patients, the percentage of patients with new hormone deficiencies 10 years after irradiation were 80, 82, and 78 percent for",
"      <span class=\"nowrap\">",
"       LH/FSH,",
"      </span>",
"      ACTH, and TSH, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A probable contributing factor is that patients in the latter study had more severe disease, as evidenced by a higher baseline serum GH concentration (36 versus 13",
"    <span class=\"nowrap\">",
"     ng/mL).",
"    </span>",
"    In addition, mean radiation dose was slightly higher in the latter study (mean dose 52 Gy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/66\">",
"     66",
"    </a>",
"    ] versus 45 Gy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/63\">",
"     63",
"    </a>",
"    ]).",
"   </p>",
"   <p>",
"    Other complications are cranial-nerve palsies, loss of vision, and memory deficits. All are rare, and usually occur only when the dose is high [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Second intracranial tumors have been reported in up to 1.7 percent of patients within the first 10 years after pituitary radiation, a considerably higher frequency (relative risk 16) than in normal subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. The reported tumors include astrocytoma, glioblastoma, meningioma, and sarcoma [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/71\">",
"     71",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Some evidence points to radiotherapy as being a significant independent determinant of overall mortality in acromegaly [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/72,73\">",
"     72,73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Single dose radiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gamma radiation has been available more widely than the other forms of single dose radiation, protons and x-radiation from a linear accelerator, so more data are available about it.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H410180\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In three studies of 35 to 96 acromegalic patients followed for a mean or median period of 53 to 120 months after gamma radiation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/74,75\">",
"     74,75",
"    </a>",
"    ], cure rates (defined as normal age- and gender-adjusted IGF-1 concentrations and basal GH of &lt;2.5",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    or post-glucose values of &lt;1.0",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    were 46 to 60 percent in 5 to 10 years.",
"   </p>",
"   <p>",
"    In a study of 22 patients with persistent acromegaly followed for a median of 6.3 years after a single dose of protons, 59 percent developed a normal serum IGF-1 in a median time of 42 months [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with fractionated radiation, cure rates due to single dose radiation are higher the smaller the size of the adenoma and the lower the IGF-1 and growth hormone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H410242\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypopituitarism occurs after single dose radiation, as it does with fractionated, in approximately 40 percent of those treated by both gamma and proton radiation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/74-76\">",
"     74-76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     MANAGEMENT DURING PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most women with untreated acromegaly have menstrual dysfunction due to one or more of the following [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/77\">",
"     77",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decreased secretion of luteinizing hormone (LH) and follicle stimulating hormone (FSH) due to compression of gonadotroph cells by a macroadenoma",
"     </li>",
"     <li>",
"      Hyperprolactinemia due to pituitary stalk compression",
"     </li>",
"     <li>",
"      Hyperprolactinemia due to a mixed GH-prolactin secreting adenoma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although data are limited, when women with acromegaly do conceive, the majority have uncomplicated pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/78\">",
"     78",
"    </a>",
"    ]. In one retrospective multicenter study of 59 pregnancies in 46 women with GH-secreting pituitary macroadenomas or less often microadenomas, 43 of the 46 women had previously been treated with surgery or radiotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/79\">",
"     79",
"    </a>",
"    ]. Prior to conception, GH and IGF-1 hypersecretion was controlled in 23 (40 percent) and uncontrolled in 34 (60 percent) patients. Medical therapy was discontinued in early pregnancy in all but four women. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pregnancy was uneventful for most women; the 59 pregnancies resulted in 64 healthy babies.",
"     </li>",
"     <li>",
"      No major neonatal malformations were encountered. However, in four women who continued somatostatin analog therapy during pregnancy, all gave birth to a small for gestational age infant.",
"     </li>",
"     <li>",
"      Gestational diabetes mellitus (GDM) and gestational hypertension, which developed in 7 and 14 percent of pregnancies, was more common in women with active or uncontrolled acromegaly. Among those who had postpartum MRI imaging data available, only 2 of 22 (7 percent) showed an increase in pituitary tumor size.",
"     </li>",
"     <li>",
"      Seventeen women breastfed with no complications (there are concerns about pituitary apoplexy postpartum in women with residual tumor and lactotroph hyperplasia; however, the available evidence is inadequate to warrant advising a woman not to nurse).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a second report of 13 pregnancies in women with acromegaly, similar findings were seen; 10 of 13 received no medical therapy during the pregnancy. There were no pregnancy complications and no congenital malformations, but one of the three infants whose mother had received medical therapy (somatostatin analog) had low birth weight [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon these findings, we suggest the following approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pregnancy should be postponed, if possible, until GH and IGF-1 levels are controlled and no residual adenoma mass is seen.",
"     </li>",
"     <li>",
"      The serum GH and IGF-1 concentrations should be as tightly controlled as possible in women with known acromegaly before pregnancy occurs to minimize the risk of gestational diabetes and gestation hypertension.",
"     </li>",
"     <li>",
"      GH suppressive medical therapy should be withdrawn when pregnancy is confirmed since the majority of small pituitary adenomas do not grow during pregnancy and continued treatment with somatostatin analogs may result in small for gestational age infants [",
"      <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/78,79\">",
"       78,79",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      If the pregnancy is uneventful, routine monitoring of GH and IGF-1 during pregnancy may not be necessary. In addition, pregnancy may alter the results of measured GH or IGF-1 values. We suggest monitoring visual fields during each trimester of pregnancy in women with known macroadenomas. MRI should be reserved for those who have visual symptoms. If visual impairment is confirmed, surgery may be necessary.",
"     </li>",
"     <li>",
"      Breastfeeding is a reasonable option for women who do not require treatment to suppress growth hormone immediately after delivery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     LONG-TERM MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several steps are involved in the long-term management of patients with acromegaly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22740659\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Clinical and biochemical evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following initial treatment, patients should be evaluated every three to four months by both clinical examination and measurement of serum IGF-1 levels. Measuring random GH or post-OGTT nadir GH levels may not add helpful information if IGF-1 levels are normal. Patients who are being treated with a medication should have the dose adjusted, if necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/71\">",
"     71",
"    </a>",
"    ]. If normal values are not achieved, alternative therapy should be considered (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Surgical cure rate'",
"    </a>",
"    above). In patients well controlled on medical therapy, we suggest biochemical testing (serum GH, IGF-1) every six months. Other pituitary hormones should be evaluated yearly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Adenoma size",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI should be repeated yearly for the first several years after initial treatment and less often thereafter. Visual field assessment is indicated for patients whose adenomas threaten their optic chiasm [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Systemic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acromegaly appears to be associated with an excess risk of colonic polyps. Based upon these observations, we suggest that colonoscopy be performed at baseline and then every three to four years thereafter in patients over age 50, especially when GH levels are not strictly controlled. This recommendation is consistent with the 2009 guidelines from the Acromegaly Consensus Group [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/80\">",
"     80",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30776?source=see_link&amp;anchor=H16#H16\">",
"     \"Causes and clinical manifestations of acromegaly\", section on 'Other tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Comprehensive cardiovascular evaluation should be performed regularly, and hypertension and heart failure should be treated [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/80\">",
"     80",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30776?source=see_link&amp;anchor=H12#H12\">",
"     \"Causes and clinical manifestations of acromegaly\", section on 'Cardiovascular disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22740699\">",
"    <span class=\"h2\">",
"     Treatment of GH deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is estimated that 50 to 70 percent of patients with acromegaly treated with surgery alone or surgery combined with radiation therapy develop GH deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/22\">",
"     22",
"    </a>",
"    ], a complication that is associated with a decreased quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/81\">",
"     81",
"    </a>",
"    ]. However, the impact of growth hormone therapy in those who develop growth hormone deficiency is still unclear. In one trial, patients with cured acromegaly who developed growth hormone deficiency had improved body composition (decrease in total body fat mass and abdominal fat) with growth hormone therapy compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/82\">",
"     82",
"    </a>",
"    ]. In contrast, a second trial reported an increase in vascular events after two years of growth hormone therapy in adults with growth hormone deficiency previously treated for acromegaly [",
"    <a class=\"abstract\" href=\"UTD.htm?7/9/7322/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given these conflicting data, we do not suggest the routine use of growth hormone therapy in these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/8/40066?source=see_link\">",
"       \"Patient information: Acromegaly (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?42/27/43443?source=see_link\">",
"       \"Patient information: Acromegaly (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients can also get information about pituitary adenomas and their consequences from",
"    <a class=\"external\" href=\"file://www.pituitarysociety.org/\">",
"     The Pituitary Society",
"    </a>",
"    and",
"    <a class=\"external\" href=\"file://www.endo-society.org/\">",
"     The Endocrine Society",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A strategy for managing patients with acromegaly and a summary of treatment effects are summarized in the algorithm and table (",
"    <a class=\"graphic graphic_algorithm graphicRef61609 \" href=\"UTD.htm?31/8/31886\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef55079 \" href=\"UTD.htm?30/56/31628\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with a microadenoma, a macroadenoma that appears to be fully resectable, or a macroadenoma threatening or impairing vision, we recommend transsphenoidal surgery performed by a neurosurgeon with considerable experience (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Transsphenoidal surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with an adenoma that does not appear to be fully resectable and for patients whose risk of surgery is great or who choose not to have surgery, we suggest primary therapy with a long-acting somatostatin analog (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Somatostatin analogs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If transsphenoidal surgery results in normalization of serum IGF-1 concentration, we suggest no further therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Transsphenoidal surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If transsphenoidal surgery does not normalize the serum IGF-1 concentration, we suggest therapy with a long-acting somatostatin analog (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Somatostatin analogs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If a somatostatin analog, with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7206?source=see_link\">",
"       cabergoline",
"      </a>",
"      , is ineffective, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/23/24948?source=see_link\">",
"       pegvisomant",
"      </a>",
"      alone or in combination with the somatostatin analog (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Dopamine agonists'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'GH receptor antagonist'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If adenoma size increases despite medical therapy (ie, somatostatin analog plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/23/24948?source=see_link\">",
"       pegvisomant",
"      </a>",
"      ), we suggest radiotherapy or repeat surgery (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Radiation therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For women who desire pregnancy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pregnancy should be postponed, if possible, until GH and IGF-1 levels are controlled and no residual tumor mass is seen. We suggest controlling the serum GH and IGF1 concentrations as tightly as possible in women with known acromegaly before pregnancy occurs to minimize the risk of gestational diabetes and gestational hypertension (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Management during pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest stopping GH suppressive medical therapy when pregnancy is confirmed (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The majority of tumors do not grow during pregnancy, and continued treatment with somatostatin analogs may result in small for gestational age infants. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Management during pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Visual fields should be monitored during pregnancy in women with known macroadenomas by the end of the first trimester and every six weeks thereafter. MRI should be performed if vision appears to be affected. If visual impairment is confirmed, surgery will likely be necessary. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Management during pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/1\">",
"      Melmed S. Acromegaly pathogenesis and treatment. J Clin Invest 2009; 119:3189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/2\">",
"      Freda PU, Post KD, Powell JS, Wardlaw SL. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. J Clin Endocrinol Metab 1998; 83:3808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/3\">",
"      Dimaraki EV, Jaffe CA, DeMott-Friberg R, et al. Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. J Clin Endocrinol Metab 2002; 87:3537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/4\">",
"      Puder JJ, Nilavar S, Post KD, Freda PU. Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly. J Clin Endocrinol Metab 2005; 90:1972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/5\">",
"      Swearingen B, Barker FG 2nd, Katznelson L, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998; 83:3419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/6\">",
"      Abosch A, Tyrrell JB, Lamborn KR, et al. Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab 1998; 83:3411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/7\">",
"      Melmed S. Medical progress: Acromegaly. N Engl J Med 2006; 355:2558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/8\">",
"      Biermasz NR, Pereira AM, Smit JW, et al. Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life. J Clin Endocrinol Metab 2005; 90:2731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/9\">",
"      Ross DA, Wilson CB. Results of transsphenoidal microsurgery for growth hormone-secreting pituitary adenoma in a series of 214 patients. J Neurosurg 1988; 68:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/10\">",
"      Fahlbusch R, Honegger J, Buchfelder M. Surgical management of acromegaly. Endocrinol Metab Clin North Am 1992; 21:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/11\">",
"      Ben-Shlomo A, Melmed S. Clinical review 154: The role of pharmacotherapy in perioperative management of patients with acromegaly. J Clin Endocrinol Metab 2003; 88:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/12\">",
"      Jane JA Jr, Starke RM, Elzoghby MA, et al. Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications, and predictors of outcome. J Clin Endocrinol Metab 2011; 96:2732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/13\">",
"      Hofstetter CP, Mannaa RH, Mubita L, et al. Endoscopic endonasal transsphenoidal surgery for growth hormone-secreting pituitary adenomas. Neurosurg Focus 2010; 29:E6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/14\">",
"      Freda PU, Wardlaw SL, Post KD. Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly. J Neurosurg 1998; 89:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/15\">",
"      Jenkins D, O'Brien I, Johnson A, et al. The Birmingham pituitary database: auditing the outcome of the treatment of acromegaly. Clin Endocrinol (Oxf) 1995; 43:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/16\">",
"      Feelders RA, Bidlingmaier M, Strasburger CJ, et al. Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels. J Clin Endocrinol Metab 2005; 90:6480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/17\">",
"      Sze L, Schmid C, Bloch KE, et al. Effect of transsphenoidal surgery on sleep apnoea in acromegaly. Eur J Endocrinol 2007; 156:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/18\">",
"      Colao A, Marzullo P, Vallone G, et al. Reversibility of joint thickening in acromegalic patients: an ultrasonography study. J Clin Endocrinol Metab 1998; 83:2121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/19\">",
"      Kreutzer J, Vance ML, Lopes MB, Laws ER Jr. Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. J Clin Endocrinol Metab 2001; 86:4072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/20\">",
"      Biermasz NR, van Dulken H, Roelfsema F. Ten-year follow-up results of transsphenoidal microsurgery in acromegaly. J Clin Endocrinol Metab 2000; 85:4596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/21\">",
"      Freda PU, Nuruzzaman AT, Reyes CM, et al. Significance of \"abnormal\" nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels. J Clin Endocrinol Metab 2004; 89:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/22\">",
"      Ronchi CL, Giavoli C, Ferrante E, et al. Prevalence of GH deficiency in cured acromegalic patients: impact of different previous treatments. Eur J Endocrinol 2009; 161:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/23\">",
"      Ciric I, Ragin A, Baumgartner C, Pierce D. Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience. Neurosurgery 1997; 40:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/24\">",
"      Barker FG 2nd, Klibanski A, Swearingen B. Transsphenoidal surgery for pituitary tumors in the United States, 1996-2000: mortality, morbidity, and the effects of hospital and surgeon volume. J Clin Endocrinol Metab 2003; 88:4709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/25\">",
"      Cozzi R, Montini M, Attanasio R, et al. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab 2006; 91:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/26\">",
"      Shimon I, Yan X, Taylor JE, et al. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J Clin Invest 1997; 100:2386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/27\">",
"      Reubi JC, Landolt AM. The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status. J Clin Endocrinol Metab 1989; 68:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/28\">",
"      Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996; 334:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/29\">",
"      Thapar K, Kovacs KT, Stefaneanu L, et al. Antiproliferative effect of the somatostatin analogue octreotide on growth hormone-producing pituitary tumors: results of a multicenter randomized trial. Mayo Clin Proc 1997; 72:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/30\">",
"      Losa M, Ciccarelli E, Mortini P, et al. Effects of octreotide treatment on the proliferation and apoptotic index of GH-secreting pituitary adenomas. J Clin Endocrinol Metab 2001; 86:5194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/31\">",
"      Murray RD, Melmed S. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab 2008; 93:2957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/32\">",
"      Bevan JS, Atkin SL, Atkinson AB, et al. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 2002; 87:4554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/33\">",
"      Freda PU. Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2002; 87:3013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/34\">",
"      Lamberts SW, Zweens M, Verschoor L, del Pozo E. A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201-995, bromocriptine, and the combination of both drugs. J Clin Endocrinol Metab 1986; 63:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/35\">",
"      Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004; 25:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/36\">",
"      Grunstein RR, Ho KK, Sullivan CE. Effect of octreotide, a somatostatin analog, on sleep apnea in patients with acromegaly. Ann Intern Med 1994; 121:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/37\">",
"      Herrmann BL, Wessendorf TE, Ajaj W, et al. Effects of octreotide on sleep apnoea and tongue volume (magnetic resonance imaging) in patients with acromegaly. Eur J Endocrinol 2004; 151:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/38\">",
"      Lim MJ, Barkan AL, Buda AJ. Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion. Ann Intern Med 1992; 117:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/39\">",
"      Colao A, Cuocolo A, Marzullo P, et al. Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly. J Clin Endocrinol Metab 1999; 84:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/40\">",
"      Maison P, Tropeano AI, Macquin-Mavier I, et al. Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis. J Clin Endocrinol Metab 2007; 92:1743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/41\">",
"      Melmed S, Sternberg R, Cook D, et al. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 2005; 90:4405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/42\">",
"      Colao A, Pivonello R, Auriemma RS, et al. Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab 2006; 91:2112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/43\">",
"      Mazziotti G, Floriani I, Bonadonna S, et al. Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J Clin Endocrinol Metab 2009; 94:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/44\">",
"      Shi YF, Zhu XF, Harris AG, et al. Prospective study of the long-term effects of somatostatin analog (octreotide) on gallbladder function and gallstone formation in Chinese acromegalic patients. J Clin Endocrinol Metab 1993; 76:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/45\">",
"      Caron P, Beckers A, Cullen DR, et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab 2002; 87:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/46\">",
"      Sandret L, Maison P, Chanson P. Place of cabergoline in acromegaly: a meta-analysis. J Clin Endocrinol Metab 2011; 96:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/47\">",
"      Rickels MR, Snyder PJ. Cabergoline decreases somatotroph adenoma size: a case report. Pituitary 2004; 7:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/48\">",
"      Abs R, Verhelst J, Maiter D, et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 1998; 83:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/49\">",
"      Freda PU, Reyes CM, Nuruzzaman AT, et al. Cabergoline therapy of growth hormone &amp; growth hormone/prolactin secreting pituitary tumors. Pituitary 2004; 7:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/50\">",
"      Pradhananga S, Wilkinson I, Ross RJ. Pegvisomant: structure and function. J Mol Endocrinol 2002; 29:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/51\">",
"      Jehle S, Reyes CM, Sundeen RE, Freda PU. Alternate-day administration of pegvisomant maintains normal serum insulin-like growth factor-I levels in patients with acromegaly. J Clin Endocrinol Metab 2005; 90:1588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/52\">",
"      Parkinson C, Burman P, Messig M, Trainer PJ. Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant. J Clin Endocrinol Metab 2007; 92:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/53\">",
"      Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000; 342:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/54\">",
"      Biering H, Saller B, Bauditz J, et al. Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis. Eur J Endocrinol 2006; 154:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/55\">",
"      van der Lely AJ, Biller BM, Brue T, et al. Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab 2012; 97:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/56\">",
"      Buhk JH, Jung S, Psychogios MN, et al. Tumor volume of growth hormone-secreting pituitary adenomas during treatment with pegvisomant: a prospective multicenter study. J Clin Endocrinol Metab 2010; 95:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/57\">",
"      Trainer PJ. ACROSTUDY: the first 5 years. Eur J Endocrinol 2009; 161 Suppl 1:S19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/58\">",
"      Bonert VS, Kennedy L, Petersenn S, et al. Lipodystrophy in patients with acromegaly receiving pegvisomant. J Clin Endocrinol Metab 2008; 93:3515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/59\">",
"      Feenstra J, de Herder WW, ten Have SM, et al. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 2005; 365:1644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/60\">",
"      Trainer PJ, Ezzat S, D'Souza GA, et al. A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly. Clin Endocrinol (Oxf) 2009; 71:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/61\">",
"      Madsen M, Poulsen PL, Orskov H, et al. Cotreatment with pegvisomant and a somatostatin analog (SA) in SA-responsive acromegalic patients. J Clin Endocrinol Metab 2011; 96:2405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/62\">",
"      Loeffler JS, Shih HA. Radiation therapy in the management of pituitary adenomas. J Clin Endocrinol Metab 2011; 96:1992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/63\">",
"      Jenkins PJ, Bates P, Carson MN, et al. Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly. J Clin Endocrinol Metab 2006; 91:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/64\">",
"      Thalassinos NC, Tsagarakis S, Ioannides G, et al. Megavoltage pituitary irradiation lowers but seldom leads to safe GH levels in acromegaly: a long-term follow-up study. Eur J Endocrinol 1998; 138:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/65\">",
"      Powell JS, Wardlaw SL, Post KD, Freda PU. Outcome of radiotherapy for acromegaly using normalization of insulin-like growth factor I to define cure. J Clin Endocrinol Metab 2000; 85:2068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/66\">",
"      Barrande G, Pittino-Lungo M, Coste J, et al. Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center. J Clin Endocrinol Metab 2000; 85:3779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/67\">",
"      Cozzi R, Barausse M, Asnaghi D, et al. Failure of radiotherapy in acromegaly. Eur J Endocrinol 2001; 145:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/68\">",
"      Epaminonda P, Porretti S, Cappiello V, et al. Efficacy of radiotherapy in normalizing serum IGF-I, acid-labile subunit (ALS) and IGFBP-3 levels in acromegaly. Clin Endocrinol (Oxf) 2001; 55:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/69\">",
"      Brada M, Ford D, Ashley S, et al. Risk of second brain tumour after conservative surgery and radiotherapy for pituitary adenoma. BMJ 1992; 304:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/70\">",
"      Tsang RW, Laperriere NJ, Simpson WJ, et al. Glioma arising after radiation therapy for pituitary adenoma. A report of four patients and estimation of risk. Cancer 1993; 72:2227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/71\">",
"      Ahmed M, Kanaan I, Rifai A, et al. An unusual treatment-related complication in a patient with growth hormone-secreting pituitary tumor. J Clin Endocrinol Metab 1997; 82:2816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/72\">",
"      Sherlock M, Reulen RC, Alonso AA, et al. ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly. J Clin Endocrinol Metab 2009; 94:4216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/73\">",
"      Ayuk J, Clayton RN, Holder G, et al. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 2004; 89:1613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/74\">",
"      Jezkov&aacute; J, Marek J, H&aacute;na V, et al. Gamma knife radiosurgery for acromegaly--long-term experience. Clin Endocrinol (Oxf) 2006; 64:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/75\">",
"      Ronchi CL, Attanasio R, Verrua E, et al. Efficacy and tolerability of gamma knife radiosurgery in acromegaly: a 10-year follow-up study. Clin Endocrinol (Oxf) 2009; 71:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/76\">",
"      Petit JH, Biller BM, Coen JJ, et al. Proton stereotactic radiosurgery in management of persistent acromegaly. Endocr Pract 2007; 13:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/77\">",
"      Grynberg M, Salenave S, Young J, Chanson P. Female gonadal function before and after treatment of acromegaly. J Clin Endocrinol Metab 2010; 95:4518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/78\">",
"      Cheng S, Grasso L, Martinez-Orozco JA, et al. Pregnancy in acromegaly: experience from two referral centers and systematic review of the literature. Clin Endocrinol (Oxf) 2012; 76:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/79\">",
"      Caron P, Broussaud S, Bertherat J, et al. Acromegaly and pregnancy: a retrospective multicenter study of 59 pregnancies in 46 women. J Clin Endocrinol Metab 2010; 95:4680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/80\">",
"      Melmed S, Colao A, Barkan A, et al. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 2009; 94:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/81\">",
"      Wexler T, Gunnell L, Omer Z, et al. Growth hormone deficiency is associated with decreased quality of life in patients with prior acromegaly. J Clin Endocrinol Metab 2009; 94:2471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/82\">",
"      Miller KK, Wexler T, Fazeli P, et al. Growth hormone deficiency after treatment of acromegaly: a randomized, placebo-controlled study of growth hormone replacement. J Clin Endocrinol Metab 2010; 95:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/9/7322/abstract/83\">",
"      Norrman LL, Johannsson G, Sunnerhagen KS, Svensson J. Baseline characteristics and the effects of two years of growth hormone (GH) replacement therapy in adults with GH deficiency previously treated for acromegaly. J Clin Endocrinol Metab 2008; 93:2531.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6625 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-201.65.114.212-1237D62C13-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_9_7322=[""].join("\n");
var outline_f7_9_7322=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GOALS OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H689545547\">",
"      SUGGESTED APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TRANSSPHENOIDAL SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Surgical cure rate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MEDICAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Somatostatin analogs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1740166\">",
"      - Mechanisms of action",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H337158\">",
"      Serum IGF-1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H337175\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2963829\">",
"      Adenoma size",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H337139\">",
"      Dose and administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Dopamine agonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H337399\">",
"      - Cabergoline",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H408702\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H337380\">",
"      - Dose and administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      GH receptor antagonist",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Dose and administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Adenoma size",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H420273\">",
"      - Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      RADIATION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H408852\">",
"      Types of radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H408862\">",
"      - Fractionated radiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H408870\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Single dose radiation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H410180\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H410242\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      MANAGEMENT DURING PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      LONG-TERM MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22740659\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Clinical and biochemical evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Adenoma size",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Systemic evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22740699\">",
"      Treatment of GH deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/6625\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/6625|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?31/8/31886\" title=\"algorithm 1\">",
"      Summary of management strategy for patients with acromegaly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/6625|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?5/1/5136\" title=\"diagnostic image 1\">",
"      Shrinkage of a macroadenoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/6625|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/10/39086\" title=\"figure 1\">",
"      Efficacy octreotide acromegaly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/5/7250\" title=\"figure 2\">",
"      Octreotide adenoma size",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/56/26500\" title=\"figure 3\">",
"      Pegvisomant acromegaly IGF1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/6625|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/56/31628\" title=\"table 1\">",
"      Therapies for acromegaly",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30776?source=related_link\">",
"      Causes and clinical manifestations of acromegaly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43076?source=related_link\">",
"      Diagnosis of acromegaly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?42/27/43443?source=related_link\">",
"      Patient information: Acromegaly (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/8/40066?source=related_link\">",
"      Patient information: Acromegaly (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32762?source=related_link\">",
"      Pharmacologic treatment of Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31561?source=related_link\">",
"      Treatment of hyperprolactinemia due to lactotroph adenoma and other causes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_9_7323="ACCAHAESC WPW abl";
var content_f7_9_7323=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F72357&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F72357&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for prevention of sudden cardiac death: Wolff-Parkinson-White syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       &nbsp;",
"      </td>",
"      <td class=\"subtitle1\">",
"       Recommendations",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Catheter ablation in patients resuscitated from sudden cardiac arrest due to atrial fibrillation and rapid condunction over the accessory pathway causing ventricular fibrillation)",
"      </td>",
"      <td>",
"       Class I - Procedure should be performed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Catheter ablation in symptomatic patients WPW syndrome who have accessory pathways with refractory periods less than 240 ms in duration",
"      </td>",
"      <td>",
"       Class IIa - Procedure is reasonable",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006; 48:e247.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_9_7323=[""].join("\n");
var outline_f7_9_7323=null;
var title_f7_9_7324="Pulmonary biopsies in farmers";
var content_f7_9_7324=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F70307&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F70307&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary of the morphologic features in pulmonary biopsies of farmer's lung patients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Morphologic criteria",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent of cases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interstitial infiltrate",
"       </td>",
"       <td>",
"        100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unresolved pneumonia",
"       </td>",
"       <td>",
"        65",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interstitial fibrosis",
"       </td>",
"       <td>",
"        65",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bronchiolitis obliterans",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pleural fibrosis",
"       </td>",
"       <td>",
"        48",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Foam cells",
"       </td>",
"       <td>",
"        65",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Edema",
"       </td>",
"       <td>",
"        52",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Granulomas",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        70",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        With giant cells*",
"       </td>",
"       <td class=\"sublist_other\">",
"        50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Without giant cells",
"       </td>",
"       <td class=\"sublist_other\">",
"        58",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Solitary giant cells",
"       </td>",
"       <td>",
"        53",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Foreign bodies",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Birefringent*",
"       </td>",
"       <td class=\"sublist_other\">",
"        47",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Non-birefringent",
"       </td>",
"       <td class=\"sublist_other\">",
"        40",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The discrepancy in the total numbers is due to the fact that in some cases, granulomas with and without giant cells may be found. This discrepancy also applies to the foreign bodies.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Reyes, CN, Wenzel, FJ, Lawton, BR, Emanuel, DA. Chest 1982; 82:142.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_9_7324=[""].join("\n");
var outline_f7_9_7324=null;
var title_f7_9_7325="Daytime vs nocturnal PCO2 COPD";
var content_f7_9_7325=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F64203&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F64203&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Effect of nocturnal assisted ventilation on daytime versus nocturnal PCO2 in COPD",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 292px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    There was a close correlation between change in daytime arterial tension of carbon dioxide (vertical axis) and change in mean overnight transcutaneous tension of carbon dioxide (horizontal axis) for individual patients with COPD after three months of nocturnal assisted ventilation.",
"    <div class=\"footnotes\">",
"     PaCO",
"     <sub>",
"      2",
"     </sub>",
"     : arterial tension of carbon dioxide; PtCO",
"     <sub>",
"      2",
"     </sub>",
"     : transcutaneous tension of carbon dioxide.",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Meecham-Jones DJ, Paul EA, Jones PW, Wedzicha JA. Am J Respir Crit Care 1995; 152:538.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_9_7325=[""].join("\n");
var outline_f7_9_7325=null;
var title_f7_9_7326="Intraoperative PTH monitoring - Criteria used to guide surgery";
var content_f7_9_7326=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F64080&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F64080&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Intraoperative PTH monitoring - Criteria used to guide surgery",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Investigators",
"       </td>",
"       <td class=\"subtitle1\">",
"        IPM criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Irvin",
"        <sup>",
"         [1-5]",
"        </sup>",
"        <br/>",
"        Micolli",
"        <sup>",
"         [6]",
"        </sup>",
"        <br/>",
"        Vignali",
"        <sup>",
"         [7]",
"        </sup>",
"        <br/>",
"       </td>",
"       <td>",
"        &gt;50 percent PTH drop from the highest baseline at 10 minutes after gland excision",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Gordon",
"        <sup>",
"         [8]",
"        </sup>",
"        <br/>",
"        Johnson",
"        <sup>",
"         [9]",
"        </sup>",
"        <br/>",
"        Agarwal",
"        <sup>",
"         [10]",
"        </sup>",
"        <br/>",
"        Gauger",
"        <sup>",
"         [11]",
"        </sup>",
"        <br/>",
"        Miura",
"        <sup>",
"         [12]",
"        </sup>",
"        <br/>",
"        Perrier",
"        <sup>",
"         [13]",
"        </sup>",
"        <br/>",
"        Libutti",
"        <sup>",
"         [14]",
"        </sup>",
"        <br/>",
"        Riss",
"        <sup>",
"         [15]",
"        </sup>",
"        <br/>",
"       </td>",
"       <td>",
"        &gt;50 percent PTH drop from pre-incision at 10 minutes after gland excision",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Burkey",
"        <sup>",
"         [16]",
"        </sup>",
"        <br/>",
"        Yang",
"        <sup>",
"         [17]",
"        </sup>",
"        <br/>",
"        Chiu",
"        <sup>",
"         [18]",
"        </sup>",
"        <br/>",
"        Carty",
"        <sup>",
"         [19]",
"        </sup>",
"        <br/>",
"       </td>",
"       <td>",
"        &gt;50 percent PTH drop from baseline level and a return to normal range 10 minutes after gland excision",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Irvin",
"        <sup>",
"         [20]",
"        </sup>",
"       </td>",
"       <td>",
"        &gt;50 percent PTH drop from highest baseline level and below pre-incision 10 minutes after gland excision",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Weber",
"        <sup>",
"         [21]",
"        </sup>",
"       </td>",
"       <td>",
"        &gt;50 percent PTH drop from pre-excision at 10 minutes after gland excision",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Their",
"        <sup>",
"         [22]",
"        </sup>",
"       </td>",
"       <td>",
"        &gt;50 percent PTH drop in 5 minutes or &gt;60 percent PTH drop from baseline at 15 minutes after gland excision",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Di Stasio",
"        <sup>",
"         [23]",
"        </sup>",
"       </td>",
"       <td>",
"        &gt;50 percent PTH drop and return to normal range in 20 minutes",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Lupoli",
"        <sup>",
"         [24]",
"        </sup>",
"       </td>",
"       <td>",
"        &gt;70 percent PTH drop from baseline 10 minutes after gland excision",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PTH: parathyroid hormone.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Irvin GL 3rd, Molinari AS, Figueroa C, Carneiro DM. Improved success rate in reoperative parathyroidectomy with intraoperative PTH assay. Ann Surg 1999; 229:874.",
"       </li>",
"       <li>",
"        Irvin GL 3rd, Carneiro DM, Solorzano CC. Progress in the operative management of sporadic primary hyperparathyroidism over 34 years. Ann Surg 2004; 239:704.",
"       </li>",
"       <li>",
"        Carneiro DM, Solorzano CC, Irvin GL 3rd. Recurrent disease after limited parathyroidectomy for sporadic primary hyperparathyroidism. J Am Coll Surg 2004; 199:849.",
"       </li>",
"       <li>",
"        Carneiro DM, Solorzano CC, Nader MC, Ramirez M, Irvin GL 3rd. Comparison of intraoperative iPTH assay (QPTH) criteria in guiding parathyroidectomy: which criterion is the most accurate? Surgery 2003; 134:973.",
"       </li>",
"       <li>",
"        Carneiro DM, Irvin GL 3rd. Late parathyroid function after successful parathyroidectomy guided by intraoperative hormone assay (QPTH) compared with the standard bilateral neck exploration. Surgery 2000; 128:925.",
"       </li>",
"       <li>",
"        Miccoli P, Berti P, Materazzi G, Ambrosini CE, Fregoli L, Donatini G. Endoscopic bilateral neck exploration versus quick intraoperative parathormone assay (qPTHa) during endoscopic parathyroidectomy: A prospective randomized trial. Surg Endosc 2008; 22:398.",
"       </li>",
"       <li>",
"        Vignali E, Picone A, Materazzi G, et al. A quick intraoperative parathyroid hormone assay in the surgical management of patients with primary hyperparathyroidism: a study of 206 consecutive cases. Eur J Endocrinol 2002; 146:783.",
"       </li>",
"       <li>",
"        Gordon LL, Snyder WH 3rd, Wians F Jr, Nwariaku F, Kim LT. The validity of quick intraoperative parathyroid hormone assay: an evaluation in seventy-two patients based on gross morphologic criteria. Surgery 1999; 126:1030.",
"       </li>",
"       <li>",
"        Johnson LR, Doherty G, Lairmore T, et al. Evaluation of the performance and clinical impact of a rapid intraoperative parathyroid hormone assay in conjunction with preoperative imaging and concise parathyroidectomy. Clin Chem 2001; 47:919.",
"       </li>",
"       <li>",
"        Agarwal G, Barakate MS, Robinson B, et al. Intraoperative quick parathyroid hormone versus same-day parathyroid hormone testing for minimally invasive parathyroidectomy: a cost-effectiveness study. Surgery 2001; 130:963.",
"       </li>",
"       <li>",
"        Gauger PG, Agarwal G, England BG, et al. Intraoperative parathyroid hormone monitoring fails to detect double parathyroid adenomas: a 2-institution experience. Surgery 2001; 130:1005.",
"       </li>",
"       <li>",
"        Miura D, Wada N, Arici C, Morita E, Duh QY, Clark OH. Does intraoperative quick parathyroid hormone assay improve the results of parathyroidectomy? World J Surg 2002; 26:926.",
"       </li>",
"       <li>",
"        Perrier ND, Ituarte PH, Morita E, et al. Parathyroid surgery: separating promise from reality. J Clin Endocrinol Metab 2002; 87:1024.",
"       </li>",
"       <li>",
"        Libutti SK, Alexander HR, Bartlett DL, et al. Kinetic analysis of the rapid intraoperative parathyroid hormone assay in patients during operation for hyperparathyroidism. Surgery 1999; 126:1145.",
"       </li>",
"       <li>",
"        Riss P, Kaczirek K, Heinz G, Bieglmayer C, Niederle B. A \"defined baseline\" in PTH monitoring increases surgical success in patients with multiple gland disease. Surgery 2007; 142:398.",
"       </li>",
"       <li>",
"        Burkey SH, Van Heerden JA, Farley DR, Thompson GB, Grant CS, Curlee KJ. Will directed parathyroidectomy utilizing the gamma probe or intraoperative parathyroid hormone assay replace bilateral cervical exploration as the preferred operation for primary hyperparathyroidism? World J Surg 2002; 26:914.",
"       </li>",
"       <li>",
"        Yang GP, Levine S, Weigel RJ. A spike in parathyroid hormone during neck exploration may cause a false-negative intraoperative assay result. Arch Surg 2001; 136:945.",
"       </li>",
"       <li>",
"        Chiu B, Sturgeon C, Angelos P. Which intraoperative parathyroid hormone assay criterion best predicts operative success? A study of 352 consecutive patients. Arch Surg 2006; 141:483.",
"       </li>",
"       <li>",
"        Carty SE, Worsey J, Virji MA, Brown ML, Watson CG. Concise parathyroidectomy: the impact of preoperative SPECT 99mTc sestamibi scanning and intraoperative quick parathormone assay. Surgery 1997; 122:1107.",
"       </li>",
"       <li>",
"        Irvin GL 3rd, Molinari AS, Figueroa C, Carneiro DM. Improved success rate in reoperative parathyroidectomy with intraoperative PTH assay. Ann Surg 1999; 229:874.",
"       </li>",
"       <li>",
"        Weber CJ, Ritchie JC. Retrospective analysis of sequential changes in serum intact parathyroid hormone levels during conventional parathyroid exploration. Surgery 1999; 126:1139.",
"       </li>",
"       <li>",
"        Thier M, Nordenstrom E, Bergenfelz A, Westerdahl J. Surgery for patients with primary hyperparathyroidism and negative sestamibi scintigraphy--a feasibility study. Langenbecks Arch Surg 2009; 394:881.",
"       </li>",
"       <li>",
"        Di Stasio E, Carrozza C, Pio Lombardi C, et al. Parathyroidectomy monitored by intra-operative PTH: the relevance of the 20 min end-point. Clin Biochem 2007; 40:595.",
"       </li>",
"       <li>",
"        Lupoli GA, Fonderico F, Panico A, et al. Stricter criteria increase the validity of a quick intraoperative parathyroid hormone assay in primary hyperparathyroidism. Med Sci Monit 2009; 15:CR111.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_9_7326=[""].join("\n");
var outline_f7_9_7326=null;
var title_f7_9_7327="Comminuted clavicle fracture";
var content_f7_9_7327=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F54493&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F54493&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Comminuted clavicle fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 269px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This plain radiograph shows a&nbsp;middle third clavicle fracture with comminution (3rd bone fragment clearly seen between proximal and distal fragments). Nonoperative management was chosen because the fracture was nondisplaced.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert L Hatch, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_9_7327=[""].join("\n");
var outline_f7_9_7327=null;
